Key Takeaways AMN expects Q3 Nurse and Allied Solutions revenues to rise 9-11% as staffing demand strengthens.MSP arrangements generated about 46% of AMN Healthcare's consolidated revenues in Q2'26.AMN is expanding AI-enabled language, leadership and workforce tools to diversify beyond staffing. AMN Healthcare Services, Inc. (AMN - Free Report) is well-poised for growth in the coming quarters, courtesy of its broad array of services. The optimism is led by strong momentum in its Managed Services Program (MSP), favorable healthcare staffing demand, diversified workforce solutions, and investments in technology and AI-driven platforms. However, stiff competition, industry regulations and changing marketplace conditions are major downsides.
Shares of this Zacks Rank #3 (Hold) company have skyrocketed 114.5% year to date against the industry's 12% decline. However, the S&P 500 Index has risen 12.2% in the said timeframe.
This renowned player in the healthcare total talent services space has a market capitalization of $1.31 billion. The company projects 144.1% year-over-year earnings growth for 2026 and expects to witness continued improvements in its business. AMN Healthcare surpassed the Zacks Consensus Estimate in the trailing four quarters, delivering an average earnings surprise of 96.63%.
Image Source: Zacks Investment Research
Factors Favoring AMN StockFavorable Healthcare Staffing Demand: Demand for healthcare staffing remains supported by population growth, aging demographics, increasing care complexity and persistent labor shortages. Healthcare providers are increasingly using flexible workforce models and external staffing partners to manage labor variability and improve efficiency.
In second-quarter 2026, travel nurse volume increased 6% year over year, while allied volume rose 7%, the strongest growth rates in four years. Travel nurse orders turned positive in May and reached approximately 40% growth by early August, while allied orders grew in the mid-teens during June and July. Management expects more than 10% year-over-year growth in both businesses in the third quarter and forecasts Nurse and Allied Solutions revenue growth of 9-11%. Sustained demand could drive stronger staffing volumes and support AMN’s revenue recovery.
Expanding MSP Penetration: AMN Healthcare’s Managed Services Programs (MSPs) strengthen client relationships by helping providers manage supplemental labor across AMN and third-party suppliers. MSP arrangements accounted for approximately 46% of consolidated revenues in second-quarter 2026. In 2025, AMN managed $1.8 billion of spend through MSPs and $3.3 billion, including vendor-neutral programs. Broad-based demand across regions, provider sizes and service models further supports the platform’s workforce optimization capabilities. The scale of AMN’s MSP platform provides recurring access to large healthcare staffing demand and strengthens client retention while creating opportunities to capture additional market share.
Diversified Workforce Solutions: AMN has expanded beyond traditional staffing into technology-enabled total talent solutions spanning staffing, recruitment, MSP, Vendor Management Systems (VMS), language services, consulting and workforce optimization. Second-quarter growth included travel nurse, allied and international nurse staffing, while physician search increased new searches 40% year over year and executive search rose 30%.
AMN also expanded its WorkWise platform with supplier and rate intelligence, while Passport users surpassed 400,000. In June 2026, the company acquired Jaide Health to enhance AI-enabled language interpretation and ESSENTIAL Leadership Assessment to expand leadership evaluation, coaching and succession planning capabilities. This broad service portfolio creates multiple avenues for growth beyond traditional healthcare staffing.
Downsides of AMN StockStiff Competition: AMN Healthcare operates in a highly competitive staffing and workforce-solutions market, with pressure from national, regional and specialized providers. Locum tenens demand is increasingly shifting toward vendor-neutral channels, which management describes as highly competitive. Language services revenues also declined as pricing per minute fell 8%, while Technology and Workforce Solutions revenues dropped 15% year over year. Continued competition could limit pricing power, fill rates and revenue growth.
Changing Marketplace Conditions: Healthcare providers continue to adjust staffing models and focus on controlling labor costs. Contingent labor premiums have fallen to the mid- to high-single digits from the mid- to high-teens before COVID-19, indicating a normalization of pandemic-era economics. Although Nurse and Allied demand is recovering, third-quarter 2026 consolidated revenue guidance calls for only 1-3% year-over-year growth as declines in other segments offset staffing gains. These market shifts could slow AMN’s overall recovery.
Healthcare Industry Regulations: Regulatory and administrative changes can affect clinician availability, client demand and international staffing. AMN’s international nurse business benefited from forward movement in visa cutoff dates, but embassy appointment backlogs remain a constraint. Management indicated that resolving these delays will influence international growth in 2027. Changes in immigration policies or continued processing delays could therefore create staffing shortages, delay placements and increase operating uncertainty.
Estimate TrendAMN Healthcare has been witnessing a positive estimate revision trend for 2026. Over the past 60 days, the Zacks Consensus Estimate for its earnings per share has improved 22.9% to $3.32.
The Zacks Consensus Estimate for third-quarter 2026 revenues and earnings per share is pegged at $648 million and 22 cents, respectively, suggesting 2.1% growth and a 43.6% decline from the year-ago reported numbers.
Key PicksSome better-ranked stocks from the broader medical space are Veracyte (VCYT - Free Report) , Globus Medical (GMED - Free Report) and West Pharmaceutical (WST - Free Report) .
Veracyte, currently flaunting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of 54 cents, which surpassed the Zacks Consensus Estimate by 25.6%. Revenues of $150.3 million beat the Zacks Consensus Estimate by 4.1%.
You can see the complete list of today’s Zacks #1 Rank stocks here.
VCYT has an estimated earnings growth rate of 8.4% for 2026. The company’s earnings beat estimates in the trailing four quarters, the average surprise being 41.8%.
Globus Medical, currently carrying a Zacks Rank #2 (Buy), reported a second-quarter 2026 adjusted EPS of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in the trailing four quarters, the average surprise being 27.9%.
West Pharmaceutical, carrying a Zacks Rank #2 at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.
WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in the trailing four quarters, the average surprise being 17.4%.
Canada Pension Plan Investment Board purchased a new position in AMN Healthcare Services Inc (NYSE:AMN – Free Report) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 44,300 shares of the company’s stock, valued at approximately $1,434,000. Canada Pension Plan Investment Board owned 0.11% of AMN Healthcare Services at the end of the most recent quarter.
Several other institutional investors and hedge funds have also modified their holdings of AMN. BlackRock Inc. purchased a new stake in shares of AMN Healthcare Services in the 2nd quarter worth $215,047,000. Arrowstreet Capital Limited Partnership lifted its position in AMN Healthcare Services by 1,278.0% during the first quarter. Arrowstreet Capital Limited Partnership now owns 1,401,725 shares of the company’s stock valued at $25,708,000 after purchasing an additional 1,300,005 shares in the last quarter. Boston Partners lifted its position in AMN Healthcare Services by 7,583.1% during the fourth quarter. Boston Partners now owns 1,035,145 shares of the company’s stock valued at $16,313,000 after purchasing an additional 1,021,672 shares in the last quarter. Woodline Partners LP purchased a new position in AMN Healthcare Services during the third quarter valued at $19,176,000. Finally, Millennium Management LLC grew its holdings in AMN Healthcare Services by 262.1% during the third quarter. Millennium Management LLC now owns 1,287,918 shares of the company’s stock valued at $24,934,000 after purchasing an additional 932,269 shares during the period. Hedge funds and other institutional investors own 99.23% of the company’s stock.
AMN Healthcare Services Stock Down 1.1% AMN opened at $34.23 on Tuesday. The stock has a market cap of $1.33 billion, a price-to-earnings ratio of 12.77, a price-to-earnings-growth ratio of 1.19 and a beta of 0.40. The company has a debt-to-equity ratio of 1.00, a quick ratio of 1.13 and a current ratio of 1.13. The firm’s fifty day moving average is $33.68 and its 200 day moving average is $26.71. AMN Healthcare Services Inc has a fifty-two week low of $14.97 and a fifty-two week high of $37.22.
AMN Healthcare Services (NYSE:AMN – Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The company reported $0.77 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.19 by $0.58. The business had revenue of $673.24 million during the quarter, compared to analyst estimates of $628.39 million. AMN Healthcare Services had a return on equity of 19.92% and a net margin of 3.06%.AMN Healthcare Services’s revenue for the quarter was up 2.3% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.30 EPS. On average, sell-side analysts forecast that AMN Healthcare Services Inc will post 3.31 earnings per share for the current fiscal year. Insider Buying and Selling at AMN Healthcare Services In other news, Director Mark G. Foletta sold 3,681 shares of the company’s stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $31.07, for a total value of $114,368.67. Following the completion of the transaction, the director owned 17,917 shares of the company’s stock, valued at $556,681.19. This represents a 17.04% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 1.07% of the stock is currently owned by company insiders.
Wall Street Analyst Weigh In A number of analysts have commented on AMN shares. Wall Street Zen cut AMN Healthcare Services from a “buy” rating to a “hold” rating in a research report on Tuesday, August 25th. Citizens Jmp lifted their price objective on AMN Healthcare Services from $36.00 to $40.00 and gave the company a “market outperform” rating in a research report on Friday, August 14th. Weiss Ratings upgraded AMN Healthcare Services from a “sell (d-)” rating to a “sell (d+)” rating in a research note on Tuesday, August 11th. Zacks Research lowered shares of AMN Healthcare Services from a “strong-buy” rating to a “hold” rating in a report on Wednesday, May 20th. Finally, BMO Capital Markets increased their target price on shares of AMN Healthcare Services from $25.00 to $26.00 and gave the stock an “outperform” rating in a report on Monday, May 11th. Four analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $31.43.
Get Our Latest Analysis on AMN
(Free Report)
AMN Healthcare Services, Inc (NYSE: AMN) is a leading provider of healthcare workforce solutions in the United States. The company specializes in staffing and recruitment services for a broad range of clinical and allied health professionals, including travel nurses, permanent placement of nursing staff, locum tenens physicians, and allied health personnel. In addition to direct staffing, AMN Healthcare offers comprehensive workforce management solutions such as vendor management systems (VMS), recruitment process outsourcing (RPO), and compliance and credentialing services through its technology platforms.
Founded in 1985 as American Mobile Nurses, the company rebranded to AMN Healthcare in 2010 to reflect its expanding portfolio of services.
Read More Five stocks we like better than AMN Healthcare Services Securing AI: 5 Most-Upgraded Stocks From the Q2 Reporting Season Insiders Are Betting Big on These 3 Healthcare Stocks 3 Stocks for Investors Who Still Believe Cash Is King Dollar General and Dollar Tree Are Recovering, But Not for the Same Reason
Receive News & Ratings for AMN Healthcare Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMN Healthcare Services and related companies with MarketBeat.com's FREE daily email newsletter.
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.
Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.
Zacks Premium includes access to the Zacks Style Scores as well.
What are the Zacks Style Scores? Developed alongside the Zacks Rank, the Zacks Style Scores are a group of complementary indicators that help investors pick stocks with the best chances of beating the market over the next 30 days.
Each stock is given an alphabetic rating of A, B, C, D or F based on their value, growth, and momentum qualities. With this system, an A is better than a B, a B is better than a C, and so on, meaning the better the score, the better chance the stock will outperform.
The Style Scores are broken down into four categories:
Value ScoreValue investors love finding good stocks at good prices, especially before the broader market catches on to a stock's true value. Utilizing ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and many other multiples, the Value Style Score identifies the most attractive and most discounted stocks.
Growth ScoreGrowth investors are more concerned with a stock's future prospects, and the overall financial health and strength of a company. Thus, the Growth Style Score analyzes characteristics like projected and historic earnings, sales, and cash flow to find stocks that will see sustainable growth over time.
Momentum ScoreMomentum traders and investors live by the saying "the trend is your friend." This investing style is all about taking advantage of upward or downward trends in a stock's price or earnings outlook. Employing factors like one-week price change and the monthly percentage change in earnings estimates, the Momentum Style Score can indicate favorable times to build a position in high-momentum stocks.
VGM ScoreIf you want a combination of all three Style Scores, then the VGM Score will be your friend. It rates each stock on their combined weighted styles, helping you find the companies with the most attractive value, best growth forecast, and most promising momentum. It's also one of the best indicators to use with the Zacks Rank.
How Style Scores Work with the Zacks Rank The Zacks Rank, which is a proprietary stock-rating model, employs earnings estimate revisions, or changes to a company's earnings expectations, to make building a winning portfolio easier.
It's highly successful, with #1 (Strong Buy) stocks producing an unmatched +23.8% average annual return since 1988. That's more than double the S&P 500. But because of the large number of stocks we rate, there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.
But it can feel overwhelming to pick the right stocks for you and your investing goals with over 800 top-rated stocks to choose from.
That's where the Style Scores come in.
To have the best chance of big returns, you'll want to always consider stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B, which will give you the highest probability of success. If you're looking at stocks with a #3 (Hold) rank, it's important they have Scores of A or B as well to ensure as much upside potential as possible.
The direction of a stock's earnings estimate revisions should always be a key factor when choosing which stocks to buy, since the Scores were created to work together with the Zacks Rank.
Here's an example: a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one with Style Scores of A and B, still has a downward-trending earnings outlook, and a bigger chance its share price will decrease too.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: AMN Healthcare Services (AMN - Free Report) AMN Healthcare Services, Inc. (AMN - Free Report) , operating from Dallas, TX, is a travel healthcare staffing company. Its business has evolved beyond traditional healthcare staffing and recruitment services, thereby becoming a strategic total talent solutions partner with its clients. It has expanded its portfolio to serve a diverse and growing set of healthcare talent-related needs. In addition to its healthcare professional staffing and recruitment services, AMN’s suite of healthcare workforce solutions includes MSP, vendor management systems (VMS), medical language interpretation services, predictive labor analytics, workforce optimization technology and consulting, recruitment process outsourcing (RPO), revenue cycle solutions, credentialing services and virtual care management services. AMN enables its clients to build, manage and optimize their healthcare talent to deliver improved patient outcomes and experience. It continues to enhance its platform with technology-enabled solutions, including digital workforce platforms, automation tools and AI-driven capabilities to improve speed, efficiency and clinician engagement.
AMN is a #3 (Hold) on the Zacks Rank, with a VGM Score of A.
Momentum investors should take note of this Business Services stock. AMN has a Momentum Style Score of A, and shares are up 3.2% over the past four weeks.
For fiscal 2026, two analysts revised their earnings estimate upwards in the last 60 days, and the Zacks Consensus Estimate has increased $0.40 to $3.10 per share. AMN boasts an average earnings surprise of +96.6%.
With a solid Zacks Rank and top-tier Momentum and VGM Style Scores, AMN should be on investors' short list.
BlackRock Inc. acquired a new position in shares of AMN Healthcare Services Inc (NYSE:AMN – Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 6,643,401 shares of the company’s stock, valued at approximately $215,047,000. BlackRock Inc. owned 17.13% of AMN Healthcare Services as of its most recent SEC filing.
A number of other large investors have also recently bought and sold shares of AMN. Summit Securities Group LLC acquired a new stake in shares of AMN Healthcare Services in the 4th quarter valued at approximately $32,000. Versant Capital Management Inc increased its position in AMN Healthcare Services by 41.8% during the 2nd quarter. Versant Capital Management Inc now owns 1,170 shares of the company’s stock worth $38,000 after purchasing an additional 345 shares in the last quarter. Johnson Financial Group Inc. bought a new position in AMN Healthcare Services in the 3rd quarter valued at approximately $63,000. Tower Research Capital LLC TRC lifted its stake in AMN Healthcare Services by 49.2% in the 2nd quarter. Tower Research Capital LLC TRC now owns 3,093 shares of the company’s stock valued at $64,000 after purchasing an additional 1,020 shares during the last quarter. Finally, Strs Ohio acquired a new stake in AMN Healthcare Services in the first quarter valued at approximately $95,000. 99.23% of the stock is currently owned by institutional investors and hedge funds.
Analysts Set New Price Targets A number of research firms have weighed in on AMN. Weiss Ratings raised shares of AMN Healthcare Services from a “sell (d-)” rating to a “sell (d+)” rating in a research note on Tuesday, August 11th. Wall Street Zen cut AMN Healthcare Services from a “buy” rating to a “hold” rating in a research note on Tuesday. BMO Capital Markets raised their price objective on AMN Healthcare Services from $25.00 to $26.00 and gave the company an “outperform” rating in a report on Monday, May 11th. Truist Financial boosted their price objective on AMN Healthcare Services from $26.00 to $40.00 and gave the stock a “buy” rating in a research report on Wednesday, July 22nd. Finally, Citigroup reaffirmed an “outperform” rating on shares of AMN Healthcare Services in a report on Friday, August 14th. Four investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $31.43.
Check Out Our Latest Analysis on AMN AMN Healthcare Services Price Performance AMN stock opened at $35.07 on Friday. The company has a market capitalization of $1.36 billion, a P/E ratio of 13.09, a PEG ratio of 1.26 and a beta of 0.40. The company has a fifty day moving average price of $33.53 and a 200-day moving average price of $26.51. The company has a debt-to-equity ratio of 1.00, a quick ratio of 1.13 and a current ratio of 1.13. AMN Healthcare Services Inc has a 52-week low of $14.97 and a 52-week high of $37.22.
AMN Healthcare Services (NYSE:AMN – Get Free Report) last announced its earnings results on Thursday, August 6th. The company reported $0.77 EPS for the quarter, beating the consensus estimate of $0.19 by $0.58. AMN Healthcare Services had a return on equity of 19.92% and a net margin of 3.06%.The business had revenue of $673.24 million for the quarter, compared to analysts’ expectations of $628.39 million. During the same period in the prior year, the business posted $0.30 earnings per share. The firm’s revenue was up 2.3% on a year-over-year basis. As a group, equities analysts expect that AMN Healthcare Services Inc will post 3.1 EPS for the current year.
Insider Buying and Selling at AMN Healthcare Services In related news, Director Mark G. Foletta sold 3,681 shares of the company’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $31.07, for a total transaction of $114,368.67. Following the transaction, the director directly owned 17,917 shares of the company’s stock, valued at approximately $556,681.19. This represents a 17.04% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 1.07% of the company’s stock.
AMN Healthcare Services Company Profile (Free Report)
AMN Healthcare Services, Inc (NYSE: AMN) is a leading provider of healthcare workforce solutions in the United States. The company specializes in staffing and recruitment services for a broad range of clinical and allied health professionals, including travel nurses, permanent placement of nursing staff, locum tenens physicians, and allied health personnel. In addition to direct staffing, AMN Healthcare offers comprehensive workforce management solutions such as vendor management systems (VMS), recruitment process outsourcing (RPO), and compliance and credentialing services through its technology platforms.
Founded in 1985 as American Mobile Nurses, the company rebranded to AMN Healthcare in 2010 to reflect its expanding portfolio of services.
Featured Stories Five stocks we like better than AMN Healthcare Services Nutanix’s Rally Has a Bigger Story Than Earnings as AMD’s AI Bet Takes Shape SEC Probe Puts Wall Street Leverage Risk Back in Focus A Bearish-Dollar Options Surge Raises the Stakes for Warsh at Jackson Hole Five Below’s Turnaround Is Working—But Has the Stock Run Too Far?
Receive News & Ratings for AMN Healthcare Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMN Healthcare Services and related companies with MarketBeat.com's FREE daily email newsletter.
Key Takeaways AMN Healthcare has rallied 118.7% YTD as Q2 revenues rose 2.3% and adjusted EPS surged 158%.AMN saw travel nurse orders rise about 40% year over year by early August as staffing demand strengthened.AMN's automation, AI recruiting and high fill rates are helping capture demand amid workforce shortages. AMN Healthcare Services (AMN - Free Report) stock has jumped 118.7% year to date, significantly outperforming its industry’s 10.9% gain and the S&P 500’s 11.7% growth. The rally reflects improving demand across staffing businesses, stronger execution and growing confidence in AMN’s ability to benefit from persistent healthcare workforce shortages.
Second-quarter performance provided a meaningful catalyst, with revenues rising 2.3% year over year to $673 million, 6% above the high end of guidance. Adjusted EPS jumped to 77 cents, up 158% year over year. Nurse and Allied Solutions revenues rose 11%, supported by stronger travel nurse and allied volumes, while search revenue increased 27%.
Image Source: Zacks Investment Research
What Is Fueling AMN’s Growth?Nurse and Allied Demand Is Showing a Strong Rebound: AMN’s core staffing businesses are benefiting from a broad-based recovery in demand. Travel nurse volume increased 6% and allied volume rose 7% in the second quarter, marking the strongest growth rates for both businesses in four years. Travel nurse orders turned positive in May and accelerated in June, with orders up about 40% year over year by early August. Third-quarter guidance calls for more than 10% volume growth in both travel nurse and allied, supporting continued momentum.
Technology and High Fill Rates Are Strengthening Execution: AMN is increasingly using automation, 24/7 operations and AI-enabled recruiting to capture higher demand. These capabilities have improved fill rates across MSP, VMS and third-party platforms, helping the company gain share as demand recovers. Its Passport clinician app surpassed 400,000 users, up 33% year over year, while monthly active users increased more than 50%.
Persistent Workforce Shortages Support Long-Term Demand: AMN’s latest workforce report points to structural staffing pressure extending through 2030. Aging demographics, chronic disease, physician shortages, rural staffing gaps and strong allied-health demand are expected to keep healthcare organizations reliant on flexible and optimized workforce solutions. The report also found that RN supply is not keeping pace with demand, while CT technologist demand has more than doubled since 2021. These trends could support demand for AMN’s nursing, allied health, physician and workforce optimization solutions.
Strategic Acquisitions Expand AMN’s Opportunity: AMN is expanding its capabilities through targeted acquisitions. The company acquired ESSENTIAL Brand Leadership Assessment and Jaide Health. Jaide Health strengthens the company’s AI-enabled language access offerings across the patient journey, while the ESSENTIAL Leadership Assessment broadens its leadership advisory, evaluation and succession-planning capabilities. These additions should deepen client relationships and support growth in higher-value, technology-enabled workforce solutions.
A Glance at AMN’s EstimatesThe Zacks Consensus Estimate for AMN’s earnings per share (EPS) implies year-over-year growth of 127.9% to $3.10 in 2026, followed by a 62.6% decline to $1.16 in 2027. In the past 60 days, the consensus mark for the company's 2026 EPS has improved 14.8%.
Revenues are projected to grow 20.9% to $3.30 billion in 2026 and decline 20.3% to $2.63 billion in 2027.
Image Source: Zacks Investment Research
AMN Stock: Risks & ChallengesChallenges remain for the company as it moves through the second half of 2026. AMN Healthcare remains dependent on sustained demand improvement in Nurse and Allied, while bill rates have yet to rise broadly and industry competition remains elevated. The Kaiser contract renewal process is expected to be competitive, with procurement generally seeking better terms. International nurse growth could moderate in 2027 if Embassy appointment delays persist, while Language Services continues to face pricing compression and softer demand tied to immigration policies. Execution on the locum tenens technology transformation, globalized language-services delivery and conversion of higher staffing orders into placements will be critical to restoring broader growth and improving profitability.
ConclusionThis Zacks Rank #3 (Hold) company’s 2026 rally appears supported by improving underlying demand rather than a single catalyst. Stronger nurse and allied volumes, better fulfillment, technology-enabled execution and persistent healthcare workforce shortages provide multiple avenues for growth. However, investors should watch the normalization of the second quarter’s one-time benefits, pricing pressure and the sustainability of the recent demand recovery. With AMN positioning itself for further organic growth and potential industry consolidation, the stock’s surge reflects growing optimism around a broader recovery in healthcare staffing.
Stocks to ConsiderSome better-ranked stocks from the broader medical space are Globus Medical (GMED - Free Report) , Veracyte (VCYT - Free Report) and West Pharmaceutical (WST - Free Report) .
Globus Medical, currently sporting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted EPS of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%. You can see the complete list of today’s Zacks #1 Rank stocks here.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
Veracyte, currently flaunting a Zacks Rank #1, reported a second-quarter 2026 adjusted EPS of 54 cents, which surpassed the Zacks Consensus Estimate by 25.6%. Revenues of $150.3 million beat the Zacks Consensus Estimate by 4.1%.
VCYT has an estimated earnings growth rate of 8.4% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 41.8%.
West Pharmaceutical, carrying a Zacks Rank #2 (Buy) at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.
WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in the trailing four quarters, the average surprise being 17.4%.
AMN Healthcare is rated BUY, driven by robust nurse staffing demand and strong YTD share price performance (+110%). AMN trades at a compelling 5.2x forward EV/EBITDA, a 59% discount to the sector and 32% below its five-year average. Secular nurse shortages, AI-driven operational efficiencies, and improving margins underpin AMN's positive outlook and earnings momentum.
Key Takeaways Weak July jobs data reduced September rate-hike expectations, supporting equities. FWRD expects to retain at least half of roughly $250 million in 2025 revenues tied to a major customer. AMN Healthcare shares have surged 132.4% YTD as healthcare demand and structural drivers aid its business. The weak July jobs data has reduced the chances of the Fed increasing interest rates at its September meeting to curb inflation in the United States. According to the July 2026 employment report, nonfarm payrolls declined by 23,000 against expectations of an 80,000 increase. Macroeconomic challenges stemming from the crisis in the Middle East have driven energy prices higher and increased operating costs, weighing on the report.
However, the disappointing jobs data has been favorable for equities, with the unemployment rate remaining relatively low at 4.1%. As soft U.S. employment data reshapes interest-rate expectations and boosts markets, investors may want to capitalize on the situation by keeping broker-favorite stocks such as Avnet (AVT - Free Report) , RXO, Inc. (RXO - Free Report) , Forward Air (FWRD - Free Report) , Air Canada (ACDVF - Free Report) and AMN Healthcare Services (AMN - Free Report) on their radar.
Since brokers closely track the stocks they cover, they revise their earnings estimates after thoroughly assessing the positive and negative implications of an event for the company concerned. Consequently, these estimate revisions serve as an important indicator of a stock’s price prospects. Given their extensive expertise, brokers are regarded as investment professionals with in-depth knowledge and a clear understanding of the intricacies of the investment landscape. Therefore, investors would be well advised to pay attention to such carefully researched information to reduce the risk of seeing their hard-earned money invested in the stock market go down the drain.
Screening Parameters # (Up- Down Rating)/ Total (4 weeks) =Top #75 (This gives the list of top 75 companies that have witnessed net upgrades over the last 4 weeks).
% change in Q (1) est. (4 weeks) = Top #10 (This gives the top 10 stocks that have witnessed earnings estimate revisions over the past 4 weeks for the upcoming quarter).
Price-to-Sales = Bot%10 (The lower the ratio, the better. Companies meeting this criterion are in the bottom 10% of our universe of over 7,700 stocks concerning this ratio).
Current Price greater than 5 (as a stock trading below $5 will not likely create significant interest for most of the investors).
Average Daily Volume greater than 100,000 shares over the last 20 trading days (Volume has to be significant to ensure that these are easily traded).
Market value ($ mil) = Top #3000 (This gives us stocks that are the top 3000 in terms of market capitalization).
Com/ADR/Canadian= Com (This eliminates the ADR and Canadian stocks).
Here are five of the 10 stocks that made it through the screen:
Based in Phoenix, AZ, Avnet is one of the world’s largest distributors of electronic components and computer products. The company’s customer base includes original equipment manufacturers, electronic manufacturing services providers, original design manufacturers and value-added resellers.
Avnet sports a Zacks Rank #1 (Strong Buy) currently. AVT surpassed the Zacks Consensus Estimate for earnings in each of the last four quarters. The average beat is 13.8%.
You can see the complete list of today’s Zacks #1 Rank stocks here
RXO is an asset-light, technology-enabled brokered transportation platform moving freight across North America. Supply-tightening, rising contract rates and AI-enabled productivity are aiding the transportation company.
RXO, currently carrying a Zacks Rank #3 (Hold), surpassed the Zacks Consensus Estimate for earnings in one of the last four quarters, missed the mark twice and reported in-line earnings once. The average miss is 22.9%.
Forward Air is a trucking company. It recently inked a non-binding memorandum of understanding with one of its largest customers regarding the continued provision of services (the MOU covers services that the customer had planned to shift to other providers as part of an effort to diversify its list of vendors). Under the MOU, Forward Air expects to retain at least half of the approximately $250 million in revenues attributable to the customer for 2025, with the potential to retain an additional approximately 25%.
FWRD, currently carrying a Zacks Rank #3, surpassed the Zacks Consensus Estimate for earnings in one of the last four quarters and missed the mark thrice. The average beat is 82%.
Air Canada has been benefiting from the impressive scenario in air travel demand. Volatile fuel prices and high labor costs represent major headwinds. The Zacks Consensus Estimate for 2026 sales has increased 7.4% on a year-over-year basis.
ACDVF surpassed the Zacks Consensus Estimate for earnings in two of the last four quarters and missed in the other two, the average beat being 51.4%. ACDVF currently carries a Zacks Rank #3.
AMN Healthcare Services, a leader and innovator in total talent solutions for healthcare, carries a Zacks Rank #3 presently. The company has a trailing four-quarter earnings surprise of 96.6%, on average.
Shares of AMN have surged 132.4% year to date. Changes in demand for healthcare services, particularly at acute care hospitals and other inpatient facilities, continue to boost demand for AMN Healthcare’s services. The company’s business is supported by long-term structural drivers including population growth, aging demographics and the increasing complexity of care delivery.
Dimensional Fund Advisors LP trimmed its position in shares of AMN Healthcare Services Inc (NYSE:AMN – Free Report) by 5.7% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 741,209 shares of the company’s stock after selling 44,529 shares during the period. Dimensional Fund Advisors LP owned approximately 1.92% of AMN Healthcare Services worth $13,595,000 at the end of the most recent quarter.
Several other hedge funds have also recently bought and sold shares of the company. Summit Securities Group LLC acquired a new position in shares of AMN Healthcare Services in the 4th quarter valued at approximately $32,000. China Universal Asset Management Co. Ltd. increased its stake in AMN Healthcare Services by 200.0% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 3,000 shares of the company’s stock valued at $47,000 after acquiring an additional 2,000 shares during the last quarter. Johnson Financial Group Inc. acquired a new position in AMN Healthcare Services during the third quarter valued at approximately $63,000. Tower Research Capital LLC TRC lifted its stake in AMN Healthcare Services by 49.2% during the second quarter. Tower Research Capital LLC TRC now owns 3,093 shares of the company’s stock worth $64,000 after purchasing an additional 1,020 shares during the last quarter. Finally, Strs Ohio bought a new stake in AMN Healthcare Services during the first quarter worth $95,000. 99.23% of the stock is owned by institutional investors.
Key AMN Healthcare Services News Here are the key news stories impacting AMN Healthcare Services this week:
Positive Sentiment: Quarterly earnings and revenue topped estimates. AMN reported adjusted EPS of $0.77, up from $0.30 a year earlier and well above analysts’ expectations of approximately $0.19-$0.22. Revenue rose 2.3% year over year to $673 million, exceeding the roughly $628 million consensus estimate. GAAP earnings were $0.53 per share, while adjusted EBITDA totaled $73 million. AMN Healthcare Announces Second Quarter 2026 Results Positive Sentiment: Growth was broad-based across staffing and search services. Results benefited from higher demand in travel nursing, allied healthcare staffing and executive search, along with activity related to labor disruptions. The earnings beat suggests AMN is gaining operating leverage as demand stabilizes. AMN Q2 Earnings Beat Estimates on Staffing and Search Growth Positive Sentiment: Third-quarter revenue guidance exceeded expectations. Management forecast Q3 revenue of $640 million to $655 million, above the consensus estimate of $618.4 million. Although the range implies a sequential decline from Q2, it indicates stronger near-term demand than analysts had projected. AMN Healthcare Quarterly Earnings Report Neutral Sentiment: The company continues to face a challenging staffing environment, including a negative reported net margin, while investors will watch whether the recent earnings strength can persist after labor-disruption-related activity. Insider Activity at AMN Healthcare Services In related news, Director Mark G. Foletta sold 3,681 shares of the business’s stock in a transaction on Monday, June 15th. The shares were sold at an average price of $31.07, for a total value of $114,368.67. Following the sale, the director owned 17,917 shares of the company’s stock, valued at $556,681.19. The trade was a 17.04% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 1.07% of the company’s stock.
Analyst Upgrades and Downgrades Several research firms recently weighed in on AMN. BMO Capital Markets raised their price objective on AMN Healthcare Services from $25.00 to $26.00 and gave the company an “outperform” rating in a research note on Monday, May 11th. Citizens Jmp reissued a “market outperform” rating and issued a $36.00 target price on shares of AMN Healthcare Services in a report on Tuesday, June 23rd. UBS Group raised their price target on shares of AMN Healthcare Services from $32.00 to $35.00 and gave the company a “neutral” rating in a research note on Friday. Weiss Ratings raised shares of AMN Healthcare Services from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, June 17th. Finally, Zacks Research cut shares of AMN Healthcare Services from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, May 20th. Four equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, AMN Healthcare Services currently has an average rating of “Hold” and an average target price of $30.86.
Get Our Latest Analysis on AMN Healthcare Services
AMN Healthcare Services Stock Up 16.7% Shares of NYSE AMN opened at $35.93 on Friday. The company has a 50 day simple moving average of $32.51 and a 200 day simple moving average of $25.09. The company has a debt-to-equity ratio of 1.04, a current ratio of 1.09 and a quick ratio of 1.09. AMN Healthcare Services Inc has a 1 year low of $14.86 and a 1 year high of $36.86. The firm has a market cap of $1.39 billion, a PE ratio of 13.41, a price-to-earnings-growth ratio of 0.83 and a beta of 0.40.
AMN Healthcare Services (NYSE:AMN – Get Free Report) last posted its earnings results on Thursday, August 6th. The company reported $0.77 earnings per share for the quarter, topping analysts’ consensus estimates of $0.19 by $0.58. AMN Healthcare Services had a net margin of 3.06% and a return on equity of 20.48%. The firm had revenue of $673.24 million for the quarter, compared to analyst estimates of $628.39 million. During the same period in the previous year, the firm posted $0.30 EPS. The company’s revenue for the quarter was up 2.3% compared to the same quarter last year. On average, research analysts forecast that AMN Healthcare Services Inc will post 2.7 EPS for the current year.
AMN Healthcare Services Company Profile (Free Report)
AMN Healthcare Services, Inc (NYSE: AMN) is a leading provider of healthcare workforce solutions in the United States. The company specializes in staffing and recruitment services for a broad range of clinical and allied health professionals, including travel nurses, permanent placement of nursing staff, locum tenens physicians, and allied health personnel. In addition to direct staffing, AMN Healthcare offers comprehensive workforce management solutions such as vendor management systems (VMS), recruitment process outsourcing (RPO), and compliance and credentialing services through its technology platforms.
Founded in 1985 as American Mobile Nurses, the company rebranded to AMN Healthcare in 2010 to reflect its expanding portfolio of services.
Featured Stories Five stocks we like better than AMN Healthcare Services Quantum Earnings Week: Winners and Losers Are Finally Emerging Axon’s Post-Earnings Pullback May Be More About Valuation Than Growth Uber Stock Lags in 2026, But Cash Flow and AV Bets Fuel Upside AppLovin Stock Hits 52-Week Low as Analysts Trim Targets, Stay Bullish
Receive News & Ratings for AMN Healthcare Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMN Healthcare Services and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEEnovis (NYSE:ENOV) vs. ADB International Group (OTCMKTS:EQUR) Financial Comparison
NEXT HEADLINE »Dimensional Fund Advisors LP Has $12.58 Million Stock Holdings in Mvb Financial Corp. $MVBF
AMN Healthcare Services NYSE: AMN reported second-quarter results above its guidance range, aided by stronger demand in travel nursing, allied staffing and search services, as well as labor disruption-related revenue and several favorable reserve items.
Revenue totaled $673 million, up 2% from a year earlier and 6% above the high end of the company’s outlook. Adjusted EBITDA rose 26% year over year to $73 million, representing 10.9% of revenue, while adjusted earnings per share were $0.77, compared with $0.30 in the prior-year quarter. The company ended the quarter with $362 million in cash and equivalents.
Get AMN alerts:
Chief Executive Officer Cary Grace said five of AMN’s solutions posted year-over-year revenue growth. She said the company is seeing rising client demand for flexible staffing as the premium for contingent labor relative to permanent labor has fallen to the mid- to high-single-digit percentage range, compared with the mid- to high-teens before the COVID-19 pandemic.
Labor disruption items boosted reported results Chief Financial Officer and Chief Operating Officer Brian Scott said the company’s second-quarter guidance had assumed $10 million in labor disruption revenue, but reported $25 million. Results also benefited from a billing-accrual true-up related to large first-quarter labor disruption events, a reserve reversal from a prior-year event and other favorable reserve adjustments.
Scott said those items added about $27 million to revenue, 290 basis points to consolidated gross margin and 370 basis points to adjusted EBITDA margin. Excluding those items, revenue would still have been nearly 2% above the high end of guidance, while EBITDA margin would have been at the top of the company’s 6.7% to 7.2% projected range.
Reported gross margin was 30.6%, and second-quarter net income was $21 million, compared with a $116 million net loss a year earlier. Adjusted SG&A expense was $135 million, down 4% from the prior-year period. SG&A included a $5 million unfavorable professional-liability actuarial adjustment, partly offset by a $3 million favorable adjustment to the allowance for credit losses.
Nurse and allied staffing demand accelerated Revenue in the Nurse and Allied Solutions segment increased 11% year over year to $422 million, with a 28.4% gross margin. Travel nurse volume rose 6%, while allied volume increased 7%, which Grace described as the strongest growth rates for those businesses in four years. International nurse revenue increased 23%.
Grace said travel nurse orders turned positive year over year in May and accelerated in June. As of early August, orders were up about 40% from a year earlier and 20% above August 2024 levels. Allied orders also accelerated through the quarter, reaching mid-teens growth in June and July, according to the company.
AMN attributed its performance to improving demand and higher fill rates, supported by process automation, round-the-clock operations and AI-enabled recruiting. Grace said demand growth has been broad-based across regions, client sizes and service models, including managed service programs, vendor-neutral channels and third-party programs.
For the third quarter, AMN expects Nurse and Allied Solutions revenue to increase 9% to 11% year over year, with travel nurse and allied volumes each expected to grow by more than 10%.
The company said average Nurse and Allied bill rates were nearly flat from a year earlier. Grace said some clients have increased rates for urgent needs, but broader rate increases have not yet emerged. She added that sustained demand, particularly during the winter-order period, could eventually support higher rates.
Search business grew while locums and technology revenue declined Physician and Leadership Solutions revenue fell 6% year over year to $165 million. However, the search business grew revenue 27%, with physician search new searches rising 37% sequentially and 40% year over year. Executive search new searches increased 30% year over year, and leadership search volume rose 60%.
Locum tenens revenue declined 8% year over year to $131 million. Scott said revenue was flat sequentially, partly due to a $2 million negative sales adjustment that reduced both revenue and gross profit. The company said locums demand is increasingly occurring in competitive vendor-neutral channels and that it is applying process and technology changes to improve fulfillment. Grace said AMN expects locums to return to year-over-year growth in 2027.
Technology and Workforce Solutions revenue decreased 15% year over year to $87 million, or 11% excluding the divestiture of Smart Square. Language services revenue was $70 million, down 8%, as pricing declined 8% while volume was flat. VMS revenue was $15 million, down 20% from a year earlier.
Grace said AMN expects pricing pressure in language services to continue through the rest of 2026, though it anticipates more muted pricing compression in 2027. The company is expanding a lower-cost service tier and globalizing portions of its workforce delivery model to support future margins.
Acquisitions, balance sheet and outlook AMN completed two small acquisitions during the quarter for a combined $3 million. It acquired Essential Leadership Assessment Solution to expand leadership selection, assessment, coaching and succession-planning capabilities. It also acquired Jade Health, which provides medically qualified language interpretation support and AI-enabled tools for patient intake and discharge communications.
The company repurchased 85,000 shares at an average price of $26.33 during the quarter. Total debt stood at $750 million, and leverage under its credit agreement was 1.5 times. Scott said AMN expects at least $225 million in cash at the end of the third quarter, even after a $20 million interest payment, higher cash taxes and repayment of remaining strike-related client deposits.
For the third quarter, AMN forecast consolidated revenue of $640 million to $655 million, gross margin of 27% to 27.5%, and adjusted EBITDA margin of 6.5% to 7%. The outlook includes approximately $7 million to $8 million of strike-related revenue, Scott said.
About AMN Healthcare Services (NYSE:AMN)AMN Healthcare Services, Inc NYSE: AMN is a leading provider of healthcare workforce solutions in the United States. The company specializes in staffing and recruitment services for a broad range of clinical and allied health professionals, including travel nurses, permanent placement of nursing staff, locum tenens physicians, and allied health personnel. In addition to direct staffing, AMN Healthcare offers comprehensive workforce management solutions such as vendor management systems (VMS), recruitment process outsourcing (RPO), and compliance and credentialing services through its technology platforms.
Founded in 1985 as American Mobile Nurses, the company rebranded to AMN Healthcare in 2010 to reflect its expanding portfolio of services.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Should You Invest $1,000 in AMN Healthcare Services Right Now?Before you consider AMN Healthcare Services, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AMN Healthcare Services wasn't on the list.
While AMN Healthcare Services currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries.
"Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.
Key Takeaways AMN Healthcare's Q2 adjusted EPS rose 158% to 77 cents, while revenues increased 2.3% to $673.2 million.Nurse and Allied Solutions revenues rose 11%, with travel nurse staffing up 10% and Allied revenues up 8%.AMN expects Q3 revenues of $640M-$655M, with Nurse and Allied Solutions growth of 9%-11% year over year. AMN Healthcare Services, Inc. (AMN - Free Report) delivered second-quarter 2026 adjusted earnings per share (EPS) of 77 cents, up 158% year over year. The figure surpassed the Zacks Consensus Estimate by 250%.
GAAP EPS for the quarter was 53 cents against a loss per share of $3.02 in the year-ago period.
AMN’s Q2 Revenues in DetailAMN Healthcare registered revenues of $673.2 million in the second quarter, up 2.3% year over year. The figure surpassed the Zacks Consensus Estimate by 7.6%. Results benefited from growth in travel nurse, allied and search businesses, along with labor disruption activity.
Shares of AMN gained 9.3% during yesterday’s after-hours trading. Year to date, the company’s shares have rallied 95.4% against the industry’s decline of 11.2%. The S&P 500 Index has increased 12.5% in the same time frame.
Image Source: Zacks Investment Research
AMN Healthcare's Q2 Segment DetailsAMN Healthcare conducts its business via three reportable segments: Nurse and Allied Solutions, Physician and Leadership Solutions, and Technology and Workforce Solutions.
Nurse and Allied Solutions revenues totaled $422 million, up 11% year over year. Travel nurse staffing revenues increased 10% year over year, while Allied revenues rose 8%. Labor disruption contributed $25 million in revenues compared with $16 million in the year-ago quarter. Average travelers on assignment increased to 9,194 from 8,700 a year earlier. The Zacks Consensus Estimate was pegged at $377 million.
Physician and Leadership Solutions revenues totaled $164.6 million, down 6% year over year. Locum tenens revenues were $131 million, declining 8%, while interim leadership revenues fell 3%. Physician and leadership search business revenues increased 27% year over year, driven by strength in executive search and physician permanent placement. Days filled declined to 46,974 from 51,325, while revenue per day filled increased to $2,784 from $2,777. The Zacks Consensus Estimate was pegged at $162 million.
Technology and Workforce Solutions revenues totaled $86.7 million, down 15% year over year. Language Services revenues were $70 million, down 8% year over year, while vendor management systems revenues declined 20% year over year to $15 million. The Zacks Consensus Estimate was pegged at $87 million.
AMN's Q2 Profitability ImprovesIn the quarter under review, AMN Healthcare’s gross profit increased 5% year over year to $205.9 million. Gross margin expanded 80 basis points to 30.6%, aided by reserve releases and billing true-ups related to large labor disruption events supported in prior periods.
Selling, general & administrative expenses declined 4.7% year over year to $147.4 million.
Operating income was $26.9 million compared with an operating loss of $123.7 million a year ago.
AMN Healthcare’s Financial PositionAMN Healthcare exited the second quarter of 2026 with cash and cash equivalents of $361.8 million compared with $560.7 million at the end of the first quarter of 2026. Total debt at the end of the second quarter of 2026 was $750 million, flat sequentially.
Net cash used in operating activities at the end of the second quarter 2026 was $189.9 million against net cash provided by operating activities of $78.5 million a year ago.
AMN's Q3 GuidanceAMN Healthcare has provided its financial outlook for the third quarter of 2026.
For the third quarter of 2026, AMN expects consolidated revenues between $640 million and $655 million, representing year-over-year growth of 1-3%. The Zacks Consensus Estimate is pegged at $619.1 million.
Nurse and Allied Solutions revenues are projected to increase 9-11% year over year. Physician and Leadership Solutions revenues are expected to decline 5-7% year over year, while Technology and Workforce Solutions revenues are projected to fall 11-13% year over year. Management forecasts a gross margin of 27-27.5% and an adjusted EBITDA margin of 6.5-7%.
Wrapping UpAMN Healthcare delivered a solid second-quarter 2026 performance, supported by improving demand in travel nurse, allied, international nurse and search solutions. Travel nurse and allied volumes marked their strongest growth rates in four years. Management noted that travel nurse orders turned positive in May and accelerated through June, while Allied demand strengthened across settings and specialties.
Technology and innovation remained key elements of AMN’s growth strategy. The company continued to enhance its WorkWise workforce management platform with expanded analytics and rate intelligence, while adoption of the AMN Passport app surpassed 400,000 users, up 33% year over year. Monthly active users increased more than 50%, reflecting deeper clinician engagement across AMN’s digital ecosystem.
AMN expanded its capabilities through two targeted acquisitions. Jaide Health strengthens the company’s AI-enabled language access offerings across the patient journey, while the ESSENTIAL Leadership Assessment broadens its leadership advisory, evaluation and succession-planning capabilities. Management indicated that these additions should deepen client relationships and support growth in higher-value, technology-enabled workforce solutions.
Commercial momentum also improved. Search revenues were supported by executive search and physician permanent placement, while new physician searches rose 40% year over year. AMN is also benefiting from higher fill rates across managed service programs, vendor-neutral platforms and third-party channels as automation, 24/7 operations and AI-enabled recruiting improve execution.
However, competitive conditions continue to pressure Language Services pricing, while Locum Tenens is still undergoing a process and technology transformation aimed at improving fulfillment in third-party channels. Management is addressing these headwinds through process and technology upgrades in locums, a tiered Language Services model and greater globalization of service delivery. Looking ahead, AMN remains focused on sustainable growth through stronger execution, technology investments and selective acquisitions.
AMN Healthcare’s Zacks Rank & Stocks to ConsiderAMN currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are West Pharmaceutical (WST - Free Report) , The Cooper Companies (COO - Free Report) and Cardinal Health (CAH - Free Report) , each carrying a Zacks Rank of 2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
West Pharmaceutical reported second-quarter 2026 adjusted earnings per share (EPS) of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.
West Pharmaceutical has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 17.40%.
The Cooper Companies reported a second-quarter fiscal 2026 adjusted EPS of $1.21, which beat the Zacks Consensus Estimate by 10.00%. Revenues of $1.08 billion beat the Zacks Consensus Estimate by 2.6%.
The Cooper Companies has an estimated long-term earnings growth rate of 8.3%. COO’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 5.80%.
Cardinal Health reported a third-quarter fiscal 2026 adjusted EPS of $3.17, which beat the Zacks Consensus Estimate by 13.2%. Revenues of $60.94 billion missed the Zacks Consensus Estimate by 2.3%.
Cardinal Health has an estimated long-term earnings growth rate of 17%. CAH’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 10.27%.
For the quarter ended June 2026, AMN Healthcare Services (AMN - Free Report) reported revenue of $673.24 million, up 2.3% over the same period last year. EPS came in at $0.77, compared to $0.30 in the year-ago quarter.
The reported revenue represents a surprise of +7.55% over the Zacks Consensus Estimate of $626.01 million. With the consensus EPS estimate being $0.22, the EPS surprise was +250%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how AMN Healthcare performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Revenue- Nurse and allied solutions: $421.97 million versus the two-analyst average estimate of $377.25 million. The reported number represents a year-over-year change of +10.5%.Revenue- Technology and workforce solutions: $86.69 million compared to the $86.52 million average estimate based on two analysts. The reported number represents a change of -14.8% year over year.Revenue- Physician and leadership solutions: $164.58 million compared to the $162.39 million average estimate based on two analysts. The reported number represents a change of -5.7% year over year.Segment operating income- Nurse and allied solutions: $58.24 million compared to the $33.23 million average estimate based on two analysts.Segment operating income- Technology and workforce solutions: $24.62 million versus the two-analyst average estimate of $26.96 million.Segment operating income- Physician and leadership solutions: $11.05 million compared to the $12.52 million average estimate based on two analysts.View all Key Company Metrics for AMN Healthcare here>>>
Shares of AMN Healthcare have returned +2.2% over the past month versus the Zacks S&P 500 composite's +3.3% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
AMN Healthcare Services (AMN - Free Report) came out with quarterly earnings of $0.77 per share, beating the Zacks Consensus Estimate of $0.22 per share. This compares to earnings of $0.3 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of +250.00%. A quarter ago, it was expected that this health care staffing company would post earnings of $1.6 per share when it actually produced earnings of $2.1, delivering a surprise of +31.25%.
Over the last four quarters, the company has surpassed consensus EPS estimates three times.
AMN Healthcare, which belongs to the Zacks Business - Services industry, posted revenues of $673.24 million for the quarter ended June 2026, surpassing the Zacks Consensus Estimate by 7.55%. This compares to year-ago revenues of $658.17 million. The company has topped consensus revenue estimates four times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
AMN Healthcare shares have added about 108.1% since the beginning of the year versus the S&P 500's gain of 12.8%.
What's Next for AMN Healthcare?While AMN Healthcare has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for AMN Healthcare was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.14 on $619.11 million in revenues for the coming quarter and $2.70 on $3.25 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Business - Services is currently in the bottom 15% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
One other stock from the same industry, Bowman Consulting (BWMN - Free Report) , is yet to report results for the quarter ended June 2026. The results are expected to be released on August 10.
This professional services firm is expected to post quarterly earnings of $0.47 per share in its upcoming report, which represents a year-over-year change of -14.6%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
Bowman Consulting's revenues are expected to be $148.48 million, up 21.6% from the year-ago quarter.
Quarterly revenue of $673 million and adjusted EBITDA of $73 million;
GAAP income of $0.53/share and adjusted EPS of $0.77
, /PRNewswire/ -- AMN Healthcare Services, Inc. (NYSE: AMN), the leader and innovator in total talent solutions for healthcare organizations across the United States, today announced its second quarter 2026 financial results. Financial highlights are as follows:
Dollars in millions, except per share amounts.
Q2 2026
% Change Q2
2025
YTD June 30,
2026
% Change YTD
June 30, 2025
Revenue
$673.2
2 %
$2,051.6
52 %
Gross profit
$205.9
5 %
$574.7
46 %
Net income
$21.2
nm
$83.3
nm
GAAP diluted EPS
$0.53
nm
$2.11
nm
Adjusted diluted EPS*
$0.77
158 %
$2.86
280 %
Adjusted EBITDA*
$73.4
26 %
$239.5
96 %
* See "Non-GAAP Measures" below for a discussion of our use of non-GAAP items and the table entitled "Non-GAAP Reconciliation Tables" for a reconciliation of non-GAAP items.
Business Highlights
Second quarter revenue and earnings exceeded guidance, driven by travel nurse, allied, search and labor disruption. Travel nursing and allied volume and revenue grew year over year for the second consecutive quarter. Search revenue grew 27% year over year with particular strength in executive search and physician permanent placement. Recent acquisitions of Jaide Health and the ESSENTIAL Leadership Assessment expanded AMN's AI native language access solutions and leadership advisory capabilities, enabling AMN to deepen client relationships and support growth in higher-value, technology-enabled workforce solutions. Our quarter-end cash balance was $362 million, with a leverage ratio, calculated under the terms of our credit agreement, of 1.5x. "We are very pleased with how the AMN team executed for our healthcare professionals and clients in the second quarter," said Cary Grace, President and Chief Executive Officer of AMN Healthcare. "Our strong performance produced year-over-year revenue growth in our travel nurse, international nurse, allied, schools, and search solutions. We continue to deepen our relationships with our clients, as reflected in our solid MSP and search revenue growth. Overall demand growth improved through the quarter, and the trend improved in July, giving us momentum that is reflected in third quarter guidance."
Second Quarter 2026 Results
Consolidated revenue for the quarter was $673 million, a 2% increase from the prior year and a 51% decrease from the prior quarter. Net income was $21 million (3.1% of revenue), or $0.53 per diluted share, compared with a net loss of $116 million (17.7% of revenue), or ($3.02) per diluted share in the second quarter of 2025. Adjusted diluted EPS in the second quarter was $0.77 compared with $0.30 in the same quarter a year ago.
Revenue for the Nurse and Allied Solutions segment was $422 million, higher by 11% year over year and down 63% from the prior quarter, due to the large labor disruption events that occurred in the first quarter. Travel nurse staffing revenue was higher by 10% year over year and down 6% sequentially. Allied division revenue increased 8% year over year and 4% sequentially. Labor disruption contributed $25 million revenue in the quarter compared to $722 million in the prior quarter and $16 million in the year-ago quarter.
The Physician and Leadership Solutions segment reported revenue of $165 million, down 6% year over year and flat sequentially. Locum tenens revenue was $131 million, down 8% year over year and flat sequentially. Interim leadership revenue was down by 3% year over year and 4% lower sequentially. Our search businesses saw a revenue increase of 27% year over year and 20% sequentially.
Technology and Workforce Solutions segment revenue was $87 million, a decrease of 15% year over year and flat sequentially. Language services revenue was $70 million in the quarter, down 8% from the prior year and up 1% sequentially. Vendor management systems revenue was $15 million, 20% lower year over year and down 5% from the prior quarter.
Consolidated gross margin was 30.6%, 80 basis points higher year over year and up 380 basis points sequentially. Higher margin in the Nurse and Allied Solutions segment, driven by reserve releases and billing true-ups from large labor disruption events that we supported in the prior periods, drove the sequential improvement.
Consolidated SG&A expenses were $147 million, or 21.9% of revenue, compared with $155 million, or 23.5% of revenue, in the same quarter last year. SG&A was $218 million, or 15.8% of revenue, in the previous quarter. The year-over-year decrease in SG&A expenses was primarily due to a lower provision for expected credit losses and lower employee headcount. The sequential decrease in SG&A expenses was primarily driven by higher labor disruption expenses related to the multiple events we supported in the prior quarter.
Income from operations was $27 million with an operating margin of 4.0%, compared with a loss of ($124 million) and (18.8%), respectively, in the same quarter last year. Adjusted EBITDA was $73 million, a year-over-year increase of 26%. Adjusted EBITDA margin was 10.9%, 200 basis points higher than the year-ago period.
At June 30, 2026, cash and cash equivalents totaled $362 million. Cash flow from operations was ($190 million) for the second quarter and $373 million year to date. The cash balance and cash flow were reduced from the prior quarter by the return of client deposits related to labor disruption events in the first quarter. Remaining client deposits of $117 million will continue to be settled in the coming months. Capital expenditures were $9 million in the second quarter. The Company ended the quarter with total debt outstanding of $750 million with nothing drawn on our revolving credit facility.
Third Quarter 2026 Outlook
Metric
Guidance*
Consolidated revenue
$640 - $655 million
Gross margin
27.0% - 27.5%
SG&A as percentage of revenue
22.0% - 22.5%
Operating margin
0.2% - 0.8%
Adjusted EBITDA margin
6.5% - 7.0%
*Note: Guidance percentage metrics are approximate. For a reconciliation of adjusted EBITDA margin, see the table entitled "Reconciliation of Guidance Operating Margin to Guidance Adjusted EBITDA Margin" below.
Revenue in the third quarter of 2026 is expected to be 1-3% higher than the prior year. Nurse and Allied Solutions segment revenue is expected to be up 9-11% year over year. Physician and Leadership Solutions segment revenue is expected to be down 5-7% year over year. Technology and Workforce Solutions segment revenue is projected to be down 11-13% year over year.
Third quarter estimates for certain other financial items include depreciation of $13 million, depreciation in cost of revenue of $2.5 million, amortization expense of $16.5 million, share-based compensation expense of $7 million, integration and other expenses of $1.5 million, interest expense of $8 million, marginal adjusted tax rate of 28%, and 40.1 million diluted average shares outstanding.
Conference Call on August 6, 2026
AMN Healthcare Services, Inc. (NYSE: AMN) will host a conference call to discuss its second quarter 2026 financial results and third quarter 2026 outlook on Thursday, August 6, 2026 at 5:00 p.m. Eastern Time. A live webcast of the call can be accessed through AMN Healthcare's website at http://ir.amnhealthcare.com. Interested parties may participate live via telephone by registering at this link. Please follow the link and register with a valid e-mail address. After registering, the system will call you instantly and connect you into the conference call automatically.
Alternatively, you may dial in to the conference call by calling 1-646-357-8785 or 1-800-836-8184 and you will be connected to the call by an operator.
About AMN Healthcare
AMN Healthcare is the leader and innovator in total talent solutions for healthcare organizations across the United States. The Company provides access to the most comprehensive network of quality healthcare professionals through its innovative recruitment strategies and breadth of career opportunities. With insights and expertise, AMN Healthcare helps providers optimize their workforce to successfully reduce complexity, increase efficiency and improve patient outcomes. AMN total talent solutions include managed services programs, clinical and interim healthcare leaders, temporary staffing, direct hire and retained search solutions, vendor management systems, recruitment process outsourcing, predictive modeling, language interpretation services, revenue cycle solutions, credentialing, and other services. Clients include acute-care hospitals, community health centers and clinics, physician practice groups, retail and urgent care centers, home health facilities, schools, and many other healthcare settings. AMN Healthcare is committed to fostering and maintaining a diverse team that reflects the communities we serve. Our commitment to the inclusion of many different backgrounds, experiences and perspectives enables our innovation and leadership in the healthcare services industry.
The Company's common stock is listed on the New York Stock Exchange under the symbol "AMN." For more information about AMN Healthcare, visit www.amnhealthcare.com, where the Company posts news releases, investor presentations, webcasts, SEC filings and other material information. The Company also utilizes email alerts and Really Simple Syndication ("RSS") as routine channels to supplement distribution of this information. To register for email alerts and RSS, visit http://ir.amnhealthcare.com.
Non-GAAP Measures
This earnings release and the non-GAAP reconciliation tables included with the earnings release contain certain non-GAAP financial information, which the Company provides as additional information, and not as an alternative, to the Company's condensed consolidated financial statements presented in accordance with GAAP. These non-GAAP financial measures include (1) adjusted EBITDA, (2) adjusted EBITDA margin, (3) adjusted net income, and (4) adjusted diluted EPS. The Company provides such non-GAAP financial measures because management believes that they are useful to both management and investors as a supplement, and not as a substitute, when evaluating the Company's operating performance. Additionally, management believes that adjusted EBITDA, adjusted EBITDA margin, and adjusted diluted EPS serve as industry-wide financial measures. The Company uses adjusted EBITDA for making financial decisions, allocating resources and for determining certain incentive compensation objectives. The non-GAAP measures in this release are not in accordance with, or an alternative to, GAAP measures and may be different from non-GAAP measures, or may be calculated differently than other similarly titled non-GAAP measures, reported by other companies. They should not be used in isolation to evaluate the Company's performance. A reconciliation of non-GAAP measures identified in this release, along with further detail about the use and limitations of certain of these non-GAAP measures, may be found below in the table entitled "Non-GAAP Reconciliation Tables" under the caption entitled "Reconciliation of Non-GAAP Items" and the footnotes thereto or on the Company's website at https://ir.amnhealthcare.com/financials/quarterly-results. Additionally, from time to time, additional information regarding non-GAAP financial measures, including pro forma measures, may be made available on the Company's website.
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include, among others, statements concerning future demand and supply for healthcare, contingent staffing and other services, client preferences, momentum in international staffing and search, our ability to advance our technology-enabled workforce solutions, settlement of client deposits, third quarter 2026 financial projections for consolidated and segment revenue, consolidated gross margin, operating margin, SG&A as a percent of revenue, adjusted EBITDA margin, labor disruption revenue, depreciation expense, depreciation in cost of revenue, share-based compensation expense, non-cash amortization expense, integration and other expenses, interest expense, adjusted tax rate, and number of diluted shares outstanding. The Company bases these forward-looking statements on its current expectations, estimates and projections about future events and the industry in which it operates using information currently available to it. Actual results could differ materially from those discussed in, or implied by, these forward-looking statements. Forward-looking statements are also identified by words such as "believe," "project," "anticipate," "expect," "intend," "plan," "will," "may," "estimates," variations of such words and other similar expressions. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements.
The targets and expectations noted in this release depend upon, among other factors, (i) the ability of our clients to increase the efficiency and effectiveness of their staffing management and recruiting efforts, through predictive analytics, online recruiting, internal travel agencies and float pools, telemedicine or otherwise and successfully hire and retain permanent staff, (ii) the duration and extent to which hospitals and other healthcare entities adjust their utilization of temporary nurses and allied healthcare professionals, physicians, healthcare leaders and other healthcare professionals and workforce technology applications as a result of the labor market or economic conditions, (iii) the magnitude and duration of the effects of the post-COVID-19 pandemic environment or any future pandemic or health crisis on demand and supply trends, our business, its financial condition and our results of operations, (iv) our ability to effectively address client demand by attracting and placing nurses and other clinicians, (v) our ability to recruit and retain sufficient quality healthcare professionals at reasonable costs, (vi) our ability to anticipate and quickly respond to changing marketplace conditions, such as alternative modes of healthcare delivery, reimbursement, or client needs and requirements, including implementing changes that will make our services more tech-enabled and integrated, (vii) our ability to manage the pricing impact that the labor market or consolidation of healthcare delivery organizations may have on our business, (viii) the effects of economic downturns, inflation or slow recoveries, which could result in less demand for our services, increased client initiatives designed to contain costs, including reevaluating their approach as it pertains to contingent labor and managed services programs, other solutions and providers, pricing pressures and negatively impact payments terms and collectability of accounts receivable, (ix) our ability to develop and evolve our current technology offerings and capabilities and implement new infrastructure and technology systems to optimize our operating results and manage our business effectively, (x) our ability and the expense to comply with extensive and complex federal and state laws and regulations related to the conduct of our operations, costs and payment for services and payment for referrals as well as laws regarding employment practices, (xi) our ability to consummate and effectively incorporate acquisitions into our business, (xii) the negative effects that intermediary organizations may have on our ability to secure new and profitable contracts, (xiii) the extent to which the Great Resignation or a future spike in the COVID-19 pandemic or other pandemic or health crisis may disrupt our operations due to the unavailability of our employees or healthcare professionals due to burnout, illness, risk of illness, quarantines, travel restrictions, mandatory vaccination requirements, or other factors that limit our existing or potential workforce and pool of candidates, (xiv) security breaches and cybersecurity incidents, including ransomware, that could compromise our information and systems, which could adversely affect our business operations and reputation and could subject us to substantial liabilities and (xv) the severity and duration of the impact the labor market, economic downturn or any future pandemic or health crisis has on the financial condition and cash flow of many hospitals and healthcare systems such that it impairs their ability to make payments to us, timely or otherwise, for services rendered.
For a discussion of additional risk factors and a more complete discussion of some of the cautionary statements noted above that could cause actual results to differ from those implied by the forward-looking statements contained in this press release, please refer to our most recent Annual Report on Form 10-K for the year ended December 31, 2025. Be advised that developments subsequent to this press release are likely to cause these statements to become outdated and the Company is under no obligation (and expressly disclaims any such obligation) to update or revise any forward-looking statements whether as a result of new information, future events, or otherwise.
AMN Healthcare Services, Inc.
Condensed Consolidated Statements of Comprehensive Income (Loss)
(in thousands, except per share amounts)
(unaudited)
Three Months Ended
Six Months Ended
June 30,
March 31,
June 30,
2026
2025
2026
2026
2025
Revenue
$ 673,237
$ 658,175
$ 1,378,361
$ 2,051,598
$ 1,347,708
Cost of revenue
467,355
461,776
1,009,525
1,476,880
953,189
Gross profit
205,882
196,399
368,836
574,718
394,519
Gross margin
30.6 %
29.8 %
26.8 %
28.0 %
29.3 %
Operating expenses:
Selling, general and administrative
(SG&A)
147,391
154,584
218,425
365,816
302,315
SG&A as a % of revenue
21.9 %
23.5 %
15.8 %
17.8 %
22.4 %
Depreciation and amortization
(exclusive of depreciation included in
cost of revenue)
31,583
37,753
33,240
64,823
75,635
Goodwill impairment loss
—
109,515
—
—
109,515
Long-lived assets impairment loss
—
18,262
—
—
18,262
Total operating expenses
178,974
320,114
251,665
430,639
505,727
Income (loss) from operations
26,908
(123,715)
117,171
144,079
(111,208)
Operating margin (1)
4.0 %
(18.8) %
8.5 %
7.0 %
(8.3) %
Interest expense, net, and other
7,009
11,360
6,712
13,721
23,684
Income (loss) before income taxes
19,899
(135,075)
110,459
130,358
(134,892)
Income tax expense (benefit)
(1,261)
(18,873)
48,293
47,032
(17,598)
Net income (loss)
$ 21,160
$ (116,202)
$ 62,166
$ 83,326
$ (117,294)
Net income (loss) as a % of revenue
3.1 %
(17.7) %
4.5 %
4.1 %
(8.7) %
Other comprehensive income (loss):
Unrealized gains (losses) on
available-for-sale securities, net, and
other
(105)
145
(185)
(290)
206
Other comprehensive income (loss)
(105)
145
(185)
(290)
206
Comprehensive income (loss)
$ 21,055
$ (116,057)
$ 61,981
$ 83,036
$ (117,088)
Net income (loss) per common share:
Basic
$ 0.54
$ (3.02)
$ 1.60
$ 2.14
$ (3.06)
Diluted
$ 0.53
$ (3.02)
$ 1.59
$ 2.11
$ (3.06)
Weighted average common shares
outstanding:
Basic
39,021
38,414
38,902
38,962
38,363
Diluted
39,732
38,414
39,118
39,503
38,363
AMN Healthcare Services, Inc.
Condensed Consolidated Balance Sheets
(dollars in thousands)
(unaudited)
June 30, 2026
December 31,
2025
June 30, 2025
Assets
Current assets:
Cash and cash equivalents
$ 361,836
$ 33,972
$ 41,503
Accounts receivable, net
382,506
382,560
387,768
Accounts receivable, subcontractor
42,167
48,041
59,102
Prepaid and other current assets
82,746
80,803
82,978
Total current assets
869,255
545,376
571,351
Restricted cash, cash equivalents and investments
39,703
45,606
44,141
Fixed assets, net
117,344
136,361
158,215
Other assets
280,798
282,552
257,979
Assets held for sale
—
—
42,671
Deferred income taxes, net
47,784
44,877
59,537
Goodwill
758,999
755,809
755,809
Intangible assets, net
250,094
283,526
322,518
Total assets
$ 2,363,977
$ 2,094,107
$ 2,212,221
Liabilities and stockholders' equity
Current liabilities:
Accounts payable and accrued expenses
$ 193,212
$ 161,968
$ 175,623
Accrued compensation and benefits
325,028
298,837
274,631
Other current liabilities
252,249
116,809
123,389
Total current liabilities
770,489
577,614
573,643
Revolving credit facility
—
25,000
70,000
Notes payable, net
742,935
742,053
846,463
Liabilities held for sale
—
—
6,632
Other long-term liabilities
109,275
107,334
107,887
Total liabilities
1,622,699
1,452,001
1,604,625
Commitments and contingencies
Stockholders' equity:
741,278
642,106
607,596
Total liabilities and stockholders' equity
$ 2,363,977
$ 2,094,107
$ 2,212,221
AMN Healthcare Services, Inc.
Summary Condensed Consolidated Statements of Cash Flows
(dollars in thousands)
(unaudited)
Three Months Ended
Six Months Ended
June 30,
March 31,
June 30,
2026
2025
2026
2026
2025
Net cash provided by (used in) operating
activities
$ (189,930)
$ 78,548
$ 562,452
$ 372,522
$ 171,219
Net cash used in investing activities
(12,210)
(20,591)
(7,504)
(19,714)
(46,637)
Net cash used in financing activities
(2,365)
(80,226)
(27,135)
(29,500)
(141,437)
Net increase (decrease) in cash, cash
equivalents and restricted cash
(204,505)
(22,269)
527,813
323,308
(16,855)
Cash, cash equivalents and restricted cash at
beginning of period
594,984
94,719
67,171
67,171
89,305
Cash, cash equivalents and restricted cash at
end of period
$ 390,479
$ 72,450
$ 594,984
$ 390,479
$ 72,450
AMN Healthcare Services, Inc.
Non-GAAP Reconciliation Tables
(dollars in thousands, except per share data)
(unaudited)
Three Months Ended
Six Months Ended
June 30,
March 31,
June 30,
2026
2025
2026
2026
2025
Reconciliation of Non-GAAP Items:
Net income (loss)
$ 21,160
$ (116,202)
$ 62,166
$ 83,326
$ (117,294)
Income tax expense (benefit)
(1,261)
(18,873)
48,293
47,032
(17,598)
Income (loss) before income taxes
19,899
(135,075)
110,459
130,358
(134,892)
Interest expense, net, and other
7,009
11,360
6,712
13,721
23,684
Income (loss) from operations
26,908
(123,715)
117,171
144,079
(111,208)
Depreciation and amortization
31,583
37,753
33,240
64,823
75,635
Depreciation (included in cost of revenue) (2)
2,515
2,132
2,420
4,935
4,107
Goodwill impairment loss
—
109,515
—
—
109,515
Long-lived assets impairment loss
—
18,262
—
—
18,262
Share-based compensation
9,855
8,827
9,892
19,747
18,208
Acquisition, integration, and other costs (3)
2,496
5,515
3,402
5,898
7,970
Adjusted EBITDA (4)
$ 73,357
$ 58,289
$ 166,125
$ 239,482
$ 122,489
Adjusted EBITDA margin (5)
10.9 %
8.9 %
12.1 %
11.7 %
9.1 %
Net income (loss)
$ 21,160
$ (116,202)
$ 62,166
$ 83,326
$ (117,294)
Adjustments:
Amortization of intangible assets
17,500
19,608
17,945
35,445
39,035
Acquisition, integration, and other costs (3)
2,496
5,515
3,402
5,898
7,970
Goodwill impairment loss
—
109,515
—
—
109,515
Long-lived assets impairment loss
—
18,262
—
—
18,262
Tax effect on above adjustments
(5,199)
(26,011)
(5,550)
(10,749)
(31,700)
Tax effect of COLI fair value changes (6)
(5,354)
(2,779)
2,065
(3,289)
(2,076)
State tax audit reserve (7)
—
2,889
—
—
2,889
Tax deficiencies related to equity awards and ESPP (8)
65
764
2,151
2,216
2,287
Adjusted net income (9)
$ 30,668
$ 11,561
$ 82,179
$ 112,847
$ 28,888
GAAP diluted net income (loss) per share (EPS)
$ 0.53
$ (3.02)
$ 1.59
$ 2.11
$ (3.06)
Adjustments
0.24
3.32
0.51
0.75
3.81
Adjusted diluted EPS (10) (11)
$ 0.77
$ 0.30
$ 2.10
$ 2.86
$ 0.75
AMN Healthcare Services, Inc.
Supplemental Segment Financial and Operating Data
(dollars in thousands, except operating data)
(unaudited)
Three Months Ended
Six Months Ended
June 30,
March 31,
June 30,
2026
2025
2026
2026
2025
Revenue
Nurse and allied solutions
$ 421,968
$ 381,871
$ 1,127,342
$ 1,549,310
$ 795,132
Physician and leadership solutions
164,582
174,531
163,924
328,506
348,596
Technology and workforce solutions
86,687
101,773
87,095
173,782
203,980
$ 673,237
$ 658,175
$ 1,378,361
$ 2,051,598
$ 1,347,708
Segment operating income (12)
Nurse and allied solutions
$ 58,239
$ 28,483
$ 153,330
$ 211,569
$ 60,721
Physician and leadership solutions
11,046
13,486
10,818
21,864
27,948
Technology and workforce solutions
24,621
35,209
25,270
49,891
70,459
93,906
77,178
189,418
283,324
159,128
Unallocated corporate overhead (13)
20,549
18,889
23,293
43,842
36,639
Adjusted EBITDA (4)
$ 73,357
$ 58,289
$ 166,125
$ 239,482
$ 122,489
Gross Margin
Nurse and allied solutions
28.4 %
23.9 %
25.1 %
26.0 %
23.3 %
Physician and leadership solutions
26.5 %
28.2 %
26.1 %
26.3 %
27.7 %
Technology and workforce solutions
48.6 %
55.1 %
50.0 %
49.3 %
55.3 %
Operating Data:
Nurse and allied solutions
Average travelers on assignment (14)
9,194
8,700
9,227
9,211
8,841
Physician and leadership solutions
Days filled (15)
46,974
51,325
46,645
93,620
102,667
Revenue per day filled (16)
$ 2,784
$ 2,777
$ 2,812
$ 2,798
$ 2,760
As of June 30,
As of December 31,
2026
2025
2025
Leverage ratio (17)
1.5
3.3
3.3
AMN Healthcare Services, Inc.
Additional Supplemental Non-GAAP Disclosure
Reconciliation of Guidance Operating Margin to Guidance
Adjusted EBITDA Margin
(unaudited)
Three Months Ended
September 30, 2026
Low(18)
High(18)
Operating margin
0.2 %
0.8 %
Depreciation and amortization (total)
5.0 %
4.9 %
EBITDA margin
5.2 %
5.7 %
Share-based compensation
1.1 %
1.1 %
Integration and other costs
0.2 %
0.2 %
Adjusted EBITDA margin
6.5 %
7.0 %
(1)
Operating margin represents income (loss) from operations divided by revenue.
(2)
A portion of depreciation expense for AMN Language Services is included in cost of revenue. We exclude the impact of depreciation included in cost of revenue from the calculation of adjusted EBITDA.
(3)
Acquisition, integration, and other costs include acquisition and integration costs, net changes in the fair value of contingent consideration liabilities for recently acquired companies, certain legal expenses, restructuring expenses and other costs associated with exit or disposal activities, and certain nonrecurring expenses, which we exclude from the calculation of adjusted EBITDA, adjusted net income, and adjusted diluted EPS because we believe that these expenses are not indicative of the Company's operating performance. For the three and six months ended June 30, 2026, acquisition and integration costs were approximately $0.4 million and $1.3 million, respectively, and restructuring expenses and other costs associated with exit or disposal activities were approximately $2.0 million and $2.6 million, respectively. For six months ended June 30, 2026, certain legal expenses were approximately $1.0 million, expenses related to the closures of certain office leases were approximately $0.1 million, and other nonrecurring expenses were approximately $0.9 million. For the three and six months ended June 30, 2025, acquisition and integration costs were approximately $0.7 million and $1.0 million, respectively, certain legal expenses were approximately $3.2 million and $4.3 million, respectively, restructuring expenses and other costs associated with exit or disposal activities were approximately $0.3 million and $0.7 million, respectively, and other nonrecurring expenses were approximately $1.2 million and $1.6 million, respectively.
(4)
Adjusted EBITDA represents net income (loss) plus interest expense (net of interest income) and other, income tax expense (benefit), depreciation and amortization, depreciation (included in cost of revenue), goodwill impairment loss, long-lived assets impairment loss, share-based compensation, acquisition, integration, and other costs, restructuring expenses, and certain legal expenses. Management believes that adjusted EBITDA provides an effective measure of the Company's results, as it excludes certain items that management believes are not indicative of the Company's operating performance. Adjusted EBITDA is not intended to represent cash flows for the period, nor has it been presented as an alternative to income from operations or net income (loss) as an indicator of operating performance. Although management believes that some of the items excluded from adjusted EBITDA are not indicative of the Company's operating performance, these items do impact the statement of comprehensive income (loss), and management therefore utilizes adjusted EBITDA as an operating performance measure in conjunction with GAAP measures such as net income (loss).
(5)
Adjusted EBITDA margin represents adjusted EBITDA divided by revenue.
(6)
The Company records net tax expense (benefit) related to the income tax treatment of the fair value changes in the cash surrender value of its company owned life insurance ("COLI"). Since this change in fair value is unrelated to the Company's operating performance, we excluded the impact on adjusted net income and adjusted diluted EPS.
(7)
The Company recorded a reserve related to a state tax audit during the three and six months ended June 30, 2025. Since this reserve is largely unrelated to our loss before taxes and is unrepresentative of our normal effective tax rate, we excluded its impact in the calculation of adjusted net income and adjusted diluted EPS.
(8)
The consolidated effective tax rate is affected by the recording of tax benefits and tax deficiencies related to equity awards vested during the period and tax benefits recognized for disqualifying dispositions related to our employee stock purchase plan ("ESPP"). The magnitude of the impact of tax benefits and tax deficiencies generated in the future related to equity awards and ESPP is dependent upon the Company's future grants of share-based compensation, the Company's future stock price on the date equity awards vest in relation to the fair value of the awards on the grant date, the Company's future stock price on either the ESPP's offering date or purchase date, whichever is lower, and the length of time the shares issued under the ESPP are held by employees. Since these tax benefits and tax deficiencies related to equity awards and ESPP are largely unrelated to our income (loss) before income taxes and are unrepresentative of our normal effective tax rate, we excluded their impact in the calculation of adjusted net income and adjusted diluted EPS.
(9)
Adjusted net income represents GAAP net income (loss) excluding the impact of the (A) amortization of intangible assets, (B) acquisition, integration, and other costs, (C) goodwill impairment loss, (D) long-lived assets impairment loss, (E) tax effect, if any, of the foregoing adjustments, (F) net tax expense (benefit) related to the income tax treatment of fair value changes in the cash surrender value of its COLI, (G) tax deficiencies related to equity awards vested and ESPP, and (H) state tax audit reserve. Management included this non-GAAP measure to provide investors and prospective investors with an alternative method for assessing the Company's operating results in a manner that is focused on its operating performance and to provide a more consistent basis for comparison between periods. However, investors and prospective investors should note that this non-GAAP measure involves judgment by management (in particular, judgment as to what is classified as a special item to be excluded in the calculation of adjusted net income). Although management believes the items in the calculation of adjusted net income are not indicative of the Company's operating performance, these items do impact the statement of comprehensive income (loss), and management therefore utilizes adjusted net income as an operating performance measure in conjunction with GAAP measures such as GAAP net income (loss).
(10)
Adjusted diluted EPS represents adjusted net income divided by diluted weighted average common shares outstanding. Management included this non-GAAP measure to provide investors and prospective investors with an alternative method for assessing the Company's operating results in a manner that is focused on its operating performance and to provide a more consistent basis for comparison between periods. However, investors and prospective investors should note that this non-GAAP measure involves judgment by management (in particular, judgment as to what is classified as a special item to be excluded in the calculation of adjusted net income). Although management believes the items in the calculation of adjusted net income are not indicative of the Company's operating performance, these items do impact the statement of comprehensive income (loss), and management therefore utilizes adjusted diluted EPS as an operating performance measure in conjunction with GAAP measures such as GAAP diluted EPS.
(11)
As GAAP net loss is reported for the three and six months ended June 30, 2025, basic weighted average common shares outstanding was used to calculate GAAP diluted EPS for those periods because the dilutive potential common shares have an anti-dilutive effect (i.e., result in a lower loss per share). As adjusted net income is reported for the three and six months ended June 30, 2025, diluted weighted average common shares outstanding (including dilutive potential common shares) of 38,571 and 38,473, respectively, were used to calculate adjusted diluted EPS.
(12)
Segment operating income represents net income (loss) plus interest expense (net of interest income) and other, income tax expense (benefit), depreciation and amortization, depreciation (included in cost of revenue), unallocated corporate overhead, acquisition, integration, and other costs, legal settlement changes, share-based compensation, goodwill impairment loss and long-lived assets impairment loss.
(13)
Unallocated corporate overhead (as presented in the tables above) consists of unallocated corporate overhead (as reflected in our quarterly and annual financial statements filed with the SEC) less acquisition, integration, and other costs.
(14)
Average travelers on assignment represents the average number of nurse and allied healthcare professionals on assignment during the period presented.
(15)
Days filled is calculated by dividing the locum tenens hours filled during the period by eight hours.
(16)
Revenue per day filled represents revenue of the Company's locum tenens business divided by days filled for the period presented.
(17)
Leverage ratio represents the ratio of the consolidated funded indebtedness (as calculated per the Company's credit agreement) at the end of the subject period to the consolidated adjusted EBITDA (as calculated per the Company's credit agreement) for the twelve-month period ended at the end of the subject period.
Arrowstreet Capital Limited Partnership grew its holdings in shares of AMN Healthcare Services Inc (NYSE:AMN – Free Report) by 1,278.0% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,401,725 shares of the company’s stock after purchasing an additional 1,300,005 shares during the quarter. Arrowstreet Capital Limited Partnership owned approximately 3.61% of AMN Healthcare Services worth $25,708,000 at the end of the most recent reporting period.
A number of other hedge funds also recently made changes to their positions in the business. Summit Securities Group LLC bought a new position in AMN Healthcare Services during the fourth quarter valued at about $32,000. China Universal Asset Management Co. Ltd. grew its position in shares of AMN Healthcare Services by 200.0% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 3,000 shares of the company’s stock valued at $47,000 after acquiring an additional 2,000 shares during the period. Tower Research Capital LLC TRC grew its position in shares of AMN Healthcare Services by 49.2% during the 2nd quarter. Tower Research Capital LLC TRC now owns 3,093 shares of the company’s stock valued at $64,000 after acquiring an additional 1,020 shares during the period. Johnson Financial Group Inc. purchased a new stake in shares of AMN Healthcare Services during the 3rd quarter worth approximately $63,000. Finally, Strs Ohio purchased a new stake in shares of AMN Healthcare Services during the 1st quarter worth approximately $95,000. 99.23% of the stock is currently owned by institutional investors.
Insider Transactions at AMN Healthcare Services In other AMN Healthcare Services news, Director Mark G. Foletta sold 3,681 shares of the business’s stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $31.07, for a total value of $114,368.67. Following the completion of the transaction, the director owned 17,917 shares of the company’s stock, valued at $556,681.19. The trade was a 17.04% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 1.07% of the stock is currently owned by insiders.
AMN Healthcare Services Stock Performance NYSE:AMN opened at $34.41 on Thursday. The stock has a market cap of $1.33 billion, a P/E ratio of -39.56, a PEG ratio of 0.80 and a beta of 0.41. The company has a quick ratio of 1.09, a current ratio of 1.09 and a debt-to-equity ratio of 1.04. The business’s 50-day moving average price is $31.68 and its two-hundred day moving average price is $24.35. AMN Healthcare Services Inc has a twelve month low of $14.86 and a twelve month high of $36.27.
AMN Healthcare Services (NYSE:AMN – Get Free Report) last issued its quarterly earnings data on Thursday, May 7th. The company reported $2.10 EPS for the quarter, topping the consensus estimate of $1.60 by $0.50. The company had revenue of $1.38 billion during the quarter, compared to analyst estimates of $1.23 billion. AMN Healthcare Services had a positive return on equity of 18.01% and a negative net margin of 0.95%.AMN Healthcare Services’s revenue was up 99.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.45 earnings per share. As a group, equities analysts predict that AMN Healthcare Services Inc will post 2.7 EPS for the current fiscal year.
Analysts Set New Price Targets Several equities research analysts have commented on AMN shares. UBS Group upped their price objective on shares of AMN Healthcare Services from $19.50 to $32.00 and gave the company a “neutral” rating in a report on Wednesday, May 13th. Citizens Jmp reiterated a “market outperform” rating and issued a $36.00 target price on shares of AMN Healthcare Services in a research note on Tuesday, June 23rd. Robert W. Baird boosted their price target on shares of AMN Healthcare Services from $23.00 to $26.00 and gave the company a “neutral” rating in a research report on Monday, May 11th. Weiss Ratings upgraded AMN Healthcare Services from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, June 17th. Finally, Wall Street Zen raised AMN Healthcare Services from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 16th. Four equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $29.00.
Read Our Latest Report on AMN
AMN Healthcare Services Company Profile (Free Report)
AMN Healthcare Services, Inc (NYSE: AMN) is a leading provider of healthcare workforce solutions in the United States. The company specializes in staffing and recruitment services for a broad range of clinical and allied health professionals, including travel nurses, permanent placement of nursing staff, locum tenens physicians, and allied health personnel. In addition to direct staffing, AMN Healthcare offers comprehensive workforce management solutions such as vendor management systems (VMS), recruitment process outsourcing (RPO), and compliance and credentialing services through its technology platforms.
Founded in 1985 as American Mobile Nurses, the company rebranded to AMN Healthcare in 2010 to reflect its expanding portfolio of services.
Further Reading Five stocks we like better than AMN Healthcare Services Why SK hynix Could Be the Best AI Chip Stock to Buy Now Seagate Technology Stock Surges as Earnings Beat Silences AI Doubters Alphabet Is Down 18% From Its High After a Stellar Quarter—Overdone, or More Downside Ahead? Why Bloom Energy May Be the Most Important AI Infrastructure Stock
Receive News & Ratings for AMN Healthcare Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMN Healthcare Services and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEArkadios Wealth Advisors Purchases 5,088 Shares of Tesla, Inc. $TSLA
NEXT HEADLINE »Ashton Thomas Securities LLC Buys New Shares in iShares S&P 500 Value ETF $IVE
Investors interested in Business - Services stocks are likely familiar with AMN Healthcare Services (AMN) and Rentokil Initial PLC (RTO). But which of these two stocks presents investors with the better value opportunity right now?
For those looking to find strong Business Services stocks, it is prudent to search for companies in the group that are outperforming their peers. AMN Healthcare Services (AMN - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the stock's year-to-date performance to find out.
AMN Healthcare Services is a member of our Business Services group, which includes 246 different companies and currently sits at #9 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. AMN Healthcare Services is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for AMN's full-year earnings has moved 40.1% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Based on the most recent data, AMN has returned 112.3% so far this year. At the same time, Business Services stocks have lost an average of 8.1%. This shows that AMN Healthcare Services is outperforming its peers so far this year.
Another stock in the Business Services sector, Dave Inc. (DAVE - Free Report) , has outperformed the sector so far this year. The stock's year-to-date return is 83.2%.
Over the past three months, Dave Inc.'s consensus EPS estimate for the current year has increased 22%. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, AMN Healthcare Services belongs to the Business - Services industry, a group that includes 20 individual stocks and currently sits at #183 in the Zacks Industry Rank. Stocks in this group have lost about 11.9% so far this year, so AMN is performing better this group in terms of year-to-date returns.
In contrast, Dave Inc. falls under the Technology Services industry. Currently, this industry has 121 stocks and is ranked #144. Since the beginning of the year, the industry has moved -7.5%.
Going forward, investors interested in Business Services stocks should continue to pay close attention to AMN Healthcare Services and Dave Inc. as they could maintain their solid performance.
For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.
Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.
It also includes access to the Zacks Style Scores.
What are the Zacks Style Scores? Developed alongside the Zacks Rank, the Zacks Style Scores are a group of complementary indicators that help investors pick stocks with the best chances of beating the market over the next 30 days.
Each stock is assigned a rating of A, B, C, D, or F based on their value, growth, and momentum characteristics. Just like in school, an A is better than a B, a B is better than a C, and so on -- that means the better the score, the better chance the stock will outperform.
The Style Scores are broken down into four categories:
Value ScoreFinding good stocks at good prices, and discovering which companies are trading under their true value, are what value investors like to focus on. So, the Value Style Score takes into account ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to highlight the most attractive and discounted stocks.
Growth ScoreGrowth investors, on the other hand, are more concerned with a company's financial strength and health, and its future outlook. The Growth Style Score examines things like projected and historic earnings, sales, and cash flow to find stocks that will experience sustainable growth over time.
Momentum ScoreMomentum investors, who live by the saying "the trend is your friend," are most interested in taking advantage of upward or downward trends in a stock's price or earnings outlook. Utilizing one-week price change and the monthly percentage change in earnings estimates, among other factors, the Momentum Style Score can help determine favorable times to buy high-momentum stocks.
VGM ScoreIf you want a combination of all three Style Scores, then the VGM Score will be your friend. It rates each stock on their combined weighted styles, helping you find the companies with the most attractive value, best growth forecast, and most promising momentum. It's also one of the best indicators to use with the Zacks Rank.
How Style Scores Work with the Zacks Rank A proprietary stock-rating model, the Zacks Rank utilizes the power of earnings estimate revisions, or changes to a company's earnings outlook, to help investors create a successful portfolio.
It's highly successful, with #1 (Strong Buy) stocks producing an unmatched +23.94% average annual return since 1988. That's more than double the S&P 500. But because of the large number of stocks we rate, there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.
But it can feel overwhelming to pick the right stocks for you and your investing goals with over 800 top-rated stocks to choose from.
That's where the Style Scores come in.
To maximize your returns, you want to buy stocks with the highest probability of success. This means picking stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you find yourself looking at stocks with a #3 (Hold) rank, make sure they have Scores of A or B as well to ensure as much upside potential as possible.
As mentioned above, the Scores are designed to work with the Zacks Rank, so any change to a company's earnings outlook should be a deciding factor when picking which stocks to buy.
Here's an example: a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one with Style Scores of A and B, still has a downward-trending earnings outlook, and a bigger chance its share price will decrease too.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: AMN Healthcare Services (AMN - Free Report) AMN Healthcare Services, Inc. (AMN - Free Report) , operating from Dallas, TX, is a travel healthcare staffing company. Its business has evolved beyond traditional healthcare staffing and recruitment services, thereby becoming a strategic total talent solutions partner with its clients. It has expanded its portfolio to serve a diverse and growing set of healthcare talent-related needs. In addition to its healthcare professional staffing and recruitment services, AMN’s suite of healthcare workforce solutions includes MSP, vendor management systems (VMS), medical language interpretation services, predictive labor analytics, workforce optimization technology and consulting, recruitment process outsourcing (RPO), revenue cycle solutions, credentialing services and virtual care management services. AMN enables its clients to build, manage and optimize their healthcare talent to deliver improved patient outcomes and experience. It continues to enhance its platform with technology-enabled solutions, including digital workforce platforms, automation tools and AI-driven capabilities to improve speed, efficiency and clinician engagement.
AMN is a #3 (Hold) on the Zacks Rank, with a VGM Score of A.
Momentum investors should take note of this Business Services stock. AMN has a Momentum Style Score of B, and shares are up 0.4% over the past four weeks.
One analyst revised their earnings estimate upwards in the last 60 days for fiscal 2026. The Zacks Consensus Estimate has increased $0.17 to $2.70 per share. AMN boasts an average earnings surprise of +53.3%.
With a solid Zacks Rank and top-tier Momentum and VGM Style Scores, AMN should be on investors' short list.
It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.
The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.
Zacks Premium also includes the Zacks Style Scores.
What are the Zacks Style Scores? Developed alongside the Zacks Rank, the Zacks Style Scores are a group of complementary indicators that help investors pick stocks with the best chances of beating the market over the next 30 days.
Each stock is given an alphabetic rating of A, B, C, D or F based on their value, growth, and momentum qualities. With this system, an A is better than a B, a B is better than a C, and so on, meaning the better the score, the better chance the stock will outperform.
The Style Scores are broken down into four categories:
Value ScoreValue investors love finding good stocks at good prices, especially before the broader market catches on to a stock's true value. Utilizing ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and many other multiples, the Value Style Score identifies the most attractive and most discounted stocks.
Growth ScoreWhile good value is important, growth investors are more focused on a company's financial strength and health, and its future outlook. The Growth Style Score takes projected and historic earnings, sales, and cash flow into account to uncover stocks that will see long-term, sustainable growth.
Momentum ScoreMomentum investors, who live by the saying "the trend is your friend," are most interested in taking advantage of upward or downward trends in a stock's price or earnings outlook. Utilizing one-week price change and the monthly percentage change in earnings estimates, among other factors, the Momentum Style Score can help determine favorable times to buy high-momentum stocks.
VGM ScoreIf you like to use all three kinds of investing, then the VGM Score is for you. It's a combination of all Style Scores, and is an important indicator to use with the Zacks Rank. The VGM Score rates each stock on their shared weighted styles, narrowing down the companies with the most attractive value, best growth forecast, and most promising momentum.
How Style Scores Work with the Zacks Rank The Zacks Rank is a proprietary stock-rating model that harnesses the power of earnings estimate revisions, or changes to a company's earnings expectations, to help investors build a successful portfolio.
Investors can count on the Zacks Rank's success, with #1 (Strong Buy) stocks producing an unmatched +23.94% average annual return since 1988, more than double the S&P 500's performance. But the model rates a large number of stocks, and there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.
With more than 800 top-rated stocks to choose from, it can certainly feel overwhelming to pick the ones that are right for you and your investing journey.
That's where the Style Scores come in.
You want to make sure you're buying stocks with the highest likelihood of success, and to do that, you'll need to pick stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you like a stock that only has a #3 (Hold) rank, it should also have Scores of A or B to guarantee as much upside potential as possible.
The direction of a stock's earnings estimate revisions should always be a key factor when choosing which stocks to buy, since the Scores were created to work together with the Zacks Rank.
Here's an example: a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one with Style Scores of A and B, still has a downward-trending earnings outlook, and a bigger chance its share price will decrease too.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: AMN Healthcare Services (AMN - Free Report) AMN Healthcare Services, Inc. (AMN - Free Report) , operating from Dallas, TX, is a travel healthcare staffing company. Its business has evolved beyond traditional healthcare staffing and recruitment services, thereby becoming a strategic total talent solutions partner with its clients. It has expanded its portfolio to serve a diverse and growing set of healthcare talent-related needs. In addition to its healthcare professional staffing and recruitment services, AMN’s suite of healthcare workforce solutions includes MSP, vendor management systems (VMS), medical language interpretation services, predictive labor analytics, workforce optimization technology and consulting, recruitment process outsourcing (RPO), revenue cycle solutions, credentialing services and virtual care management services. AMN enables its clients to build, manage and optimize their healthcare talent to deliver improved patient outcomes and experience. It continues to enhance its platform with technology-enabled solutions, including digital workforce platforms, automation tools and AI-driven capabilities to improve speed, efficiency and clinician engagement.
AMN is a #3 (Hold) on the Zacks Rank, with a VGM Score of A.
It also boasts a Value Style Score of A thanks to attractive valuation metrics like a forward P/E ratio of 12.25; value investors should take notice.
For fiscal 2026, one analyst revised their earnings estimate upwards in the last 60 days, and the Zacks Consensus Estimate has increased $0.17 to $2.70 per share. AMN boasts an average earnings surprise of +53.3%.
With a solid Zacks Rank and top-tier Value and VGM Style Scores, AMN should be on investors' short list.
DALLAS, July 21, 2026 (GLOBE NEWSWIRE) -- As demand for orthodontic care continues to rise—valued at approximately $22 billion in 2025 and projected to reach $26.9 billion by 2030—and Smile Doctors expands its national footprint, the organization today announced the appointment of Jeff Knudson as chief financial officer. An accomplished healthcare and multisite finance executive, Knudson will lead the company’s financial strategy and finance organization.
As the company continues to expand its network of affiliated practices, invest in new locations and technology, and meet rising demand from patients, he will help ensure the business is well positioned to deliver on its growth objectives while maintaining its commitment to supporting doctors, practice teams and exceptional patient care.
"Jeff brings the strategic perspective we need to lead the business through its next phase," said J. Hedrick, chief executive officer of Smile Doctors. "He has a proven ability to build strong financial organizations, guide complex healthcare companies and turn growth opportunities into long-term value. His leadership will be critical as we continue expanding our platform, investing in our affiliated practices and strengthening the foundation for what comes next."
Knudson brings more than a decade of experience as a chief financial officer, with a career focused on helping multi-site organizations build the financial discipline and operational capabilities needed to scale successfully. Most recently, he served as CFO of National Veterinary Associates Group. Previously, he was CFO of publicly traded AMN Healthcare Services, Inc. (NYSE: AMN) and At Home Group and held senior finance leadership roles at CVS Health, L Brands, Express Scripts and PwC.
"Healthcare organizations have an opportunity to grow in ways that strengthen—not dilute—the patient experience," said Knudson. "The finance function plays an important role in making that possible by helping organizations invest thoughtfully, allocate capital responsibly and build the capabilities that allow doctors and care teams to focus on what matters most: delivering exceptional care for every patient. I'm excited to join Smile Doctors at such an important point in its journey and help support the company's continued momentum."
Smile Doctors currently supports 591 affiliated locations across 36 states and expects to surpass 600 locations before the end of 2026. During the first half of the year, the organization delivered double-digit revenue growth, driven by strong same-store performance, new orthodontist affiliations, seven de novo practice openings and increasing adult demand through Smile Express® powered by Invisalign®. To support continued expansion, Smile Doctors also secured an additional $125 million in growth capital during the second quarter and expects to open 18 additional locations over the next 12 months.
To learn more about Smile Doctors, visit www.smiledoctors.com.
About Smile Doctors
Smile Doctors LLC, is the largest ortho-focused support organization (OSO) in the U.S. As the fastest-growing network of leading orthodontists with 591 convenient locations in 36 states, Smile Doctors has a rich history of developing and growing affiliated practices by providing tools and technology that allow orthodontists to focus entirely on patient care. Smile Doctors supports the largest network of Diamond Plus Invisalign® providers and its affiliated orthodontists are proud members of the American Association of Orthodontists, American Dental Association, and host for the Lecture Center for Orthodontic Excellence. Smile Doctors' mission is to create confident smiles that inspire the best in patients, each other, and the communities they serve. For more information, please visit: www.smiledoctors.com.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/0ebe59fd-6757-432e-a0bb-7f3eda95e4d2
Jeff Knudson Jeff Knudson Joins Smile Doctors as CFO
For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.
The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.
Zacks Premium also includes the Zacks Style Scores.
What are the Zacks Style Scores? Developed alongside the Zacks Rank, the Zacks Style Scores are a group of complementary indicators that help investors pick stocks with the best chances of beating the market over the next 30 days.
Based on their value, growth, and momentum characteristics, each stock is assigned a rating of A, B, C, D, or F. The better the score, the better chance the stock will outperform; an A is better than a B, a B is better than a C, and so on.
The Style Scores are broken down into four categories:
Value ScoreFinding good stocks at good prices, and discovering which companies are trading under their true value, are what value investors like to focus on. So, the Value Style Score takes into account ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to highlight the most attractive and discounted stocks.
Growth ScoreGrowth investors, on the other hand, are more concerned with a company's financial strength and health, and its future outlook. The Growth Style Score examines things like projected and historic earnings, sales, and cash flow to find stocks that will experience sustainable growth over time.
Momentum ScoreMomentum traders and investors live by the saying "the trend is your friend." This investing style is all about taking advantage of upward or downward trends in a stock's price or earnings outlook. Employing factors like one-week price change and the monthly percentage change in earnings estimates, the Momentum Style Score can indicate favorable times to build a position in high-momentum stocks.
VGM ScoreIf you want a combination of all three Style Scores, then the VGM Score will be your friend. It rates each stock on their combined weighted styles, helping you find the companies with the most attractive value, best growth forecast, and most promising momentum. It's also one of the best indicators to use with the Zacks Rank.
How Style Scores Work with the Zacks Rank The Zacks Rank is a proprietary stock-rating model that harnesses the power of earnings estimate revisions, or changes to a company's earnings expectations, to help investors build a successful portfolio.
It's highly successful, with #1 (Strong Buy) stocks producing an unmatched +23.94% average annual return since 1988. That's more than double the S&P 500. But because of the large number of stocks we rate, there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.
With more than 800 top-rated stocks to choose from, it can certainly feel overwhelming to pick the ones that are right for you and your investing journey.
That's where the Style Scores come in.
To maximize your returns, you want to buy stocks with the highest probability of success. This means picking stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you find yourself looking at stocks with a #3 (Hold) rank, make sure they have Scores of A or B as well to ensure as much upside potential as possible.
As mentioned above, the Scores are designed to work with the Zacks Rank, so any change to a company's earnings outlook should be a deciding factor when picking which stocks to buy.
A stock with a #4 (Sell) or #5 (Strong Sell) rating, for instance, even one with Scores of A and B, will still have a declining earnings forecast, and a greater chance its share price will fall too.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: AMN Healthcare Services (AMN - Free Report) AMN Healthcare Services, Inc. (AMN - Free Report) , operating from Dallas, TX, is a travel healthcare staffing company. Its business has evolved beyond traditional healthcare staffing and recruitment services, thereby becoming a strategic total talent solutions partner with its clients. It has expanded its portfolio to serve a diverse and growing set of healthcare talent-related needs. In addition to its healthcare professional staffing and recruitment services, AMN’s suite of healthcare workforce solutions includes MSP, vendor management systems (VMS), medical language interpretation services, predictive labor analytics, workforce optimization technology and consulting, recruitment process outsourcing (RPO), revenue cycle solutions, credentialing services and virtual care management services. AMN enables its clients to build, manage and optimize their healthcare talent to deliver improved patient outcomes and experience. It continues to enhance its platform with technology-enabled solutions, including digital workforce platforms, automation tools and AI-driven capabilities to improve speed, efficiency and clinician engagement.
AMN is a #3 (Hold) on the Zacks Rank, with a VGM Score of A.
Momentum investors should take note of this Business Services stock. AMN has a Momentum Style Score of A, and shares are up 2.4% over the past four weeks.
One analyst revised their earnings estimate upwards in the last 60 days for fiscal 2026. The Zacks Consensus Estimate has increased $0.17 to $2.70 per share. AMN boasts an average earnings surprise of +53.3%.
With a solid Zacks Rank and top-tier Momentum and VGM Style Scores, AMN should be on investors' short list.
, /PRNewswire/ -- AMN Healthcare Services, Inc. (NYSE: AMN), has scheduled a conference call to discuss its second quarter 2026 financial results and third quarter 2026 outlook on Thursday, August 6, 2026, at 5:00 p.m. Eastern Time. On the same day, the Company also expects to issue an earnings news release after market close at approximately 4:15 p.m. Eastern Time.
A live webcast of the call can be accessed through this webcast link, which also will be available on AMN Healthcare's investor relations website. Interested parties may participate live via telephone by registering at this conference call link. Please follow the link and register with a valid e-mail address. After registering, the system will call you instantly and connect you into the conference call automatically.
Alternatively, you may dial in to the conference call by calling 1-646-357-8785 or 1-800-836-8184 and you will be connected to the call by an operator.
Following the conclusion of the call, a replay of the webcast will be available at the Company's investor relations website, http://ir.amnhealthcare.com.
About AMN Healthcare
AMN Healthcare is the leader and innovator in total talent solutions for healthcare, bringing together the people, processes and technology to deliver better care. Through a steadfast partnership approach, we solve the most pressing workforce challenges to enable better clinical outcomes and access to care. In 2025, our healthcare professionals reached more than 13 million patients at more than 2,300 healthcare systems, including 93 percent of the top healthcare systems nationwide. We provide a comprehensive network of quality healthcare professionals and deliver a fully integrated and customizable suite of workforce technologies. For more information, visit www.amnhealthcare.com.
The Company's common stock is listed under the symbol "AMN" on the New York Stock Exchange. For more information about AMN Healthcare, visit www.amnhealthcare.com, where the Company posts news releases, investor presentations, webcasts, SEC filings and other material information. The Company also utilizes email alerts and Really Simple Syndication ("RSS") as routine channels to supplement the distribution of this information. To register for email alerts and RSS, visit http://ir.amnhealthcare.com.
Contact:
Randle Reece
Vice President, Investor Relations and Strategy
866-861-3229
Web site: http://www.amnhealthcare.com
Key Takeaways AMN Healthcare is poised for growth with its broad services, MSP momentum and demand from labor disruptions.AI tools in WorkWise and AMN Passport are boosting recruiting, engagement and workforce planning.Soft staffing markets, client concentration and regulatory challenges could pressure AMN's growth. AMN Healthcare Services, Inc. (AMN - Free Report) is well-poised for growth in the coming quarters, courtesy of its broad array of services. The optimism is led by strong momentum in its Managed Services Program (MSP), rising labor disruption demand and investments in technology and AI-driven platforms. However, industry shifts, pricing pressure and healthcare cost-consciousness are major downsides.
Shares of this Zacks Rank #3 (Hold) company have jumped 126.9% in the year-to-date period against the industry's 14.6% decline. However, the S&P 500 Index has risen 10.3% in the said timeframe.
This renowned player in the healthcare total talent services space has a market capitalization of $1.35 billion. The company projects 98.5% of earnings growth for 2026 and expects to witness continued improvements in its business. AMN Healthcare surpassed the Zacks Consensus Estimate in all the trailing four quarters, delivering an average earnings surprise of 53.25%.
Image Source: Zacks Investment Research
Factors Favoring AMN StockHealthcare Workforce Solutions Strengthening Client Relationships: AMN Healthcare is benefiting from a shift in healthcare providers' workforce priorities. During the first-quarter 2026 earnings call, management noted that hospitals are no longer primarily focused on reducing contract labor usage. They are seeking long-term workforce optimization through predictive analytics, technology-enabled staffing and total talent management. The company strengthened its MSP business by adding a new Locum MSP client, and renewing and expanding its largest Locums contract. These developments, combined with deeper client relationships built during recent labor disruption events, position AMN to capture additional market share as healthcare organizations increasingly prefer strategic workforce partners over traditional staffing vendors.
AI and Technology Investments Driving Operational Efficiency: AMN continues to leverage artificial intelligence and digital tools to improve recruiting efficiency, clinician engagement and workforce management. The company introduced new AI-powered capabilities within its WorkWise platform, including automated candidate scoring, enhanced job search functionality and AI-assisted job description creation. Its AI recruiter helped deploy more than 10,000 clinicians during the quarter, while the AMN Passport mobile app recorded more than 30% growth in users and over 50% growth in monthly active users.
The company recently partnered with Brightfield to enhance its workforce intelligence capabilities. Brightfield's Talent Data Exchange (TDX) complements AMN's proprietary workforce insights, improving market transparency and labor planning. The partnership also enhances AMN's WorkWise ecosystem with stronger decision-support capabilities.
These technology investments are improving hiring speed, strengthening clinician engagement and enhancing workforce planning capabilities, supporting management's long-term goal of expanding revenue while improving operating leverage.
Improving Core Business Momentum and Financial Strength: Beyond the temporary boost from labor disruption events, AMN Healthcare's underlying businesses showed encouraging signs of recovery. Excluding labor disruption assignments, Nurse and Allied Solutions returned to year-over-year traveler volume growth for the first time since 2022, while international staffing posted its first year-over-year revenue increase since late 2023. Leadership search also returned to growth, reflecting improving demand across multiple service lines. With improving demand trends, disciplined capital management and management targeting sustainable revenue growth alongside faster adjusted EBITDA expansion, the company appears well positioned for long-term growth.
Downsides of AMN StockSoftness in Key Staffing Markets: Although AMN's Nurse and Allied business is showing signs of recovery, some of its core staffing markets remain under pressure. During first-quarter 2026, management noted that physician staffing demand remains soft, with many Locums clients focusing on centralized program management and hiring permanent physicians. Demand has also shifted toward the more competitive third-party channel, where fill rates are lower and pricing pressure is higher. At the same time, healthcare systems are investing in internal recruiting capabilities, workforce analytics and AI-powered staffing tools, which could reduce reliance on external staffing providers over time.
Client Concentration and Industry Consolidation Risks: Consolidation among healthcare providers continues to strengthen customers' bargaining power, allowing them to negotiate lower staffing rates and centralize workforce management. Mergers may also result in the loss of contracts if the combined organizations choose existing vendors. AMN Healthcare derives approximately 22% of its consolidated revenues from Kaiser Foundation Hospitals, making the company dependent on a single large customer. As healthcare organizations use vendor management systems and group purchasing organizations, pricing pressure and customer concentration could weigh on future revenue growth and margins.
Regulatory and Competitive Challenges: AMN operates in a highly regulated and competitive healthcare staffing industry. Changes in Medicare and Medicaid reimbursement, workforce regulations, immigration policies and evolving rules surrounding AI, cybersecurity and data privacy could increase compliance costs and influence customer hiring decisions. The company also faces competition from large national staffing firms, specialized healthcare recruiters and technology-driven workforce providers. As hospitals continue expanding in-house staffing programs and adopting AI-enabled workforce management solutions, AMN Healthcare must invest in technology and service innovation to protect its competitive position.
Estimate TrendAMN Healthcare has been witnessing a positive estimate revision trend for 2026. Over the past 60 days, the Zacks Consensus Estimate for its earnings per share has improved 40% to $2.70.
The Zacks Consensus Estimate for second-quarter 2026 revenues and earnings per share is pegged at $626 million and 22 cents, respectively, suggesting 4.9% and 26.7% declines from the year-ago reported numbers.
Key PicksSome better-ranked stocks from the broader medical space are West Pharmaceutical (WST - Free Report) , Intuitive Surgical (ISRG - Free Report) and Pacific Biosciences of California (PACB - Free Report) .
West Pharmaceutical, carrying a Zacks Rank #2 (Buy) at present, reported first-quarter 2026 EPS of $2.13, which beat the Zacks Consensus Estimate by 26.8%. Revenues of $844.9 million surpassed the Zacks Consensus Estimate by 8.5%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
West Pharmaceutical has an estimated long-term earnings growth rate of 13.9%. WST’s earnings surpassed estimates in the trailing four quarters, the average surprise being 19.4%.
Intuitive Surgical, carrying a Zacks Rank #2 at present, reported first-quarter 2026 core earnings per share of 85 cents, which missed the Zacks Consensus Estimate by 20.2%. Revenues of $2.77 billion surpassed the Zacks Consensus Estimate by 6.2%.
Intuitive Surgical has a long-term estimated growth rate of 14.3%. ISRG’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%.
Pacific Biosciences of California, carrying a Zacks Rank #2 at present, reported a first-quarter 2026 adjusted loss per share of 12 cents, which came narrower than the Zacks Consensus Estimate by 29.4%. Revenues of $37.2 million missed the Zacks Consensus Estimate by 9.3%.
Pacific Biosciences of California has an estimated earnings growth rate of 22.6% for 2026. PACB’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 29.8%.
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.
The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.
Zacks Premium also includes the Zacks Style Scores.
What are the Zacks Style Scores? The Zacks Style Scores is a unique set of guidelines that rates stocks based on three popular investing types, and were developed as complementary indicators for the Zacks Rank. This combination helps investors choose securities with the highest chances of beating the market over the next 30 days.
Each stock is assigned a rating of A, B, C, D, or F based on their value, growth, and momentum characteristics. Just like in school, an A is better than a B, a B is better than a C, and so on -- that means the better the score, the better chance the stock will outperform.
The Style Scores are broken down into four categories:
Value ScoreFinding good stocks at good prices, and discovering which companies are trading under their true value, are what value investors like to focus on. So, the Value Style Score takes into account ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to highlight the most attractive and discounted stocks.
Growth ScoreGrowth investors, on the other hand, are more concerned with a company's financial strength and health, and its future outlook. The Growth Style Score examines things like projected and historic earnings, sales, and cash flow to find stocks that will experience sustainable growth over time.
Momentum ScoreMomentum investors, who live by the saying "the trend is your friend," are most interested in taking advantage of upward or downward trends in a stock's price or earnings outlook. Utilizing one-week price change and the monthly percentage change in earnings estimates, among other factors, the Momentum Style Score can help determine favorable times to buy high-momentum stocks.
VGM ScoreIf you want a combination of all three Style Scores, then the VGM Score will be your friend. It rates each stock on their combined weighted styles, helping you find the companies with the most attractive value, best growth forecast, and most promising momentum. It's also one of the best indicators to use with the Zacks Rank.
How Style Scores Work with the Zacks Rank The Zacks Rank is a proprietary stock-rating model that harnesses the power of earnings estimate revisions, or changes to a company's earnings expectations, to help investors build a successful portfolio.
It's highly successful, with #1 (Strong Buy) stocks producing an unmatched +23.94% average annual return since 1988. That's more than double the S&P 500. But because of the large number of stocks we rate, there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.
With more than 800 top-rated stocks to choose from, it can certainly feel overwhelming to pick the ones that are right for you and your investing journey.
That's where the Style Scores come in.
To have the best chance of big returns, you'll want to always consider stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B, which will give you the highest probability of success. If you're looking at stocks with a #3 (Hold) rank, it's important they have Scores of A or B as well to ensure as much upside potential as possible.
Since the Scores were created to work together with the Zacks Rank, the direction of a stock's earnings estimate revisions should be a key factor when choosing which stocks to buy.
A stock with a #4 (Sell) or #5 (Strong Sell) rating, for instance, even one with Scores of A and B, will still have a declining earnings forecast, and a greater chance its share price will fall too.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: AMN Healthcare Services (AMN - Free Report) AMN Healthcare Services, Inc. (AMN - Free Report) , operating from Dallas, TX, is a travel healthcare staffing company. Its business has evolved beyond traditional healthcare staffing and recruitment services, thereby becoming a strategic total talent solutions partner with its clients. It has expanded its portfolio to serve a diverse and growing set of healthcare talent-related needs. In addition to its healthcare professional staffing and recruitment services, AMN’s suite of healthcare workforce solutions includes MSP, vendor management systems (VMS), medical language interpretation services, predictive labor analytics, workforce optimization technology and consulting, recruitment process outsourcing (RPO), revenue cycle solutions, credentialing services and virtual care management services. AMN enables its clients to build, manage and optimize their healthcare talent to deliver improved patient outcomes and experience. It continues to enhance its platform with technology-enabled solutions, including digital workforce platforms, automation tools and AI-driven capabilities to improve speed, efficiency and clinician engagement.
AMN is a #3 (Hold) on the Zacks Rank, with a VGM Score of A.
It also boasts a Value Style Score of A thanks to attractive valuation metrics like a forward P/E ratio of 12.87; value investors should take notice.
Three analysts revised their earnings estimate higher in the last 60 days for fiscal 2026, while the Zacks Consensus Estimate has increased $0.77 to $2.70 per share. AMN also boasts an average earnings surprise of +53.3%.
With a solid Zacks Rank and top-tier Value and VGM Style Scores, AMN should be on investors' short list.
Key Takeaways AMN partnered with Brightfield to strengthen healthcare workforce intelligence and market transparency.The alliance combines Brightfield's TDX with AMN analytics to improve planning and cost benchmarking.AMN's WorkWise ecosystem gains predictive insights to support proactive, data-driven workforce planning. AMN Healthcare (AMN - Free Report) recently announced a strategic partnership with Brightfield to strengthen its healthcare workforce intelligence capabilities. By combining Brightfield's third-party Talent Data Exchange (TDX) with AMN's proprietary workforce analytics, the collaboration is expected to provide healthcare organizations with deeper market transparency and more informed labor planning.
From an investor's perspective, the partnership is likely to reinforce AMN's technology-enabled workforce solutions portfolio and enhance the value proposition of its WorkWise ecosystem. The move also reflects the company's continued focus on AI-driven analytics and data-backed decision support, which could support stronger client engagement over the long term.
Likely Trend of AMN Stock Following the NewsShares of AMN have traded flat since the announcement yesterday. In the year-to-date period, shares of the company surged 101.2% against the industry’s 18.9% decline. The S&P 500 increased 7.4% in the same time frame.
The Brightfield partnership is likely to strengthen AMN Healthcare's long-term growth strategy by enhancing the depth and credibility of its workforce intelligence offerings. The integration of independent market data with AMN's proprietary analytics is expected to improve workforce planning, labor cost benchmarking and predictive decision-making for healthcare clients, making its WorkWise ecosystem more differentiated.
As healthcare providers increasingly seek data-driven solutions to manage labor shortages and rising workforce costs, the enhanced platform is likely to support higher client retention, attract new customers and create additional cross-selling opportunities across AMN's broader total talent solutions portfolio.
AMN currently has a market capitalization of $1.21 billion.
Image Source: Zacks Investment Research
More on the AllianceThe collaboration combines Brightfield's TDX, which provides independent workforce market intelligence across both clinical and non-clinical roles, with AMN Healthcare's proprietary workforce analytics, clinical labor insights and real-time intelligence generated through its technology platforms and extensive client network. The integrated solution is expected to offer healthcare organizations a more comprehensive and validated view of workforce costs, labor rate competitiveness and broader market dynamics, enabling stakeholders across clinical, operational and financial functions to make more informed workforce decisions. The partnership also leverages the companies' AI-driven analytics capabilities to translate workforce data into actionable strategies aligned with clients' operational, financial and clinical objectives.
The alliance further strengthens AMN's broader WorkWise ecosystem strategy by enhancing its predictive workforce planning, analytics and decision-support capabilities. Through the expanded intelligence platform, healthcare organizations are expected to benchmark labor rates against independent market data, improve transparency in workforce cost discussions through third-party validation, optimize workforce mix and utilization and identify opportunities to better manage labor spending. By providing richer market intelligence and predictive insights, the collaboration is designed to help healthcare systems transition from reactive staffing decisions to more proactive, data-driven workforce planning in an increasingly complex healthcare labor market.
Favorable Industry Prospect for AMNPer a report by Grand View Research, the global healthcare staffing market size was valued at $82.2 billion in 2025 and is projected to grow from $87.9 billion in 2026 to $143.2 billion by 2033, at a CAGR of 7.2% from 2026 to 2033.
Growth is attributed to the increased knowledge of the benefits of temporary employment, job-related incentives and the availability of opportunities globally.
A Recent Development by AMNRecently, AMN announced the acquisition of Jaide Health, an AI-enabled medical interpretation and translation platform, to expand language access for patients with Limited English Proficiency across the healthcare journey. The move enhances AMN’s Language Services capabilities by extending language assistance to important touchpoints before and after treatment while maintaining the critical role of qualified human interpreters for clinical, sensitive and complex discussions.
Some better-ranked stocks from the broader medical space are Globus Medical (GMED - Free Report) , West Pharmaceutical (WST - Free Report) and Intuitive Surgical (ISRG - Free Report) .
Globus Medical, currently carrying a Zacks Rank #2 (Buy), reported a first-quarter 2026 adjusted earnings per share (EPS) of $1.12 per share, which surpassed the Zacks Consensus Estimate by 22.1%. Revenues of $759.9 million beat the Zacks Consensus Estimate by 4.0%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
GMED has an estimated long-term earnings growth rate of 10.2% compared with the industry’s 12.6% growth. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 26.3%.
West Pharmaceutical, currently flaunting a Zacks Rank #1, reported first-quarter 2026 EPS of $2.13, which beat the Zacks Consensus Estimate by 26.8%. Revenues of $844.9 million surpassed the Zacks Consensus Estimate by 8.5%.
WST has an estimated long-term earnings growth rate of 13.9% compared with the industry’s 9.5% growth. The company’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 19.4%.
Intuitive Surgical, carrying a Zacks Rank #2 at present, reported first-quarter 2026 adjusted EPS of $2.50, which beat the Zacks Consensus Estimate by 20.2%. Revenues of $2.77 billion surpassed the Zacks Consensus Estimate by 6.2%.
ISRG has a long-term estimated growth rate of 14.6% compared with the industry’s 12.6% growth. The company’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%.
Mark G. Foletta, a director of AMN Healthcare Services (AMN +1.54%), disclosed the indirect sale of 3,681 shares for a total of approximately $114,000 on June 15, 2026, as reported in the SEC Form 4 filing.
Transaction summaryMetricValueShares sold (indirect)3,681Transaction value$114,361.63Post-transaction shares (indirect)17,917Transaction value based on SEC Form 4 weighted average purchase price ($31.07).
Key questionsWhat is the significance of this sale relative to Mark G. Foletta's historical trading activity?
This is Foletta's first open-market sale since 2023, with prior transactions since then consisting exclusively of administrative filings and one purchase.How does this transaction affect Foletta's ownership structure?
All transacted shares were held via The Foletta Family Trust, and following the sale, Foletta maintains an indirect position of 17,917 shares, with no direct holdings or derivative securities remaining.Was this sale discretionary, or part of a pre-planned strategy?
The filing footnotes confirm the transaction was executed under a Rule 10b5-1 trading plan adopted on March 12, 2026, indicating the timing and size were determined in advance, independent of short-term market movements.What is the market context for the sale?
Shares were sold at a weighted average price of $31.07 per share on June 15, 2026, during a year in which AMN stock delivered a 40.9% gain, providing a supportive environment for scheduled liquidity events.Company overviewMetricValueRevenue (TTM)$3.42 billionNet income (TTM)-$32.44 million1-year price change40.90%* 1-year price change calculated as of June 15, 2026.
Company snapshotAMN Healthcare Services delivers comprehensive workforce solutions and staffing services, including nurse and allied health placements, locum tenens physicians, executive search, revenue cycle management, and workforce technology solutions.The firm operates a multi-segment business model generating revenue from temporary and permanent staffing, outsourced workforce management, and technology-enabled services for healthcare organizations.Its primary customers include hospitals, health systems, and other healthcare facilities across the United States seeking flexible workforce and staffing solutions.AMN Healthcare Services, Inc. is a leading provider of healthcare workforce solutions, leveraging a broad portfolio of staffing, technology, and outsourced services to address complex talent needs in the healthcare sector. The company operates at scale, serving a national client base with specialized offerings in both clinical and non-clinical roles. Its integrated approach and recognized brands provide a competitive edge in delivering flexible, high-quality staffing and workforce optimization solutions to healthcare organizations.
What this transaction means for investorsBecause this sale was part of a trading plan, and it marks Foletta's first open-market sale since 2023, it doesn’t seem like investors should read into this insider transaction. Even after the sale, he continues to hold nearly 18,000 shares through The Foletta Family Trust.
The bigger story for investors is that AMN appears to be showing signs of stabilization after a difficult stretch for healthcare staffing. Shares have rebounded roughly 41% over the past year, climbing sharply after first-quarter results came in well ahead of expectations. Revenue doubled year over year to $1.38 billion, helped by labor disruption assignments, while adjusted EBITDA surged 159% to $166.1 million. Adjusted earnings climbed to $2.10 per share from $0.45 a year earlier.
CEO Cary Grace said the company delivered "strong execution" across its business, pointing to renewed growth in travel nursing, international staffing, and search services, while also highlighting progress in technology-enabled workforce solutions.
For long-term investors, the key question is whether AMN can sustain momentum once labor disruption revenue normalizes. Management's second-quarter outlook calls for revenue to decline 4% to 6% year over year, a sign that the recovery remains uneven. Still, a strengthened balance sheet and improving operating performance suggest the company is in a far stronger position than it was a year ago.
Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
Brightfield Strategic collaboration expands AMN's healthcare workforce intelligence with broader and enriched market data to help healthcare organizations make smarter, faster, and more confident labor decisions
, /PRNewswire/ -- AMN Healthcare, the leader and innovator in healthcare total talent solutions, today announced it is expanding its workforce intelligence capabilities through a strategic partnership with Brightfield, a leader in measurable workforce intelligence, to deliver enhanced market intelligence and greater transparency to healthcare organizations. Brightfield's Talent Data Exchange, or TDX, adds third-party market data and validation to AMN's proprietary healthcare workforce insights. TDX provides an external view of workforce trends across both clinical and non-clinical roles, complementing AMN's deep healthcare workforce intelligence data that is powered by clinical labor insights, proprietary analytics, and real-time intelligence from its technology platforms and extensive client network.
The partnership delivers a more complete and validated view of workforce costs, rate competitiveness and market dynamics—combining proprietary data with expanded market context—to help health systems align stakeholders, strengthen decision-making, and drive more effective, data-backed workforce strategies.
"Healthcare organizations are under growing pressure to balance cost, quality, access and workforce stability in an increasingly complex labor market," said Kristy Willis, Chief Commercial Officer at AMN Healthcare. "By pairing Brightfield's independent data and analytics with AMN's deep healthcare workforce intelligence and analytics, we can give clients the most complete view of the market with third-party validation as a key differentiator — helping organizations build confidence, create alignment and make smarter workforce decisions backed by data they can trust."
The partnership leverages the strengths of both organization's extensive data and AI-driven analytics to translate meaningful insights into actionable workforce strategies aligned to each client's operational, financial and clinical goals. The collaboration is part of AMN's broader WorkWise ecosystem strategy, strengthening the company's ability to bring healthcare systems a more unified, data-driven approach to predictive workforce planning, analytics and decision support.
"At Brightfield, our focus is helping organizations bring greater intelligence, transparency and discipline to extended workforce decisions," said Sarah Koshiol, Chief Revenue Officer at Brightfield. "Together with AMN, we have an opportunity to bring that value to healthcare in a meaningful way — helping systems better understand the market, validate decisions and build more resilient workforce strategies for the future."
The partnership is designed to help healthcare organizations:
Benchmark labor rates against independent market intelligence Strengthen transparency in workforce cost and rate discussions validated through a third party Support more confident decision-making across clinical, operational and financial stakeholders Identify opportunities to optimize workforce mix, utilization and spend Move from reactive staffing decisions to more proactive workforce planning backed by even more market data About AMN Healthcare
AMN Healthcare is the leader and innovator in total talent solutions for healthcare, bringing together the people, processes and technology to deliver better care. Through a steadfast partnership approach, we solve the most pressing workforce challenges to enable better clinical outcomes and access to care. In 2025, our healthcare professionals reached more than 13 million patients at more than 2,300 healthcare systems, including 93 percent of the top healthcare systems nationwide. We provide a comprehensive network of quality healthcare professionals and deliver a fully integrated and customizable suite of workforce technologies.
About Brightfield
Brightfield is the leader in AI-driven workforce intelligence, helping Global 2000 enterprises optimize contingent and services procurement spend. Its proprietary platform, TDX, benchmarks millions of roles and rate points to deliver precise market intelligence, identify misclassifications, and unlock measurable savings. Brightfield empowers organizations to make smarter workforce decisions, reduce risk, and drive long-term value through data and AI.
It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.
The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.
It also includes access to the Zacks Style Scores.
What are the Zacks Style Scores? Developed alongside the Zacks Rank, the Zacks Style Scores are a group of complementary indicators that help investors pick stocks with the best chances of beating the market over the next 30 days.
Each stock is given an alphabetic rating of A, B, C, D or F based on their value, growth, and momentum qualities. With this system, an A is better than a B, a B is better than a C, and so on, meaning the better the score, the better chance the stock will outperform.
The Style Scores are broken down into four categories:
Value ScoreFor value investors, it's all about finding good stocks at good prices, and discovering which companies are trading under their true value before the broader market catches on. The Value Style Score utilizes ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to help pick out the most attractive and discounted stocks.
Growth ScoreWhile good value is important, growth investors are more focused on a company's financial strength and health, and its future outlook. The Growth Style Score takes projected and historic earnings, sales, and cash flow into account to uncover stocks that will see long-term, sustainable growth.
Momentum ScoreMomentum trading is all about taking advantage of upward or downward trends in a stock's price or earnings outlook, and these investors live by the saying "the trend is your friend." The Momentum Style Score can pinpoint good times to build a position in a stock, using factors like one-week price change and the monthly percentage change in earnings estimates.
VGM ScoreIf you like to use all three kinds of investing, then the VGM Score is for you. It's a combination of all Style Scores, and is an important indicator to use with the Zacks Rank. The VGM Score rates each stock on their shared weighted styles, narrowing down the companies with the most attractive value, best growth forecast, and most promising momentum.
How Style Scores Work with the Zacks Rank The Zacks Rank, which is a proprietary stock-rating model, employs earnings estimate revisions, or changes to a company's earnings expectations, to make building a winning portfolio easier.
#1 (Strong Buy) stocks have produced an unmatched +24% average annual return since 1988, which is more than double the S&P 500's performance over the same time frame. However, the Zacks Rank examines a ton of stocks, and there can be more than 200 companies with a Strong Buy rank, and another 600 with a #2 (Buy) rank, on any given day.
This totals more than 800 top-rated stocks, and it can be overwhelming to try and pick the best stocks for you and your portfolio.
That's where the Style Scores come in.
To maximize your returns, you want to buy stocks with the highest probability of success. This means picking stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you find yourself looking at stocks with a #3 (Hold) rank, make sure they have Scores of A or B as well to ensure as much upside potential as possible.
The direction of a stock's earnings estimate revisions should always be a key factor when choosing which stocks to buy, since the Scores were created to work together with the Zacks Rank.
Here's an example: a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one with Style Scores of A and B, still has a downward-trending earnings outlook, and a bigger chance its share price will decrease too.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: AMN Healthcare Services (AMN - Free Report) AMN Healthcare Services, Inc. (AMN - Free Report) , operating from Dallas, TX, is a travel healthcare staffing company. Its business has evolved beyond traditional healthcare staffing and recruitment services, thereby becoming a strategic total talent solutions partner with its clients. It has expanded its portfolio to serve a diverse and growing set of healthcare talent-related needs. In addition to its healthcare professional staffing and recruitment services, AMN’s suite of healthcare workforce solutions includes MSP, vendor management systems (VMS), medical language interpretation services, predictive labor analytics, workforce optimization technology and consulting, recruitment process outsourcing (RPO), revenue cycle solutions, credentialing services and virtual care management services. AMN enables its clients to build, manage and optimize their healthcare talent to deliver improved patient outcomes and experience. It continues to enhance its platform with technology-enabled solutions, including digital workforce platforms, automation tools and AI-driven capabilities to improve speed, efficiency and clinician engagement.
AMN is a #3 (Hold) on the Zacks Rank, with a VGM Score of A.
Momentum investors should take note of this Business Services stock. AMN has a Momentum Style Score of A, and shares are up 14.8% over the past four weeks.
Three analysts revised their earnings estimate higher in the last 60 days for fiscal 2026, while the Zacks Consensus Estimate has increased $0.77 to $2.70 per share. AMN also boasts an average earnings surprise of +53.3%.
With a solid Zacks Rank and top-tier Momentum and VGM Style Scores, AMN should be on investors' short list.
It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.
The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.
Zacks Premium includes access to the Zacks Style Scores as well.
What are the Zacks Style Scores? The Zacks Style Scores, developed alongside the Zacks Rank, are complementary indicators that rate stocks based on three widely-followed investing methodologies; they also help investors pick stocks with the best chances of beating the market over the next 30 days.
Based on their value, growth, and momentum characteristics, each stock is assigned a rating of A, B, C, D, or F. The better the score, the better chance the stock will outperform; an A is better than a B, a B is better than a C, and so on.
The Style Scores are broken down into four categories:
Value ScoreValue investors love finding good stocks at good prices, especially before the broader market catches on to a stock's true value. Utilizing ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and many other multiples, the Value Style Score identifies the most attractive and most discounted stocks.
Growth ScoreWhile good value is important, growth investors are more focused on a company's financial strength and health, and its future outlook. The Growth Style Score takes projected and historic earnings, sales, and cash flow into account to uncover stocks that will see long-term, sustainable growth.
Momentum ScoreMomentum traders and investors live by the saying "the trend is your friend." This investing style is all about taking advantage of upward or downward trends in a stock's price or earnings outlook. Employing factors like one-week price change and the monthly percentage change in earnings estimates, the Momentum Style Score can indicate favorable times to build a position in high-momentum stocks.
VGM ScoreIf you want a combination of all three Style Scores, then the VGM Score will be your friend. It rates each stock on their combined weighted styles, helping you find the companies with the most attractive value, best growth forecast, and most promising momentum. It's also one of the best indicators to use with the Zacks Rank.
How Style Scores Work with the Zacks Rank A proprietary stock-rating model, the Zacks Rank utilizes the power of earnings estimate revisions, or changes to a company's earnings outlook, to help investors create a successful portfolio.
Investors can count on the Zacks Rank's success, with #1 (Strong Buy) stocks producing an unmatched +24% average annual return since 1988, more than double the S&P 500's performance. But the model rates a large number of stocks, and there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.
With more than 800 top-rated stocks to choose from, it can certainly feel overwhelming to pick the ones that are right for you and your investing journey.
That's where the Style Scores come in.
You want to make sure you're buying stocks with the highest likelihood of success, and to do that, you'll need to pick stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you like a stock that only has a #3 (Hold) rank, it should also have Scores of A or B to guarantee as much upside potential as possible.
Since the Scores were created to work together with the Zacks Rank, the direction of a stock's earnings estimate revisions should be a key factor when choosing which stocks to buy.
A stock with a #4 (Sell) or #5 (Strong Sell) rating, for instance, even one with Scores of A and B, will still have a declining earnings forecast, and a greater chance its share price will fall too.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: AMN Healthcare Services (AMN - Free Report) AMN Healthcare Services, Inc. (AMN - Free Report) , operating from Dallas, TX, is a travel healthcare staffing company. Its business has evolved beyond traditional healthcare staffing and recruitment services, thereby becoming a strategic total talent solutions partner with its clients. It has expanded its portfolio to serve a diverse and growing set of healthcare talent-related needs. In addition to its healthcare professional staffing and recruitment services, AMN’s suite of healthcare workforce solutions includes MSP, vendor management systems (VMS), medical language interpretation services, predictive labor analytics, workforce optimization technology and consulting, recruitment process outsourcing (RPO), revenue cycle solutions, credentialing services and virtual care management services. AMN enables its clients to build, manage and optimize their healthcare talent to deliver improved patient outcomes and experience. It continues to enhance its platform with technology-enabled solutions, including digital workforce platforms, automation tools and AI-driven capabilities to improve speed, efficiency and clinician engagement.
AMN is a #3 (Hold) on the Zacks Rank, with a VGM Score of A.
It also boasts a Value Style Score of A thanks to attractive valuation metrics like a forward P/E ratio of 11.81; value investors should take notice.
Three analysts revised their earnings estimate upwards in the last 60 days for fiscal 2026. The Zacks Consensus Estimate has increased $0.77 to $2.70 per share. AMN boasts an average earnings surprise of +53.3%.
With a solid Zacks Rank and top-tier Value and VGM Style Scores, AMN should be on investors' short list.
On June 16, 2026, AMN Healthcare Services Inc AMN shares rose 3.2% today to a current price of $31.88. The stock has experienced a notable 52-week range, with a low of $14.87 and a high of $32.52, reflecting significant volatility and investor interest in the healthcare sector.
GF Value™ verdict: Current price of $31.88 is 4.2% overvalued compared to a GF Value™ of $30.60.GF Score™ stands at 70/100, indicating an above-average potential for long-term returns.Notable signal: There have been no insider transactions in the last 3 months, suggesting a lack of insider buying or selling activity. Is AMN Overvalued or Undervalued? The current price of AMN Healthcare Services Inc is $31.88, which positions the stock as 4.2% overvalued when compared to the GF Value™ of $30.60. This slight overvaluation indicates that there may be limited margin of safety for potential investors, as the stock is trading above its calculated intrinsic value. The GF Valuation label categorizes AMN as fairly valued, but the current trading price suggests that investors may be paying a premium for the stock without clear justification based on its intrinsic value.
Investors should be cautious, as this overvaluation could pose risks, particularly in a fluctuating market. If the stock were to experience a downturn or if earnings fail to meet expectations, it could lead to a decline in stock price, exacerbating the risks associated with an overvalued stock. GF Value™ is GuruFocus' proprietary measure of intrinsic value, calculated from historical trading multiples, past business growth, and future performance estimates.
How Does AMN's Valuation Compare to Its History? Metric Current Historical P/E (TTM) 12.0x 12.5x AMN's current P/E ratio of 12.0x is slightly below its 5-year median P/E of 12.5x, indicating that the stock is trading at a lower valuation compared to its historical levels. This suggests a potential mispricing relative to its historical performance, but it also aligns with the GF Value™ verdict of being overvalued. Thus, the P/E analysis supports the notion that while the stock may be undervalued relative to its history, the current price still reflects a premium over its intrinsic value.
What Does AMN's GF Score™ Tell Us? Metric Rating GF Score™ 70 Financial Strength 6/10 Profitability 7/10 Growth 1/10 Valuation 9/10 Momentum 6/10 AMN's GF Score™ of 70/100 reflects a well-rounded profile, with strengths in profitability (7/10) and valuation (9/10), indicating that the company has maintained solid profitability metrics and is perceived as relatively attractively priced. However, the growth rank of 1/10 suggests significant challenges in expanding revenue or earnings, which could limit future upside potential. The financial strength score of 6/10 indicates moderate stability, while the momentum rank of 6/10 suggests a mixed performance trend. Overall, the scores highlight the importance of focusing on both current valuation and potential growth challenges for AMN.
What Are Insiders Doing with AMN Stock? In the last three months, there have been no insider transactions reported for AMN Healthcare Services Inc. This lack of insider buying or selling activity could suggest that insiders are either confident in the company's current valuation or are awaiting more favorable conditions before making any transactions. Generally, insider buying can be a positive signal about the company's future prospects, while a lack of activity might imply uncertainty or a wait-and-see approach.
What This Means for Investors Based on the GF Value™, AMN Healthcare Services Inc is currently overvalued with a price of $31.88 compared to a GF Value™ of $30.60. While the company's GF Score™ indicates a solid performance in profitability and valuation, the growth rank signals potential limitations in its ability to expand. Investors should consider these factors carefully when evaluating AMN’s stock.
For the complete analysis, visit the AMN Healthcare Services Inc AMN stock page. You can also explore the GF Value™ page for detailed valuation methodology, or use the GuruFocus Stock Screener to find similar opportunities.
Frequently Asked Questions What is AMN's GF Score™?
AMN's GF Score™ is 70/100, indicating an above-average potential for long-term returns based on its financial metrics.
Is AMN overvalued or undervalued?
AMN is currently overvalued, with a GF Value™ of $30.60 compared to its current price of $31.88.
What is AMN's P/E ratio?
AMN's current P/E ratio is 12.0x, which is below its 5-year median P/E of 12.5x, suggesting the stock is trading at a lower valuation compared to its historical levels.
This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Executive appointments reflect leadership momentum and coordinated investment in growth and people
, /PRNewswire/ -- AMN Healthcare, the leader and innovator in healthcare total talent solutions, today announced the appointments of Kristy Willis as Chief Commercial Officer and Holly Novak as Chief People Officer, both effective June 15. In these roles, Willis and Novak will strengthen the company's executive leadership team as it advances its next phase of growth, innovation, and organizational alignment.
Holly Novak, Chief People Officer, AMN Healthcare Willis will lead a newly integrated commercial function bringing together sales, client accounts, marketing and supplier partnerships to create a growth engine for AMN's leading total talent solutions across both acute and nonacute settings powered by its AI-enabled WorkWise platform. Novak will lead the company's human resources function building on its strong culture to advance AMN Healthcare's people strategy for the future. Together, the appointments reflect a coordinated investment in the capabilities and partnerships that drive market growth and the people and culture that power long-term success.
"Kristy and Holly are exceptional leaders bringing strong expertise and skill to our leadership team in two areas that matter deeply to our future: client leadership and growth and our people," said Cary Grace, President and CEO of AMN Healthcare. "Kristy brings the commercial leadership and execution focus to help us sharpen our market strategy, differentiate our client value proposition and create stronger alignment across the client lifecycle. Holly is a transformative HR leader with the experience and expertise to continue building a place where our team members can thrive and do their best work."
As Chief Commercial Officer, Willis will lead an integrated commercial organization with a primary focus on client growth and market execution. She most recently served as President of PeopleReady, a $1.5 billion national workforce solutions business, part of the TrueBlue portfolio. Through her career, Willis has built successful commercial organizations that align sales strategy, customer experience, and execution at scale, while strengthening go-to-market discipline and driving performance in complex, highly regulated environments.
As Chief People Officer, Novak will lead AMN Healthcare's human resources function and help advance the company's people strategy during a time of growth and innovation. She brings more than 20 years of experience as a people leader and most recently served as Chief People Officer at Jack Henry, a financial technology company. Novak brings deep experience aligning people strategies to business goals and optimizing performance through talent management, succession planning, workforce analytics, and total rewards programs in complex, highly regulated organizations.
"As we continue evolving to meet the needs of our valued clients, clinicians, and team members, we are building an organization that is more connected, more agile, and well equipped to execute with speed and quality," added Grace.
About AMN Healthcare
AMN Healthcare is the leader and innovator in total talent solutions for healthcare, bringing together the people, processes and technology to deliver better care. Through a steadfast partnership approach, we solve the most pressing workforce challenges to enable better clinical outcomes and access to care. In 2025 our healthcare professionals reached more than 13 million patients at more than 2,300 healthcare systems, including 93 percent of the top healthcare systems nationwide. We provide a comprehensive network of quality healthcare professionals and deliver a fully integrated and customizable suite of workforce technologies.
For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.
Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.
It also includes access to the Zacks Style Scores.
What are the Zacks Style Scores? The Zacks Style Scores, developed alongside the Zacks Rank, are complementary indicators that rate stocks based on three widely-followed investing methodologies; they also help investors pick stocks with the best chances of beating the market over the next 30 days.
Each stock is assigned a rating of A, B, C, D, or F based on their value, growth, and momentum characteristics. Just like in school, an A is better than a B, a B is better than a C, and so on -- that means the better the score, the better chance the stock will outperform.
The Style Scores are broken down into four categories:
Value ScoreFor value investors, it's all about finding good stocks at good prices, and discovering which companies are trading under their true value before the broader market catches on. The Value Style Score utilizes ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to help pick out the most attractive and discounted stocks.
Growth ScoreGrowth investors, on the other hand, are more concerned with a company's financial strength and health, and its future outlook. The Growth Style Score examines things like projected and historic earnings, sales, and cash flow to find stocks that will experience sustainable growth over time.
Momentum ScoreMomentum trading is all about taking advantage of upward or downward trends in a stock's price or earnings outlook, and these investors live by the saying "the trend is your friend." The Momentum Style Score can pinpoint good times to build a position in a stock, using factors like one-week price change and the monthly percentage change in earnings estimates.
VGM ScoreIf you like to use all three kinds of investing, then the VGM Score is for you. It's a combination of all Style Scores, and is an important indicator to use with the Zacks Rank. The VGM Score rates each stock on their shared weighted styles, narrowing down the companies with the most attractive value, best growth forecast, and most promising momentum.
How Style Scores Work with the Zacks Rank The Zacks Rank, which is a proprietary stock-rating model, employs earnings estimate revisions, or changes to a company's earnings expectations, to make building a winning portfolio easier.
Investors can count on the Zacks Rank's success, with #1 (Strong Buy) stocks producing an unmatched +23.93% average annual return since 1988, more than double the S&P 500's performance. But the model rates a large number of stocks, and there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.
But it can feel overwhelming to pick the right stocks for you and your investing goals with over 800 top-rated stocks to choose from.
That's where the Style Scores come in.
You want to make sure you're buying stocks with the highest likelihood of success, and to do that, you'll need to pick stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you like a stock that only has a #3 (Hold) rank, it should also have Scores of A or B to guarantee as much upside potential as possible.
As mentioned above, the Scores are designed to work with the Zacks Rank, so any change to a company's earnings outlook should be a deciding factor when picking which stocks to buy.
For instance, a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one that boasts Scores of A and B, still has a downward-trending earnings forecast, and a much greater likelihood its share price will decline as well.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: AMN Healthcare Services (AMN - Free Report) AMN Healthcare Services, Inc. (AMN - Free Report) , operating from Dallas, TX, is a travel healthcare staffing company. Its business has evolved beyond traditional healthcare staffing and recruitment services, thereby becoming a strategic total talent solutions partner with its clients. It has expanded its portfolio to serve a diverse and growing set of healthcare talent-related needs. In addition to its healthcare professional staffing and recruitment services, AMN’s suite of healthcare workforce solutions includes MSP, vendor management systems (VMS), medical language interpretation services, predictive labor analytics, workforce optimization technology and consulting, recruitment process outsourcing (RPO), revenue cycle solutions, credentialing services and virtual care management services. AMN enables its clients to build, manage and optimize their healthcare talent to deliver improved patient outcomes and experience. It continues to enhance its platform with technology-enabled solutions, including digital workforce platforms, automation tools and AI-driven capabilities to improve speed, efficiency and clinician engagement.
AMN is a #2 (Buy) on the Zacks Rank, with a VGM Score of A.
It also boasts a Value Style Score of A thanks to attractive valuation metrics like a forward P/E ratio of 10.88; value investors should take notice.
One analyst revised their earnings estimate upwards in the last 60 days for fiscal 2026. The Zacks Consensus Estimate has increased $0.47 to $1.93 per share. AMN boasts an average earnings surprise of +79.6%.
With a solid Zacks Rank and top-tier Value and VGM Style Scores, AMN should be on investors' short list.
Quarterly revenue of $1.378 billion and adjusted EBITDA of $166 million;
GAAP income of $1.59/share and adjusted EPS of $2.10
DALLAS, May 07, 2026 (GLOBE NEWSWIRE) -- AMN Healthcare Services, Inc. (NYSE: AMN), the leader and innovator in total talent solutions for healthcare organizations across the United States, today announced its first quarter 2026 financial results. Financial highlights are as follows:
Dollars in millions, except per share amounts.
Q1 2026% Change Q1 2025Revenue$1,378.4100%Gross profit$368.886%Net income$62.2nmGAAP diluted EPS$1.59nmAdjusted diluted EPS*$2.10366%Adjusted EBITDA*$166.1159% * See “Non-GAAP Measures” below for a discussion of our use of non-GAAP items and the table entitled “Non-GAAP Reconciliation Tables” for a reconciliation of non-GAAP items.
Business Highlights
First quarter revenue and earnings exceeded guidance with labor disruption, travel nurse, allied, and international nurse exceeding expectations.Travel nursing volume and revenue grew year over year for the first time since 2022.Allied, schools, international nurse, and search also delivered year-over-year revenue growth.Cash flow from operations of $562 million and our quarter-end cash balance of $561 million benefited from favorable timing of working capital related to recent labor disruption events.We ended the quarter with $750 million of debt, an undrawn revolving credit facility and a leverage ratio, calculated under the terms of our credit agreement, of 1.6x. “Our first quarter performance demonstrated strong execution across AMN, with results exceeding our expectations and guidance while navigating a dynamic market environment,” said Cary Grace, President and Chief Executive Officer of AMN Healthcare. “We delivered solid underlying growth in Nurse and Allied Solutions, saw momentum return in international staffing and search, and continued to advance our technology-enabled workforce solutions. The AMN team did an outstanding job supporting our clients and healthcare professionals, demonstrating the power of our enhanced technology platform and solutions to deliver at our highest level since the pandemic.”
First Quarter 2026 Results
Consolidated revenue for the quarter was $1.378 billion, a 100% increase from prior year and an 84% increase from the prior quarter. Net income was $62 million (4.5% of revenue), or $1.59 per diluted share, compared with net loss of $1 million (0.2% of revenue), or ($0.03) per diluted share in the first quarter of 2025. Adjusted diluted EPS in the first quarter was $2.10 compared with $0.45 in the same quarter a year ago.
Revenue for the Nurse and Allied Solutions segment was $1.127 billion, higher by 173% year over year and up 130% from the prior quarter. Travel nurse staffing revenue was higher by 12% year over year and 16% sequentially. Allied division revenue increased 3% year over year and sequentially. Labor disruption events contributed $722 million revenue in the quarter.
The Physician and Leadership Solutions segment reported revenue of $164 million, down 6% year over year and 3% lower sequentially. Locum tenens revenue was $131 million, down 7% year over year and 4% sequentially. Interim leadership revenue was down by 4% year over year and 5% lower sequentially. Our search businesses saw revenue increase by 4% both year over year and sequentially.
Technology and Workforce Solutions segment revenue was $87 million, a decrease of 15% year over year and 1% sequentially. Language services revenue was $69 million in the quarter, down 8% from the prior year and down 1% sequentially. Vendor management systems revenue was $16 million, 18% lower year over year and down 2% from the prior quarter.
Consolidated gross margin was 26.8%, 190 basis points lower year over year and up 70 basis points sequentially. Higher margins in the Nurse and Allied Solutions and Technology and Workforce Solutions segments drove the sequential improvement.
Consolidated SG&A expenses were $218 million, or 15.8% of revenue, compared with $148 million, or 21.4% of revenue, in the same quarter last year. SG&A was $152 million, or 20.3% of revenue, in the previous quarter. The year-over-year increase in SG&A costs was driven primarily by expenses related to the large labor disruption events in the quarter.
Income from operations was $117 million with an operating margin of 8.5%, compared with income of $13 million and 1.8%, respectively, in the same quarter last year. Adjusted EBITDA was $166 million, a year-over-year increase of 159%. Adjusted EBITDA margin was 12.1%, 280 basis points higher than the year-ago period.
At March 31, 2026, cash and cash equivalents totaled $561 million. Cash flow from operations was $562 million for the first quarter. The cash balance and cash flow benefited from favorable timing of working capital related to labor disruption events resulting in $367 million of client deposits at quarter end that will be settled in the coming months. Capital expenditures were $7 million. The Company ended the quarter with total debt outstanding of $750 million with nothing drawn on our revolving credit facility.
Second Quarter 2026 Outlook
MetricGuidance*Consolidated revenue$620 - $635 millionGross margin28.0% - 28.5%SG&A as percentage of revenue23.0% - 23.5%Operating margin(0.6%) - 0.1%Adjusted EBITDA margin6.7% - 7.2% *Note: Guidance percentage metrics are approximate. For a reconciliation of adjusted EBITDA margin, see the table entitled “Reconciliation of Guidance Operating Margin to Guidance Adjusted EBITDA Margin” below.
Revenue in the second quarter of 2026 is expected to be 4-6% lower than the prior year, or down 3-5% excluding labor disruption revenue of approximately $10 million this quarter compared with $16 million in the second quarter of 2025. Nurse and Allied Solutions segment revenue is expected to be down 0-2% year over year. Physician and Leadership Solutions segment revenue is expected to be down 6-8% year over year. Technology and Workforce Solutions segment revenue is projected to be down 14-16% year over year, including a (4%) effect from the divestiture of Smart Square at the beginning of third quarter 2025.
Second quarter estimates for certain other financial items include depreciation of $15 million, depreciation in cost of revenue of $2.5 million, non-cash amortization expense of $18 million, share-based compensation expense of $7 million, integration and other expenses of $3 million, interest expense of $8 million, marginal adjusted tax rate of 28%, and 39.3 million diluted average shares outstanding.
Conference Call on May 7, 2026
AMN Healthcare Services, Inc. (NYSE: AMN) will host a conference call to discuss its first quarter 2026 financial results and second quarter 2026 outlook on Thursday, May 7, 2026 at 5:00 p.m. Eastern Time. A live webcast of the call can be accessed through AMN Healthcare’s website at http://ir.amnhealthcare.com. Interested parties may participate live via telephone by registering at this link. Registrants will receive confirmation and dial-in details. Following the conclusion of the call, a replay of the webcast will be available at the Company’s investor relations website.
About AMN Healthcare
AMN Healthcare is the leader and innovator in total talent solutions for healthcare organizations across the United States. The Company provides access to the most comprehensive network of quality healthcare professionals through its innovative recruitment strategies and breadth of career opportunities. With insights and expertise, AMN Healthcare helps providers optimize their workforce to successfully reduce complexity, increase efficiency and improve patient outcomes. AMN total talent solutions include managed services programs, clinical and interim healthcare leaders, temporary staffing, direct hire and retained search solutions, vendor management systems, recruitment process outsourcing, predictive modeling, language interpretation services, revenue cycle solutions, credentialing, and other services. Clients include acute-care hospitals, community health centers and clinics, physician practice groups, retail and urgent care centers, home health facilities, schools, and many other healthcare settings. AMN Healthcare is committed to fostering and maintaining a diverse team that reflects the communities we serve. Our commitment to the inclusion of many different backgrounds, experiences and perspectives enables our innovation and leadership in the healthcare services industry.
The Company’s common stock is listed on the New York Stock Exchange under the symbol “AMN.” For more information about AMN Healthcare, visit www.amnhealthcare.com, where the Company posts news releases, investor presentations, webcasts, SEC filings and other material information. The Company also utilizes email alerts and Really Simple Syndication (“RSS”) as routine channels to supplement distribution of this information. To register for email alerts and RSS, visit http://ir.amnhealthcare.com.
Non-GAAP Measures
This earnings release and the non-GAAP reconciliation tables included with the earnings release contain certain non-GAAP financial information, which the Company provides as additional information, and not as an alternative, to the Company’s condensed consolidated financial statements presented in accordance with GAAP. These non-GAAP financial measures include (1) adjusted EBITDA, (2) adjusted EBITDA margin, (3) adjusted net income, and (4) adjusted diluted EPS. The Company provides such non-GAAP financial measures because management believes that they are useful to both management and investors as a supplement, and not as a substitute, when evaluating the Company’s operating performance. Additionally, management believes that adjusted EBITDA, adjusted EBITDA margin, and adjusted diluted EPS serve as industry-wide financial measures. The Company uses adjusted EBITDA for making financial decisions, allocating resources and for determining certain incentive compensation objectives. The non-GAAP measures in this release are not in accordance with, or an alternative to, GAAP measures and may be different from non-GAAP measures, or may be calculated differently than other similarly titled non-GAAP measures, reported by other companies. They should not be used in isolation to evaluate the Company’s performance. A reconciliation of non-GAAP measures identified in this release, along with further detail about the use and limitations of certain of these non-GAAP measures, may be found below in the table entitled “Non-GAAP Reconciliation Tables” under the caption entitled “Reconciliation of Non-GAAP Items” and the footnotes thereto or on the Company’s website at https://ir.amnhealthcare.com/financials/quarterly-results. Additionally, from time to time, additional information regarding non-GAAP financial measures, including pro forma measures, may be made available on the Company’s website.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include, among others, statements concerning future demand and supply for healthcare, contingent staffing and other services, client preferences, momentum in international staffing and search, our ability to advance our technology-enabled workforce solutions, settlement of client deposits, second quarter 2026 financial projections for consolidated and segment revenue, consolidated gross margin, operating margin, SG&A as a percent of revenue, adjusted EBITDA margin, labor disruption revenue, depreciation expense, depreciation in cost of revenue, share-based compensation expense, non-cash amortization expense, integration and other expenses, interest expense, adjusted tax rate, and number of diluted shares outstanding. The Company bases these forward-looking statements on its current expectations, estimates and projections about future events and the industry in which it operates using information currently available to it. Actual results could differ materially from those discussed in, or implied by, these forward-looking statements. Forward-looking statements are also identified by words such as “believe,” "project," “anticipate,” “expect,” “intend,” “plan,” “will,” “may,” “estimates,” variations of such words and other similar expressions. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements.
The targets and expectations noted in this release depend upon, among other factors, (i) the ability of our clients to increase the efficiency and effectiveness of their staffing management and recruiting efforts, through predictive analytics, online recruiting, internal travel agencies and float pools, telemedicine or otherwise and successfully hire and retain permanent staff, (ii) the duration and extent to which hospitals and other healthcare entities adjust their utilization of temporary nurses and allied healthcare professionals, physicians, healthcare leaders and other healthcare professionals and workforce technology applications as a result of the labor market or economic conditions, (iii) the magnitude and duration of the effects of the post-COVID-19 pandemic environment or any future pandemic or health crisis on demand and supply trends, our business, its financial condition and our results of operations, (iv) our ability to effectively address client demand by attracting and placing nurses and other clinicians, (v) our ability to recruit and retain sufficient quality healthcare professionals at reasonable costs, (vi) our ability to anticipate and quickly respond to changing marketplace conditions, such as alternative modes of healthcare delivery, reimbursement, or client needs and requirements, including implementing changes that will make our services more tech-enabled and integrated, (vii) our ability to manage the pricing impact that the labor market or consolidation of healthcare delivery organizations may have on our business, (viii) the effects of economic downturns, inflation or slow recoveries, which could result in less demand for our services, increased client initiatives designed to contain costs, including reevaluating their approach as it pertains to contingent labor and managed services programs, other solutions and providers, pricing pressures and negatively impact payments terms and collectability of accounts receivable, (ix) our ability to develop and evolve our current technology offerings and capabilities and implement new infrastructure and technology systems to optimize our operating results and manage our business effectively, (x) our ability and the expense to comply with extensive and complex federal and state laws and regulations related to the conduct of our operations, costs and payment for services and payment for referrals as well as laws regarding employment practices, (xi) our ability to consummate and effectively incorporate acquisitions into our business, (xii) the negative effects that intermediary organizations may have on our ability to secure new and profitable contracts, (xiii) the extent to which the Great Resignation or a future spike in the COVID-19 pandemic or other pandemic or health crisis may disrupt our operations due to the unavailability of our employees or healthcare professionals due to burnout, illness, risk of illness, quarantines, travel restrictions, mandatory vaccination requirements, or other factors that limit our existing or potential workforce and pool of candidates, (xiv) security breaches and cybersecurity incidents, including ransomware, that could compromise our information and systems, which could adversely affect our business operations and reputation and could subject us to substantial liabilities and (xv) the severity and duration of the impact the labor market, economic downturn or any future pandemic or health crisis has on the financial condition and cash flow of many hospitals and healthcare systems such that it impairs their ability to make payments to us, timely or otherwise, for services rendered.
For a discussion of additional risk factors and a more complete discussion of some of the cautionary statements noted above that could cause actual results to differ from those implied by the forward-looking statements contained in this press release, please refer to our most recent Annual Report on Form 10-K for the year ended December 31, 2025. Be advised that developments subsequent to this press release are likely to cause these statements to become outdated and the Company is under no obligation (and expressly disclaims any such obligation) to update or revise any forward-looking statements whether as a result of new information, future events, or otherwise.
AMN Healthcare Services, Inc.
Condensed Consolidated Statements of Comprehensive Income (Loss)
(in thousands, except per share amounts)
(unaudited)
Three Months Ended March 31, December 31, 2026 2025 2025Revenue$1,378,361 $689,533 $748,225 Cost of revenue 1,009,525 491,413 553,098 Gross profit 368,836 198,120 195,127 Gross margin 26.8% 28.7% 26.1%Operating expenses: Selling, general and administrative (SG&A) 218,425 147,731 152,113 SG&A as a % of revenue 15.8% 21.4% 20.3% Depreciation and amortization (exclusive of depreciation included in cost of revenue) 33,240 37,882 34,854 Loss on sale of disposal group — — 42 Total operating expenses 251,665 185,613 187,009 Income from operations 117,171 12,507 8,118 Operating margin (1) 8.5% 1.8% 1.1% Interest expense, net, and other 6,712 12,324 12,280 Income (loss) before income taxes 110,459 183 (4,162) Income tax expense 48,293 1,275 3,534 Net income (loss)$62,166 $(1,092) $(7,696)Net income (loss) as a % of revenue 4.5% (0.2)% (1.0)% Other comprehensive income (loss): Unrealized gains (losses) on available-for-sale securities, net, and other (185) 61 (286)Other comprehensive income (loss) (185) 61 (286) Comprehensive income (loss)$61,981 $(1,031) $(7,982) Net income (loss) per common share: Basic$1.60 $(0.03) $(0.20)Diluted$1.59 $(0.03) $(0.20)Weighted average common shares outstanding: Basic 38,902 38,312 38,733 Diluted 39,118 38,312 38,733 AMN Healthcare Services, Inc.
Condensed Consolidated Balance Sheets
(dollars in thousands)
(unaudited)
March 31, 2026
December 31, 2025
March 31, 2025
Assets Current assets: Cash and cash equivalents$560,738 $33,972 $55,777 Accounts receivable, net 394,668 382,560 421,869 Accounts receivable, subcontractor 47,501 48,041 65,307 Prepaid and other current assets 133,613 80,803 84,404 Total current assets 1,136,520 545,376 627,357 Restricted cash, cash equivalents and investments 45,814 45,606 45,070 Fixed assets, net 126,029 136,361 177,996 Other assets 263,408 282,552 253,670 Deferred income taxes, net 11,212 44,877 31,637 Goodwill 755,809 755,809 897,456 Intangible assets, net 265,581 283,526 361,937 Total assets$2,604,373 $2,094,107 $2,395,123 Liabilities and stockholders’ equity Current liabilities: Accounts payable and accrued expenses$197,385 $161,968 $195,974 Accrued compensation and benefits 317,137 298,837 269,497 Other current liabilities 529,668 116,809 116,778 Total current liabilities 1,044,190 577,614 582,249 Revolving credit facility — 25,000 150,000 Notes payable, net 742,491 742,053 846,167 Other long-term liabilities 104,886 107,334 101,656 Total liabilities 1,891,567 1,452,001 1,680,072 Commitments and contingencies Stockholders’ equity: 712,806 642,106 715,051 Total liabilities and stockholders’ equity$2,604,373 $2,094,107 $2,395,123 AMN Healthcare Services, Inc.
Summary Condensed Consolidated Statements of Cash Flows
(dollars in thousands)
(unaudited)
Three Months Ended March 31, December 31, 2026 2025 2025 Net cash provided by operating activities$562,452 $92,671 $75,572 Net cash used in investing activities (7,504) (26,046) (8,053)Net cash used in financing activities (27,135) (61,211) (83,242)Net increase (decrease) in cash, cash equivalents and restricted cash 527,813 5,414 (15,723)Cash, cash equivalents and restricted cash at beginning of period 67,171 89,305 82,894 Cash, cash equivalents and restricted cash at end of period$594,984 $94,719 $67,171 AMN Healthcare Services, Inc.
Non-GAAP Reconciliation Tables
(dollars in thousands, except per share data)
(unaudited)
Three Months Ended March 31, December 31, 2026 2025 2025Reconciliation of Non-GAAP Items: Net income (loss)$62,166 $(1,092) $(7,696)Income tax expense 48,293 1,275 3,534 Income (loss) before income taxes 110,459 183 (4,162)Interest expense, net, and other 6,712 12,324 12,280 Income from operations 117,171 12,507 8,118 Depreciation and amortization 33,240 37,882 34,854 Depreciation (included in cost of revenue) (2) 2,420 1,975 2,376 Loss on sale of disposal group — — 42 Share-based compensation 9,892 9,381 5,762 Acquisition, integration, and other costs (3) 3,402 2,455 3,331 Adjusted EBITDA (4)$166,125 $64,200 $54,483 Adjusted EBITDA margin (5) 12.1% 9.3% 7.3% Net income (loss)$62,166 $(1,092) $(7,696)Adjustments: Amortization of intangible assets 17,945 19,427 18,551 Acquisition, integration, and other costs (3) 3,402 2,455 3,331 Loss on sale of disposal group — — 42 Debt financing related costs — — 1,156 Tax effect on above adjustments (5,550) (5,689) (6,001)Tax effect of COLI fair value changes (6) 2,065 703 (1,713)Tax deficiencies (benefits) related to equity awards and ESPP (7) 2,151 1,523 892 Adjusted net income (8)$82,179 $17,327 $8,562 GAAP diluted net income (loss) per share (EPS)$1.59 $(0.03) $(0.20)Adjustments 0.51 0.48 0.42 Adjusted diluted EPS (9) (10)$2.10 $0.45 $0.22 AMN Healthcare Services, Inc.
Supplemental Segment Financial and Operating Data
(dollars in thousands, except operating data)
(unaudited)
Three Months Ended March 31, December 31, 2026 2025 2025Revenue Nurse and allied solutions$1,127,342 $413,261 $490,710 Physician and leadership solutions 163,924 174,065 169,552 Technology and workforce solutions 87,095 102,207 87,963 $1,378,361 $689,533 $748,225 Segment operating income (11) Nurse and allied solutions$153,330 $32,238 $36,484 Physician and leadership solutions 10,818 14,462 12,918 Technology and workforce solutions 25,270 35,250 24,896 189,418 81,950 74,298 Unallocated corporate overhead (12) 23,293 17,750 19,815 Adjusted EBITDA (4)$166,125 $64,200 $54,483 Gross Margin Nurse and allied solutions 25.1% 22.7% 21.6%Physician and leadership solutions 26.1% 27.3% 27.5%Technology and workforce solutions 50.0% 55.5% 48.1% Operating Data: Nurse and allied solutions Average travelers on assignment (13) 9,227 8,981 8,722 Physician and leadership solutions Days filled (14) 46,645 51,342 48,004 Revenue per day filled (15)$2,812 $2,743 $2,834 As of March 31, As of December 31, 2026 2025 2025Leverage ratio (16)1.6 3.1 3.3 AMN Healthcare Services, Inc.
Additional Supplemental Non-GAAP Disclosure
Reconciliation of Guidance Operating Margin to Guidance
Adjusted EBITDA Margin
(unaudited)
Three Months Ended June 30, 2026 Low(17) High(17) Operating margin(0.6)% 0.1%Depreciation and amortization (total)5.7% 5.5%EBITDA margin5.1% 5.6%Share-based compensation1.1% 1.1%Integration and other costs0.5% 0.5%Adjusted EBITDA margin6.7% 7.2% (1)Operating margin represents income from operations divided by revenue.(2)A portion of depreciation expense for AMN Language Services is included in cost of revenue. We exclude the impact of depreciation included in cost of revenue from the calculation of adjusted EBITDA.(3)Acquisition, integration, and other costs include acquisition and integration costs, net changes in the fair value of contingent consideration liabilities for recently acquired companies, certain legal expenses, restructuring expenses and other costs associated with exit or disposal activities, and certain nonrecurring expenses, which we exclude from the calculation of adjusted EBITDA, adjusted net income, and adjusted diluted EPS because we believe that these expenses are not indicative of the Company’s operating performance. For the three months ended March 31, 2026, acquisition and integration costs were approximately $0.9 million, certain legal expenses were approximately $1.0 million, restructuring expenses and other costs associated with exit or disposal activities were approximately $0.6 million, and other nonrecurring expenses were approximately $0.9 million. For the three months ended March 31, 2025, acquisition and integration costs were approximately $0.3 million, expenses related to the closures of certain office leases were approximately $0.2 million, certain legal expenses were approximately $1.1 million, restructuring expenses and other costs associated with exit or disposal activities were approximately $0.4 million, and other nonrecurring expenses were approximately $0.4 million. For the three months ended December 31, 2025, acquisition and integration costs were approximately $0.5 million, certain legal expenses were approximately $0.8 million, expenses related to the closures of certain office leases were approximately $0.2 million, restructuring expenses and other costs associated with exit or disposal activities were approximately $0.8 million, and other expenses were approximately $1.0 million.(4)Adjusted EBITDA represents net income (loss) plus interest expense (net of interest income) and other, income tax expense, depreciation and amortization, depreciation (included in cost of revenue), loss on sale of disposal group, share-based compensation, acquisition, integration, and other costs, restructuring expenses, and certain legal expenses. Management believes that adjusted EBITDA provides an effective measure of the Company’s results, as it excludes certain items that management believes are not indicative of the Company’s operating performance. Adjusted EBITDA is not intended to represent cash flows for the period, nor has it been presented as an alternative to income from operations or net income (loss) as an indicator of operating performance. Although management believes that some of the items excluded from adjusted EBITDA are not indicative of the Company’s operating performance, these items do impact the statement of comprehensive income (loss), and management therefore utilizes adjusted EBITDA as an operating performance measure in conjunction with GAAP measures such as net income (loss).(5)Adjusted EBITDA margin represents adjusted EBITDA divided by revenue.(6)The Company records net tax expense (benefit) related to the income tax treatment of the fair value changes in the cash surrender value of its company owned life insurance (“COLI”). Since this change in fair value is unrelated to the Company’s operating performance, we excluded the impact on adjusted net income and adjusted diluted EPS.(7)The consolidated effective tax rate is affected by the recording of tax benefits and tax deficiencies related to equity awards vested during the period and tax benefits recognized for disqualifying dispositions related to our employee stock purchase plan (“ESPP”). The magnitude of the impact of tax benefits and tax deficiencies generated in the future related to equity awards and ESPP is dependent upon the Company’s future grants of share-based compensation, the Company’s future stock price on the date equity awards vest in relation to the fair value of the awards on the grant date, the Company’s future stock price on either the ESPP’s offering date or purchase date, whichever is lower, and the length of time the shares issued under the ESPP are held by employees. Since these tax benefits and tax deficiencies related to equity awards and ESPP are largely unrelated to our income (loss) before income taxes and are unrepresentative of our normal effective tax rate, we excluded their impact in the calculation of adjusted net income and adjusted diluted EPS.(8)Adjusted net income represents GAAP net income (loss) excluding the impact of the (A) amortization of intangible assets, (B) acquisition, integration, and other costs, (C) loss on sale of disposal group, (D) deferred financing related costs, (E) tax effect, if any, of the foregoing adjustments, (F) net tax expense (benefit) related to the income tax treatment of fair value changes in the cash surrender value of its COLI and (G) tax deficiencies and tax benefits related to equity awards vested and ESPP. Management included this non-GAAP measure to provide investors and prospective investors with an alternative method for assessing the Company’s operating results in a manner that is focused on its operating performance and to provide a more consistent basis for comparison between periods. However, investors and prospective investors should note that this non-GAAP measure involves judgment by management (in particular, judgment as to what is classified as a special item to be excluded in the calculation of adjusted net income). Although management believes the items in the calculation of adjusted net income are not indicative of the Company’s operating performance, these items do impact the statement of comprehensive income (loss), and management therefore utilizes adjusted net income as an operating performance measure in conjunction with GAAP measures such as GAAP net income (loss).(9)Adjusted diluted EPS represents adjusted net income divided by diluted weighted average common shares outstanding. Management included this non-GAAP measure to provide investors and prospective investors with an alternative method for assessing the Company’s operating results in a manner that is focused on its operating performance and to provide a more consistent basis for comparison between periods. However, investors and prospective investors should note that this non-GAAP measure involves judgment by management (in particular, judgment as to what is classified as a special item to be excluded in the calculation of adjusted net income). Although management believes the items in the calculation of adjusted net income are not indicative of the Company’s operating performance, these items do impact the statement of comprehensive income (loss), and management therefore utilizes adjusted diluted EPS as an operating performance measure in conjunction with GAAP measures such as GAAP diluted EPS.(10)As GAAP net loss is reported for the three months ended March 31, 2025 and December 31, 2025, basic weighted average common shares outstanding was used to calculate GAAP diluted EPS for those periods because the dilutive potential common shares have an anti-dilutive effect (i.e., result in a lower loss per share). As adjusted net income is reported for the three months ended March 31, 2025 and December 31, 2025, diluted weighted average common shares outstanding (including dilutive potential common shares) of 38,414 and 38,817, respectively, were used to calculate adjusted diluted EPS.(11)Segment operating income represents net income (loss) plus interest expense (net of interest income) and other, income tax expense (benefit), depreciation and amortization, depreciation (included in cost of revenue), unallocated corporate overhead, acquisition, integration, and other costs, legal settlement accrual changes, share-based compensation, and loss on sale of disposal group.(12)Unallocated corporate overhead (as presented in the tables above) consists of unallocated corporate overhead (as reflected in our quarterly and annual financial statements filed with the SEC) less acquisition, integration, and other costs and legal settlement accrual changes.(13)Average travelers on assignment represents the average number of nurse and allied healthcare professionals on assignment during the period presented.(14)Days filled is calculated by dividing the locum tenens hours filled during the period by eight hours.(15)Revenue per day filled represents revenue of the Company’s locum tenens business divided by days filled for the period presented.(16)Leverage ratio represents the ratio of the consolidated funded indebtedness (as calculated per the Company’s credit agreement) at the end of the subject period to the consolidated adjusted EBITDA (as calculated per the Company’s credit agreement) for the twelve-month period ended at the end of the subject period.(17)Guidance percentage metrics are approximate.
AMN Healthcare Services (AMN - Free Report) reported $1.38 billion in revenue for the quarter ended March 2026, representing a year-over-year increase of 99.9%. EPS of $2.10 for the same period compares to $0.45 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $1.23 billion, representing a surprise of +11.9%. The company delivered an EPS surprise of +30.98%, with the consensus EPS estimate being $1.60.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how AMN Healthcare performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Revenue- Physician and leadership solutions: $163.92 million versus $163.01 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -5.8% change.Revenue- Nurse and allied solutions: $1.13 billion versus $984.24 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +172.8% change.Revenue- Technology and workforce solutions: $87.1 million compared to the $84.69 million average estimate based on two analysts. The reported number represents a change of -14.8% year over year.Segment operating income- Nurse and allied solutions: $153.33 million compared to the $97.77 million average estimate based on two analysts.Segment operating income- Technology and workforce solutions: $25.27 million versus $25.71 million estimated by two analysts on average.Segment operating income- Physician and leadership solutions: $10.82 million versus $13.62 million estimated by two analysts on average.View all Key Company Metrics for AMN Healthcare here>>>
Shares of AMN Healthcare have returned +10.5% over the past month versus the Zacks S&P 500 composite's +11.4% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.
AMN Healthcare Services (AMN - Free Report) came out with quarterly earnings of $2.1 per share, beating the Zacks Consensus Estimate of $1.6 per share. This compares to earnings of $0.45 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of +30.98%. A quarter ago, it was expected that this health care staffing company would post earnings of $0.22 per share when it actually produced earnings of $0.22, delivering no surprise.
Over the last four quarters, the company has surpassed consensus EPS estimates three times.
AMN Healthcare, which belongs to the Zacks Business - Services industry, posted revenues of $1.38 billion for the quarter ended March 2026, surpassing the Zacks Consensus Estimate by 11.90%. This compares to year-ago revenues of $689.53 million. The company has topped consensus revenue estimates four times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
AMN Healthcare shares have added about 33.1% since the beginning of the year versus the S&P 500's gain of 7.6%.
What's Next for AMN Healthcare?While AMN Healthcare has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for AMN Healthcare was favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #2 (Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.10 on $627.69 million in revenues for the coming quarter and $1.93 on $3.14 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Business - Services is currently in the top 32% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Priority Technology (PRTH - Free Report) , another stock in the broader Zacks Business Services sector, has yet to report results for the quarter ended March 2026. The results are expected to be released on May 11.
This company is expected to post quarterly earnings of $0.22 per share in its upcoming report, which represents no change from the year-ago quarter. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
Priority Technology's revenues are expected to be $240.35 million, up 7% from the year-ago quarter.
Here are three stocks with buy rank and strong value characteristics for investors to consider today, May 8th:
Atlanticus (ATLC - Free Report) : This company, which provides credit and related financial services and products, carries a Zacks Rank #1 (Strong Buy), and has witnessed the Zacks Consensus Estimate for its current year earnings increasing 7.9% over the last 60 days.
Atlanticus has a price-to-earnings ratio (P/E) of 9.18 compared with 15.70 for the industry. The company possesses a Value Score of A.
DaVita (DVA - Free Report) : This company, which is a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure, also known as end-stage renal disease (ESRD), carries a Zacks Rank #1, and has witnessed the Zacks Consensus Estimate for its current year earnings increasing 0.8% over the last 60 days.
DaVita has a price-to-earnings ratio (P/E) of 13.59 compared with 27.40 for the industry. The company possesses a Value Score of A.
AMN Healthcare Services (AMN - Free Report) : This travel healthcare staffing company, which has expanded its portfolio to serve a diverse and growing set of healthcare talent-related needs, carries a Zacks Rank #1, and has witnessed the Zacks Consensus Estimate for its current year earnings increasing 32.2% over the last 60 days.
AMN Healthcare Services’ has a price-to-earnings ratio (P/E) of 10.88 compared with 17.20 for the industry. The company possesses a Value Score of A.
See the full list of top ranked stocks here.
Learn more about the Value score and how it is calculated here.
For those looking to find strong Business Services stocks, it is prudent to search for companies in the group that are outperforming their peers. Is AMN Healthcare Services (AMN - Free Report) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Business Services sector should help us answer this question.
AMN Healthcare Services is a member of our Business Services group, which includes 234 different companies and currently sits at #10 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. AMN Healthcare Services is currently sporting a Zacks Rank of #1 (Strong Buy).
Over the past 90 days, the Zacks Consensus Estimate for AMN's full-year earnings has moved 164.8% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
According to our latest data, AMN has moved about 42.5% on a year-to-date basis. In comparison, Business Services companies have returned an average of -10.1%. This means that AMN Healthcare Services is outperforming the sector as a whole this year.
HireQuest, Inc. (HQI - Free Report) is another Business Services stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 16.3%.
Over the past three months, HireQuest, Inc.'s consensus EPS estimate for the current year has increased 6%. The stock currently has a Zacks Rank #2 (Buy).
To break things down more, AMN Healthcare Services belongs to the Business - Services industry, a group that includes 20 individual companies and currently sits at #68 in the Zacks Industry Rank. This group has lost an average of 13.2% so far this year, so AMN is performing better in this area.
On the other hand, HireQuest, Inc. belongs to the Staffing Firms industry. This 13-stock industry is currently ranked #155. The industry has moved +7.1% year to date.
Going forward, investors interested in Business Services stocks should continue to pay close attention to AMN Healthcare Services and HireQuest, Inc. as they could maintain their solid performance.
Key Takeaways AMN posted Q1 adjusted EPS of $2.10 and revenues of $1.38B, both topping estimates.AMN's Nurse and Allied Solutions revenues surged 173% as labor disruption events added $722M.AMN expects Q2 revenues of $620M-$635M as labor disruption revenues normalize. AMN Healthcare Services, Inc. (AMN - Free Report) delivered adjusted earnings per share (EPS) of $2.10 in the first-quarter 2026, up 367% year over year. The figure surpassed the Zacks Consensus Estimate by 31.3%.
GAAP EPS for the quarter was $1.59 against a loss per share of 3 cents in the year-ago period.
AMN’s Q1 Revenues in DetailAMN Healthcare registered revenues of $1.38 billion in the first quarter, up 100% year over year. The figure surpassed the Zacks Consensus Estimate by 11.9%.
Shares of this company gained nearly 3.1% in yesterday’s after-hours trading. The company’s shares have rallied 44.8% in the year-to-date period against the industry’s decline of 13.1%. However, the S&P 500 Index has increased 8.5% in the same time frame.
Image Source: Zacks Investment Research
AMN Healthcare’s Q1 Segment DetailsAMN Healthcare conducts its business via three reportable segments: Nurse and Allied Solutions, Physician and Leadership Solutions, and Technology and Workforce Solutions.
In the first quarter of 2026, the Nurse and Allied Solutions segment’s revenues totaled $1.13 billion, up 173% year over year. Travel nurse staffing revenues were up 12% year over year, whereas Allied revenues increased 3% year over year. Labor disruption events contributed $722 million in revenues in the quarter. The Zacks Consensus Estimate was pegged at $984 million.
The Physician and Leadership Solutions segment’s revenues totaled $163.9 million, down 6% year over year. Locum tenens revenues were $131 million in the quarter, down 7% year over year. Interim leadership revenues were down 4% year over year. Physician and leadership search businesses saw a revenue increase of 4% year over year. The Zacks Consensus Estimate was pegged at $163 million.
The Technology and Workforce Solutions segment’s revenues totaled $87.1 million, down 15% year over year. Language interpretation services business revenues came in at $69 million in the quarter, down 8% year over year, while the vendor management systems business saw an 18% year-over-year revenue decline to reach $16 million. The Zacks Consensus Estimate was pegged at $85 million.
AMN’s Q1 Margin TrendIn the quarter under review, AMN Healthcare’s gross profit increased 86.2% year over year to $368.8 million. The gross margin contracted 190 basis points (bps) to 26.8%.
Selling, general & administrative expenses fell 47.8% year over year to $218.4 million.
Operating profit totaled $117.2 million, reflecting an increase of 836.8% from the prior-year quarter. The operating margin expanded 670 basis points (bps) to 8.5%.
AMN Healthcare’s Financial PositionAMN Healthcare exited first-quarter 2026 with cash and cash equivalents of $560.7 million compared with $33.9 million at 2025-end. Total debt at the end of first-quarter 2026 was $750 million compared with $775 million at 2025-end.
Net cash provided by operating activities at the end of first-quarter 2026 was $562.5 million compared with $92.7 million a year ago.
AMN’s Q2 GuidanceAMN Healthcare has provided its financial outlook for the second quarter of 2026.
For the second quarter, AMN expects revenues in the range of $620-$635 million, reflecting a decline of 4-6% compared with the prior-year figure, as labor disruption revenues normalize. The Zacks Consensus Estimate is pegged at $627.7 million.
With respect to the Nurse and Allied Solutions segment, the company expects revenues to be down 0-2% year over year. The Physician and Leadership Solutions segment’s revenues are expected to decline 6-8% year over year. The company projects second-quarter revenues in the Technology and Workforce Solutions segment to decrease 14-16% year over year.
Our Take on AMN’s Q1 ResultsAMN Healthcare delivered a standout first-quarter 2026 performance, driven by extraordinary labor disruption activity, strong, rapid response volume, momentum return in international staffing and search and advancement in technology-enabled workforce solutions. Management emphasized that the quarter was defined by AMN’s ability to rapidly scale operations and support multiple large labor disruption events without compromising day-to-day client service.
AMN continued to strengthen its market position in nurse staffing, allied staffing and international recruitment. Excluding the temporary boost from labor disruption activities, Nurse and Allied Solutions revenues marked the first return to traveler volume growth since 2022. Growth in Travel nurse and allied staffing was supported by stronger fill rates, rapid-response placements and improving demand trends. AMN also saw encouraging progress in its international staffing business, following improvements in visa processing trends.
Technology investments remained a bright spot. The enhanced capabilities within the WorkWise workforce platform and the growing adoption of the AMN Passport app are likely to strengthen client engagement, improve hiring efficiency and support long-term retention. Management highlighted that more than 10,000 clinicians were deployed through its AI recruiter during the quarter, underscoring the increasing role of automation and analytics in its operations.
However, softness in Physician and Leadership Solutions remained concerning. Locum tenens revenues and volumes continued to decline amid weaker demand and heightened competition in third-party channels. Technology and Workforce Solutions revenues also fell year over year due to pricing pressure in Language Services and an unfavorable business mix, despite sequential gross margin improvement.
Looking ahead, management remains optimistic about the company’s long-term trajectory, targeting sustainable revenue growth and adjusted EBITDA growth at roughly twice the pace of revenue growth as operational efficiencies and AI adoption continue to expand.
AMN Healthcare’s Zacks Rank & Other Stocks to ConsiderAMN currently carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks in the broader medical space that have announced quarterly results are West Pharmaceutical Services, Inc. (WST - Free Report) , Intuitive Surgical (ISRG - Free Report) and Cardinal Health, Inc. (CAH - Free Report) .
West Pharmaceutical reported first-quarter 2026 EPS of $2.13, which beat the Zacks Consensus Estimate by 26.8%. Revenues of $844.9 million surpassed the Zacks Consensus Estimate by 8.5%. It currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
West Pharmaceutical has a long-term estimated growth rate of 13.9%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 19.37%.
Intuitive Surgical reported first-quarter 2026 adjusted EPS of $2.50, beating the Zacks Consensus Estimate by 20.19%. Revenues of $2.77 billion surpassed the Zacks Consensus Estimate by 6.2%. It currently carries a Zacks Rank of 2.
Intuitive Surgical has a long-term estimated growth rate of 14.6%. ISRG’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.82%.
Cardinal Health, carrying a Zacks Rank of 2 at present, reported third-quarter fiscal 2026 adjusted EPS of $3.17, which beat the Zacks Consensus Estimate by 13.2%. Revenues of $60.94 billion missed the Zacks Consensus Estimate by 2.3%.
Cardinal Health has a long-term estimated growth rate of 15.7%. CAH’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 10.27%.
MarketBeat Instant News Alerts Trending News All MarketBeat Instant News Alerts Sort By
Time Frame
Alert Type
Keywords
Page 1 of 323
Get 30 Days of MarketBeat All Access for Free
Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools.
Start Your 30-Day Trial
Sign in to your free account to enjoy these benefits
In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer.
AMN Healthcare's Q1 looked strong, but labor disruption revenue drove most of the upside. Excluding disruption revenue, quarterly sales were roughly flat year over year. Management's Q2 guide implies that disruption revenue should fall sharply from Q1's elevated level.
DALLAS, May 13, 2026 (GLOBE NEWSWIRE) -- AMN Healthcare, the leader and innovator in total talent solutions for healthcare organizations, announced the election of Eric Palmer to its Board of Directors, effective May 1, 2026.
Palmer is a seasoned healthcare executive with more than 25 years of leadership experience across healthcare services, benefits, and insurance industries. He has a strong track record of leading large-scale operations, driving strategic growth initiatives, and executing complex mergers, acquisitions, and divestitures.
“Eric’s extensive leadership experience, understanding of the healthcare ecosystem and alignment to our mission make him a valuable addition to our Board,” said Cary Grace, President and CEO of AMN Healthcare. “His proven ability to scale complex organizations and navigate dynamic market environments will strengthen our governance and support AMN’s long-term growth strategy.”
Palmer most recently served as Chief Executive Officer of Evernorth Health Services, where he led the organization’s growth to more than $200 billion in revenue, establishing it as a market leader in specialty pharmacy, pharmacy benefits, and care management services. Prior to that, he served as Chief Financial Officer of Cigna, where he played a central role in driving the transformational acquisition of Express Scripts, successfully combining two Fortune 100 companies.
“AMN’s commitment to empowering healthcare organizations and professionals deeply aligns with the work I’ve done throughout my career,” said Palmer. “I am honored to join the Board and am excited to support AMN’s mission to empower high-quality care through innovative workforce solutions.”
Palmer currently serves on the board of directors of LifeStance Health and is on the board of trustees of Kingswood-Oxford School and Connecticut Children’s Medical Center.
For more information about AMN Healthcare’s leadership team, please visit www.amnhealthcare.com.
About AMN Healthcare
AMN Healthcare is the leader and innovator in total talent solutions for healthcare, bringing together the people, processes and technology to deliver better care. Through a steadfast partnership approach, we solve the most pressing workforce challenges to enable better clinical outcomes and access to care. In 2025 our healthcare professionals reached more than 13 million patients at more than 2,300 healthcare systems, including 93 percent of the top healthcare systems nationwide. We provide a comprehensive network of quality healthcare professionals and deliver a fully integrated and customizable suite of workforce technologies.
For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.
The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.
Zacks Premium includes access to the Zacks Style Scores as well.
What are the Zacks Style Scores? Developed alongside the Zacks Rank, the Zacks Style Scores are a group of complementary indicators that help investors pick stocks with the best chances of beating the market over the next 30 days.
Each stock is given an alphabetic rating of A, B, C, D or F based on their value, growth, and momentum qualities. With this system, an A is better than a B, a B is better than a C, and so on, meaning the better the score, the better chance the stock will outperform.
The Style Scores are broken down into four categories:
Value ScoreValue investors love finding good stocks at good prices, especially before the broader market catches on to a stock's true value. Utilizing ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and many other multiples, the Value Style Score identifies the most attractive and most discounted stocks.
Growth ScoreGrowth investors, on the other hand, are more concerned with a company's financial strength and health, and its future outlook. The Growth Style Score examines things like projected and historic earnings, sales, and cash flow to find stocks that will experience sustainable growth over time.
Momentum ScoreMomentum traders and investors live by the saying "the trend is your friend." This investing style is all about taking advantage of upward or downward trends in a stock's price or earnings outlook. Employing factors like one-week price change and the monthly percentage change in earnings estimates, the Momentum Style Score can indicate favorable times to build a position in high-momentum stocks.
VGM ScoreIf you want a combination of all three Style Scores, then the VGM Score will be your friend. It rates each stock on their combined weighted styles, helping you find the companies with the most attractive value, best growth forecast, and most promising momentum. It's also one of the best indicators to use with the Zacks Rank.
How Style Scores Work with the Zacks Rank A proprietary stock-rating model, the Zacks Rank utilizes the power of earnings estimate revisions, or changes to a company's earnings outlook, to help investors create a successful portfolio.
It's highly successful, with #1 (Strong Buy) stocks producing an unmatched +23.7% average annual return since 1988. That's more than double the S&P 500. But because of the large number of stocks we rate, there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.
With more than 800 top-rated stocks to choose from, it can certainly feel overwhelming to pick the ones that are right for you and your investing journey.
That's where the Style Scores come in.
You want to make sure you're buying stocks with the highest likelihood of success, and to do that, you'll need to pick stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you like a stock that only has a #3 (Hold) rank, it should also have Scores of A or B to guarantee as much upside potential as possible.
As mentioned above, the Scores are designed to work with the Zacks Rank, so any change to a company's earnings outlook should be a deciding factor when picking which stocks to buy.
For instance, a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one that boasts Scores of A and B, still has a downward-trending earnings forecast, and a much greater likelihood its share price will decline as well.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: AMN Healthcare Services (AMN - Free Report) AMN Healthcare Services, Inc. (AMN - Free Report) , operating from Dallas, TX, is a travel healthcare staffing company. Its business has evolved beyond traditional healthcare staffing and recruitment services, thereby becoming a strategic total talent solutions partner with its clients. It has expanded its portfolio to serve a diverse and growing set of healthcare talent-related needs. In addition to its healthcare professional staffing and recruitment services, AMN’s suite of healthcare workforce solutions includes MSP, vendor management systems (VMS), medical language interpretation services, predictive labor analytics, workforce optimization technology and consulting, recruitment process outsourcing (RPO), revenue cycle solutions, credentialing services and virtual care management services. AMN enables its clients to build, manage and optimize their healthcare talent to deliver improved patient outcomes and experience. It continues to enhance its platform with technology-enabled solutions, including digital workforce platforms, automation tools and AI-driven capabilities to improve speed, efficiency and clinician engagement.
AMN is a #3 (Hold) on the Zacks Rank, with a VGM Score of A.
Momentum investors should take note of this Business Services stock. AMN has a Momentum Style Score of A, and shares are up 41.1% over the past four weeks.
Two analysts revised their earnings estimate upwards in the last 60 days for fiscal 2026. The Zacks Consensus Estimate has increased $0.57 to $2.53 per share. AMN boasts an average earnings surprise of +53.3%.
With a solid Zacks Rank and top-tier Momentum and VGM Style Scores, AMN should be on investors' short list.
Investors in AMN Healthcare Services (AMN - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the Dec 18, 2026 $05.00 Call had some of the highest implied volatility of all equity options today.
What is Implied Volatility?Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It could also mean there is an event coming up soon that may cause a big rally or a huge sell off. However, implied volatility is only one piece of the puzzle when putting together an options trading strategy.
What do the Analysts Think?Clearly, options traders are pricing in a big move for AMN Healthcare Services share, but what is the fundamental picture for the company? Currently, AMN Healthcare Services is a Zacks Rank #3 (Hold) in the Business - Services Industry that ranks in the Top 39% of our Zacks Industry Rank. Over the last 60 days, one analyst has increased his estimate for the current quarter, while none have revised their estimates downward. The net effect has taken our Zacks Consensus Estimate for the current quarter to move from 10 cents per share to 188 cents per share in the same time period.
Given the way analysts feel about AMN Healthcare Services right now, this huge implied volatility could mean there’s a trade developing. Often times, options traders look for options with high levels of implied volatility to sell premium. This is a strategy many seasoned traders use because it captures decay. At expiration, the hope for these traders is that the underlying stock does not move as much as originally expected.
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.
The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.
Zacks Premium also includes the Zacks Style Scores.
What are the Zacks Style Scores? The Zacks Style Scores, developed alongside the Zacks Rank, are complementary indicators that rate stocks based on three widely-followed investing methodologies; they also help investors pick stocks with the best chances of beating the market over the next 30 days.
Each stock is assigned a rating of A, B, C, D, or F based on their value, growth, and momentum characteristics. Just like in school, an A is better than a B, a B is better than a C, and so on -- that means the better the score, the better chance the stock will outperform.
The Style Scores are broken down into four categories:
Value ScoreFor value investors, it's all about finding good stocks at good prices, and discovering which companies are trading under their true value before the broader market catches on. The Value Style Score utilizes ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to help pick out the most attractive and discounted stocks.
Growth ScoreWhile good value is important, growth investors are more focused on a company's financial strength and health, and its future outlook. The Growth Style Score takes projected and historic earnings, sales, and cash flow into account to uncover stocks that will see long-term, sustainable growth.
Momentum ScoreMomentum traders and investors live by the saying "the trend is your friend." This investing style is all about taking advantage of upward or downward trends in a stock's price or earnings outlook. Employing factors like one-week price change and the monthly percentage change in earnings estimates, the Momentum Style Score can indicate favorable times to build a position in high-momentum stocks.
VGM ScoreWhat if you like to use all three types of investing? The VGM Score is a combination of all Style Scores, making it one of the most comprehensive indicators to use with the Zacks Rank. It rates each stock on their combined weighted styles, which helps narrow down the companies with the most attractive value, best growth forecast, and most promising momentum.
How Style Scores Work with the Zacks Rank The Zacks Rank is a proprietary stock-rating model that harnesses the power of earnings estimate revisions, or changes to a company's earnings expectations, to help investors build a successful portfolio.
#1 (Strong Buy) stocks have produced an unmatched +23.7% average annual return since 1988, which is more than double the S&P 500's performance over the same time frame. However, the Zacks Rank examines a ton of stocks, and there can be more than 200 companies with a Strong Buy rank, and another 600 with a #2 (Buy) rank, on any given day.
This totals more than 800 top-rated stocks, and it can be overwhelming to try and pick the best stocks for you and your portfolio.
That's where the Style Scores come in.
To have the best chance of big returns, you'll want to always consider stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B, which will give you the highest probability of success. If you're looking at stocks with a #3 (Hold) rank, it's important they have Scores of A or B as well to ensure as much upside potential as possible.
As mentioned above, the Scores are designed to work with the Zacks Rank, so any change to a company's earnings outlook should be a deciding factor when picking which stocks to buy.
Here's an example: a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one with Style Scores of A and B, still has a downward-trending earnings outlook, and a bigger chance its share price will decrease too.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: AMN Healthcare Services (AMN - Free Report) AMN Healthcare Services, Inc. (AMN - Free Report) , operating from Dallas, TX, is a travel healthcare staffing company. Its business has evolved beyond traditional healthcare staffing and recruitment services, thereby becoming a strategic total talent solutions partner with its clients. It has expanded its portfolio to serve a diverse and growing set of healthcare talent-related needs. In addition to its healthcare professional staffing and recruitment services, AMN’s suite of healthcare workforce solutions includes MSP, vendor management systems (VMS), medical language interpretation services, predictive labor analytics, workforce optimization technology and consulting, recruitment process outsourcing (RPO), revenue cycle solutions, credentialing services and virtual care management services. AMN enables its clients to build, manage and optimize their healthcare talent to deliver improved patient outcomes and experience. It continues to enhance its platform with technology-enabled solutions, including digital workforce platforms, automation tools and AI-driven capabilities to improve speed, efficiency and clinician engagement.
AMN is a #3 (Hold) on the Zacks Rank, with a VGM Score of A.
It also boasts a Value Style Score of A thanks to attractive valuation metrics like a forward P/E ratio of 11.05; value investors should take notice.
For fiscal 2026, two analysts revised their earnings estimate upwards in the last 60 days, and the Zacks Consensus Estimate has increased $0.57 to $2.53 per share. AMN boasts an average earnings surprise of +53.3%.
With a solid Zacks Rank and top-tier Value and VGM Style Scores, AMN should be on investors' short list.
Key Takeaways AMN shares are up 86.1% YTD, even as the industry declined 17.4% over the same stretch.AMN posted $722M labor disruption revenues in Q1 2026, handling five events and deploying thousands.AMN faces tech and language pricing pressure: segment revenues fell 15% YoY and language services lost 8%. AMN Healthcare Services, Inc. (AMN - Free Report) is well-poised for growth in the coming quarters, courtesy of its broad array of services. The optimism is led by strong momentum in its Managed Services Program (MSP), rising labor disruption demand and investments in technology and AI-driven platforms. However, industry shifts, pricing pressure and healthcare cost-consciousness are major downsides.
Shares of this Zacks Rank #3 (Hold) company have jumped 86.1% in the year-to-date period against the industry's 17.4% decline. However, the S&P 500 Index has risen 11.1% in the said timeframe.
This renowned player in the healthcare total talent services space has a market capitalization of $1.12 billion. The company projects 98.5% of earnings growth for 2026 and expects to witness continued improvements in its business. AMN Healthcare surpassed the Zacks Consensus Estimate in all the trailing four quarters, delivering an average earnings surprise of 53.25%.
Image Source: Zacks Investment Research
Factors Favoring AMN StockHealthcare MSP: AMN Healthcare continues to expand its Managed Services Program (MSP) presence as healthcare organizations seek more efficient workforce management solutions. During first-quarter 2026, management noted that many clients have shifted their focus from reducing contract labor usage to optimizing total workforce costs through predictive analytics, workforce planning and technology-enabled staffing strategies.
First-quarter 2026 results highlighted the model’s scalability during multiple labor disruption events, and management added a new locum MSP client and expanded its largest locums contract. As healthcare providers seek strategic workforce partners rather than transactional staffing vendors, AMN’s MSP capabilities position it to deepen client relationships, improve retention and capture additional market share over time.
AI and Workforce Technology Investments Enhancing Scalability: AMN Healthcare continues to invest in AI, automation and analytics to improve hiring efficiency and clinician engagement. In first-quarter 2026, travel nurse revenues rose 13% year over year, allied revenues increased 3%, international staffing returned to growth and leadership search expanded. AMN also demonstrated rapid scalability during major labor disruptions. Through its WorkWise workforce technology platform, the company rolled out AI-driven candidate scoring, search and job-description tools. Its AI recruiter deployed over 10,000 clinicians. AMN Passport users grew over 30%, monthly active users rose over 50% and language services delivered sequential gross margin improvement.
Labor Disruption Capabilities Creating a Competitive Advantage: AMN’s ability to support multiple large labor disruption events emerged as a major strength in the first quarter of 2026. The company generated $722 million in labor disruption revenues while successfully managing five labor disruption events. Management highlighted that investments in event management systems, AI-enabled recruiting tools and scalable operating processes allowed AMN to rapidly deploy thousands of clinicians.
These capabilities strengthen relationships with strategic healthcare clients and reinforce AMN’s position as a trusted workforce partner during critical situations. The company believes this level of execution would not have been possible a few years ago, underscoring the value of its technology investments and broad clinician network.
Downsides of AMN StockHealthcare Cost-Consciousness Limiting Growth: Hospital systems remain heavily focused on workforce cost management despite improving patient utilization trends. Clients continue to prioritize efficiency, predictive workforce planning and labor optimization rather than expanding staffing budgets.
Bill-rate growth remains limited, with increases largely occurring only when difficult-to-fill positions create urgent staffing needs. AMN noted that healthcare providers are increasingly evaluating technology, analytics and workforce planning tools to improve internal staffing efficiency. Continued emphasis on cost containment could restrict demand growth, slow pricing recovery and create a challenging environment for staffing providers across several service lines.
Continued Pricing Pressure in Technology and Language Services: AMN’s Technology and Workforce Solutions segment remains under pressure from competitive pricing dynamics. Segment revenues declined 15% year over year, while language services revenues fell 8%. Management indicated that pricing pressure persists across the language services market, although conditions have become more stable than in prior periods.
The company has implemented service model changes, including greater offshore utilization and operational efficiencies, to protect profitability. However, management expects competition to remain intense and acknowledged that pricing headwinds could continue as contracts renew, creating ongoing pressure on revenue growth and margins.
Healthcare Industry Regulations: AMN Healthcare operates in a highly regulated industry subject to federal and state laws governing reimbursement, workforce practices, privacy, cybersecurity and AI usage. Although clients pay AMN directly, changes in Medicare and Medicaid reimbursement can indirectly affect demand and pricing, while client non-compliance may reduce business activity. The company also serves government clients and must meet specific regulatory requirements. Increasing regulation could raise compliance costs and operational risks. In addition, changes in immigration policies remain an important variable for international nurse staffing, which returned to year-over-year growth in first-quarter 2026 after a period of weakness.
Estimate TrendAMN Healthcare has been witnessing a positive estimate revision trend for 2026. Over the past 60 days, the Zacks Consensus Estimate for its earnings per share has improved 37.7% to $2.70.
The Zacks Consensus Estimate for second-quarter 2026 revenues and earnings per share is pegged at $625.7 million and 22 cents, respectively, suggesting 4.9% and 26.7% declines from the year-ago reported numbers.
Key PicksSome better-ranked stocks in the broader medical space are West Pharmaceutical Services (WST - Free Report) , Align Technology (ALGN - Free Report) and Biodesix (BDSX - Free Report) . While West Pharmaceutical Services and Align Technology sport a Zacks Rank #1 (Strong Buy) each at present, Biodesix carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
West Pharmaceutical Services has an estimated long-term growth rate of 13.9%. WST's earnings surpassed estimates in each of the trailing four quarters, with the average being 19.4%.
West Pharmaceutical Services’ stock has gained 14.9% against the industry's 9.3% decline in the year-to-date period.
Align Technology's earnings surpassed estimates in three of the trailing four quarters and missed one, with the average surprise being 7.8%.
ALGN's shares have risen 8.7% in the year-to-date period against the industry’s 9.3% decline.
Biodesix's earnings surpassed estimates in three of the trailing four quarters and missed one, with the average surprise being 25.6%.
BDSX's shares have rallied 124.6% in the year-to-date period against the industry’s 9.7% decline.
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.
The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.
It also includes access to the Zacks Style Scores.
What are the Zacks Style Scores? The Zacks Style Scores, developed alongside the Zacks Rank, are complementary indicators that rate stocks based on three widely-followed investing methodologies; they also help investors pick stocks with the best chances of beating the market over the next 30 days.
Each stock is given an alphabetic rating of A, B, C, D or F based on their value, growth, and momentum qualities. With this system, an A is better than a B, a B is better than a C, and so on, meaning the better the score, the better chance the stock will outperform.
The Style Scores are broken down into four categories:
Value ScoreValue investors love finding good stocks at good prices, especially before the broader market catches on to a stock's true value. Utilizing ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and many other multiples, the Value Style Score identifies the most attractive and most discounted stocks.
Growth ScoreGrowth investors, on the other hand, are more concerned with a company's financial strength and health, and its future outlook. The Growth Style Score examines things like projected and historic earnings, sales, and cash flow to find stocks that will experience sustainable growth over time.
Momentum ScoreMomentum trading is all about taking advantage of upward or downward trends in a stock's price or earnings outlook, and these investors live by the saying "the trend is your friend." The Momentum Style Score can pinpoint good times to build a position in a stock, using factors like one-week price change and the monthly percentage change in earnings estimates.
VGM ScoreWhat if you like to use all three types of investing? The VGM Score is a combination of all Style Scores, making it one of the most comprehensive indicators to use with the Zacks Rank. It rates each stock on their combined weighted styles, which helps narrow down the companies with the most attractive value, best growth forecast, and most promising momentum.
How Style Scores Work with the Zacks Rank The Zacks Rank is a proprietary stock-rating model that harnesses the power of earnings estimate revisions, or changes to a company's earnings expectations, to help investors build a successful portfolio.
#1 (Strong Buy) stocks have produced an unmatched +23.7% average annual return since 1988, which is more than double the S&P 500's performance over the same time frame. However, the Zacks Rank examines a ton of stocks, and there can be more than 200 companies with a Strong Buy rank, and another 600 with a #2 (Buy) rank, on any given day.
But it can feel overwhelming to pick the right stocks for you and your investing goals with over 800 top-rated stocks to choose from.
That's where the Style Scores come in.
To maximize your returns, you want to buy stocks with the highest probability of success. This means picking stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you find yourself looking at stocks with a #3 (Hold) rank, make sure they have Scores of A or B as well to ensure as much upside potential as possible.
Since the Scores were created to work together with the Zacks Rank, the direction of a stock's earnings estimate revisions should be a key factor when choosing which stocks to buy.
A stock with a #4 (Sell) or #5 (Strong Sell) rating, for instance, even one with Scores of A and B, will still have a declining earnings forecast, and a greater chance its share price will fall too.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: AMN Healthcare Services (AMN - Free Report) AMN Healthcare Services, Inc. (AMN - Free Report) , operating from Dallas, TX, is a travel healthcare staffing company. Its business has evolved beyond traditional healthcare staffing and recruitment services, thereby becoming a strategic total talent solutions partner with its clients. It has expanded its portfolio to serve a diverse and growing set of healthcare talent-related needs. In addition to its healthcare professional staffing and recruitment services, AMN’s suite of healthcare workforce solutions includes MSP, vendor management systems (VMS), medical language interpretation services, predictive labor analytics, workforce optimization technology and consulting, recruitment process outsourcing (RPO), revenue cycle solutions, credentialing services and virtual care management services. AMN enables its clients to build, manage and optimize their healthcare talent to deliver improved patient outcomes and experience. It continues to enhance its platform with technology-enabled solutions, including digital workforce platforms, automation tools and AI-driven capabilities to improve speed, efficiency and clinician engagement.
AMN is a #3 (Hold) on the Zacks Rank, with a VGM Score of A.
Momentum investors should take note of this Business Services stock. AMN has a Momentum Style Score of A, and shares are up 36.4% over the past four weeks.
Three analysts revised their earnings estimate upwards in the last 60 days for fiscal 2026. The Zacks Consensus Estimate has increased $0.74 to $2.70 per share. AMN boasts an average earnings surprise of +53.3%.
With a solid Zacks Rank and top-tier Momentum and VGM Style Scores, AMN should be on investors' short list.
Key Takeaways AMN acquired Jaide Health to expand language access for patients with Limited English Proficiency.AMN adds AI-assisted translation for intake, discharge and routine interactions, plus documents.Jaide's team joins AMN; terms weren't disclosed, and human interpreters stay key for complex talks. AMN Healthcare Services (AMN - Free Report) recently announced the acquisition of Jaide Health, an AI-enabled medical interpretation and translation platform, to expand language access for patients with Limited English Proficiency across the healthcare journey. The move enhances AMN’s Language Services capabilities by extending language assistance to important touchpoints before and after treatment while maintaining the critical role of qualified human interpreters for clinical, sensitive and complex discussions.
According to management, this acquisition represents a significant step forward in AMN’s commitment to making healthcare more accessible. Enhancing language support across more moments in the healthcare journey enables healthcare organizations to create seamless experiences for both patients and care teams, while still leveraging the critical expertise of qualified interpreters.
AMN Stock Trend Following the NewsFollowing the announcement, shares of AMN lost 2.3% at yesterday’s closing. In the year-to-date period, the stock surged 92.4% against the industry’s 17.9% decline. The S&P 500 has risen 8.3% in the same timeframe.
The integration of AI-assisted translation capabilities enables AMN Healthcare to offer more comprehensive end-to-end language support while preserving the critical role of human interpreters. The transaction also reflects the increasing adoption of AI solutions in healthcare administration. By combining technology-driven efficiency with human expertise, AMN is well positioned to help healthcare organizations address the rising demand for accessible and equitable patient communication.
AMN currently has a market capitalization of $1.20 billion.
Image Source: Zacks Investment Research
More on the NewsJaide Health delivers AI-assisted language support for routine verbal interactions and document translations, including patient intake, discharge instructions and other everyday communications.These capabilities reduce delays and improve language accessibility in situations where healthcare staff and patients often face communication barriers outside direct physician or acute-care encounters.For complex medical conversations, professional human interpreters remain central to ensure accuracy, empathy and patient safety.
The Jaide Health platform is already being used by clients across multiple care settings, demonstrating its ability to improve communication workflows and patient interactions. As part of the transaction, Jaide Health’s team will become part of AMN Healthcare. The companies have not disclosed the financial details of the agreement.
Industry Prospects Favoring the MarketGoing by the data provided by Precedence Research, the AI-enabled translation services market was valued at $6.51 billion in 2026 and is expected to witness a CAGR of 25.6% through 2035.
Factors like the increasing demand for real-time translators, rapid adoption by the healthcare sector and the advancements in LLMs and GenAI that offer precise and context-aware translation services with cost efficiency are boosting the market’s growth.
Other NewsAMN Healthcare recently delivered a strong first-quarter 2026 performance, fueled by labor disruption activity, growth in nurse and allied staffing, improving international recruitment and expanding technology-driven workforce solutions. The company’s AI-powered tools and the WorkWise platform continued to gain traction, enhancing hiring efficiency. However, weakness in Physician and Leadership Solutions persisted due to softer demand and competitive pressures. Management expects AI adoption and operational efficiencies to support sustainable revenue and profitability growth.
AMN’s Zacks Rank & Key PicksAMN Healthcare currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are West Pharmaceutical (WST - Free Report) , Globus Medical (GMED - Free Report) and Biodesix (BDSX - Free Report) .
West Pharmaceutical, sporting a Zacks Rank #1 (Strong Buy) at present, reported first-quarter 2026 earnings per share (EPS) of $2.13, which beat the Zacks Consensus Estimate by 26.8%. Revenues of $844.9 million surpassed the Zacks Consensus Estimate by 8.5%. You can see the complete list of today’s Zacks #1 Rank stocks here.
West Pharmaceutical has an estimated long-term earnings growth rate of 13.9%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 19.4%.
Globus Medical, currently carrying a Zacks Rank #2 (Buy), reported first-quarter 2026 adjusted EPS of $1.12, which surpassed the Zacks Consensus Estimate by 22.1%. Revenues of $759.9 million beat the Zacks Consensus Estimate by 4.0%.
Globus Medical has an estimated long-term earnings growth rate of 10.2%. GMED’s earnings beat estimates in each of the trailing four quarters, the average surprise being 26.3%.
Biodesix, currently carrying a Zacks Rank of 2, reported a first-quarter 2026 adjusted loss per share of 81 cents, which came narrower than the Zacks Consensus Estimate by 35.71%. Revenues of $26 million beat the Zacks Consensus Estimate by 12.3%.
BDSX has an estimated earnings growth rate of 36% for 2026. The company beat earnings estimates in three of the trailing four quarters and missed once, with the average surprise being 25.5%.
